[{"path":"https://sterniii3.github.io/drugdevelopR/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"MIT License","title":"MIT License","text":"Copyright (c) 2023 drugdevelopR authors Permission hereby granted, free charge, person obtaining copy software associated documentation files (‚ÄúSoftware‚Äù), deal Software without restriction, including without limitation rights use, copy, modify, merge, publish, distribute, sublicense, /sell copies Software, permit persons Software furnished , subject following conditions: copyright notice permission notice shall included copies substantial portions Software. SOFTWARE PROVIDED ‚Äú‚Äù, WITHOUT WARRANTY KIND, EXPRESS IMPLIED, INCLUDING LIMITED WARRANTIES MERCHANTABILITY, FITNESS PARTICULAR PURPOSE NONINFRINGEMENT. EVENT SHALL AUTHORS COPYRIGHT HOLDERS LIABLE CLAIM, DAMAGES LIABILITY, WHETHER ACTION CONTRACT, TORT OTHERWISE, ARISING , CONNECTION SOFTWARE USE DEALINGS SOFTWARE.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Bias adjustment - methods for discounting of phase II results","text":"Suppose developing new tumor treatment, exper. patient variable want investigate long patient survives without progression tumor (progression-free survival). time--event outcome variable. Therefore, use function optimal_bias, calculates optimal sample sizes threshold decisions values time--event outcomes bias adjustment. Within drug development program, compare experimental treatment exper control treatment contro. treatment effect measure given Œ∏=‚àílog(HR)\\theta = ‚àí\\log(HR), negative logarithm hazard ratio HRHR, ratio hazard rates. assume unfavorable events tumor progression occur 75% often control group, hazard ratio 0.75.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Bias adjustment - methods for discounting of phase II results","text":"installing package according installation instructions, can load using following code: insert input values example time--event endpoints. basic setting, treatment effect may fixed (example) follows prior distribution (see Fixed Prior). Furthermore, options adapt program specific needs also available setting (see parameters), however skipping phase II choosing different treatment effects phase II III possible. addition parameters basic setting, parameters needed specifically bias adjustment: adj = \"additive\" selects additive adjustment method number events phase III. , lower bound one-sided confidence interval adjusted according Wang et al (2006). adj = \"multiplicative\" selects multiplicative adjustment method number events phase III. , estimate retention factor used according Kirby et al.¬†(2012). adj = \"\" returns results adjustment methods, .e.¬†additive multiplicative one. adj = \"\" returns results adjustment methods addition, also returns results methods number events adjusted also threshold value decision rule. additive method, adjustment equal setting adjustment parameter 0.5. Therefore set upper limit alphaCImax 0.5. want investigate optimization region interval [0.1, 0.5] step size 0.05. Thus, set lower bound alphaCImin 0.1 step size stepalphaCI = 0.05. multiplicative method, adjustment equal setting adjustment parameter 1. Therefore set upper limit lambdamax 1. want investigate optimization region interval [0.7, 1] step size 0.05. Thus, set lower bound lambdamin 0.1 step size steplambda = 0.05. Now defined parameters needed example, ready feed package.","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel res <- optimal_bias(w = 0.3,                                 # define parameters for prior    hr1 = 0.75, hr2 = 0.8, id1 = 210, id2 = 420,              # (https://web.imbi.uni-heidelberg.de/prior/)    d2min = 20, d2max = 400, stepd2 = 5,                      # define optimization set for d2    adj = \"both\",                                             # choose both adjustment methods    lambdamin = 0.7, lambdamax = 1, steplambda = 0.05,        # optimization set for multiplicative adjustment    alphaCImin = 0.1, alphaCImax = 0.5, stepalphaCI = 0.05,   # optimization set for additive adjustment    hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.01,            # define optimization set for HRgo    alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,          # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                  # define fixed and variable costs    K = Inf, N = Inf, S = -Inf,                               # set constraints    steps1 = 1,  stepm1 = 0.95, stepl1 = 0.85,                # define boundary for  effect size categories    b1 = 1000, b2 = 2000, b3 = 3000,                          # define expected benefits    fixed = TRUE,                                             # choose if  effects are fixed or random    num_cl = 1)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Bias adjustment - methods for discounting of phase II results","text":"setting input parameters running function, let‚Äôs take look output program. program returns output values adjustment methods. important ones multiplicative method : res[1,]$Adj optimal multiplicative adjustment parameter. setting, optimal value 0.95, indicating slight bias adjustment leads higher utility. res[1,]$d2 optimal number events phase II res$d3 resulting number events phase III. see optimal scenario requires 165 events phase II 436 events phase III, correspond 236 participants phase II 624 phase III. res[1,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.85 phase II order proceed phase III. res[1,]$u expected utility program optimal sample size threshold value. case amounts 378.47, .e.¬†expected utility 37 847 000$. additive method get: res[2,]$Adj optimal additive adjustment parameter. setting, optimal value 0.5, indicating bias adjustment leads highest utility. case, results match results basic setting can verified . res[2,]$d2 optimal number events phase II res$d3 resulting number events phase III. see optimal scenario requires 165 events phase II 430 events phase III, correspond 236 participants phase II 614 phase III. res[2,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.86 phase II order proceed phase III. res[2,]$u expected utility program optimal sample size threshold value. case amounts 377.1, .e.¬†expected utility 37 710 000$.","code":"res #> Optimization result with multiplicative adjustment of the treatment effect: #>  Utility: 378.47 #>  Bias adjustment parameter: 0.95 #>  Sample size: #>    phase II: 236, phase III: 624, total: 860 #>  Expected number of events: #>    phase II: 165, phase III: 436, total: 601 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.79 #>  Total cost: #>    phase II: 277, phase III: 742, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.63 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.09, medium: 0.3, large: 0.24 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [HRgo]  #>  Assumed true effect: 0.75 [hr]  #>  #> Optimization result with additive adjustment of the treatment effect: #>  Utility: 377.1 #>  Bias adjustment parameter: 0.5 #>  Sample size: #>    phase II: 236, phase III: 614, total: 850 #>  Expected number of events: #>    phase II: 165, phase III: 430, total: 595 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.81 #>  Total cost: #>    phase II: 277, phase III: 736, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.62 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.09, medium: 0.29, large: 0.24 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.86 [HRgo]  #>  Assumed true effect: 0.75 [hr]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Bias adjustment - methods for discounting of phase II results","text":"article presented example methods discount results phase II can included purpose bias adjustment. Note example restricted time--event endpoints can also applied binary normally distributed endpoints using functions optimal_bias_binary optimal_bias_normal. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"Bias adjustment - methods for discounting of phase II results","text":"Kirby, S., Burke, J., Chuang-Stein, C., Sin, C. (2012). Discounting phase 2 results planning phase 3 clinical trials. Pharmaceutical Statistics, 11(5):373‚Äì385. Wang, S.-J., Hung, H. J., O‚ÄôNeill, R. T. (2006). Adapting sample size planning phase III trial based phase II data. Pharmaceutical Statistics, 5(2):85‚Äì97.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Binary outcome variables","text":"Suppose developing new treatment prevent strokes, exper. patient variable want investigate patient experienced stroke (unfavorable outcome value 1) (favourable outcome value 0) pre-defined observation period. binary outcome variable. Within drug development program, compare experimental treatment exper control treatment contro. treatment effect measure given œÅ=‚àílog(RR)\\rho = ‚àí\\log(RR), negative logarithm risk ratio (relative risk) RR=p1p0RR = \\frac{p_1}{p_0}. , p1p_1 failure probability experimental treatment (.e.¬†‚Ñô(Xi=1|experimental)\\mathbb{P}(X_i = 1|\\text{experimental}), probability patient ii stroke) analogously p0p_0 failure probability control treatment.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Binary outcome variables","text":"installing package according installation instructions, can load using following code:","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html","id":"defining-all-necessary-parameters","dir":"Articles","previous_headings":"Applying the package to the example","what":"Defining all necessary parameters","title":"Binary outcome variables","text":"order apply package setting example, need specify following parameters: p11 assumed true probability unfavorable outcome occurs experimental treatment exper. p0 assumed true probability unfavorable outcome occurs control treatment contro. Let‚Äôs assume 30% patients experimental group stroke 50% control group. Therefore, set p11 = 0.3 p0 = 0.5. now, assume probabilities fixed independent prior distribution. Thus, set fixed = TRUE. n2min n2max specify minimal maximal number participants phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 400 participants. addition, tell program search region steps four participants time setting stepn2 = 4. rrgomin rrgomax specify minimal maximal threshold value go/-go decision rule terms negative logarithm risk ratio. package search optimal threshold value within region. now, want program search interval 0.7 0.9 going steps steprrgo = 0.01. Note lower bound decision rule represents smallest size treatment effect observed phase II allowing go phase III, can used model minimal clinically relevant effect size. Moreover, note interval specified corresponds set {‚àílog(0.9),...,‚àílog(0.7)}\\{-\\log(0.9), ..., -\\log(0.7)\\}. c02 c03 fixed costs phase II phase III, respectively. set phase II costs 100 phase III costs 150 (10510^5$), .e.¬†fixed costs 10 000 000$ phase II 15 000 000$ phase III. Note currency input values matter, input value c02 15 also interpreted fixed costs 1 500 000‚Ç¨ necessary. c2 c3 per-patient costs phase II phase III. set 0.75 phase II 0.1 phase III. , values given 10510^5$, .e.¬†per-patient costs 75 000$ phase II 100 000$ phase III. b1, b2 b3 expected small, medium large benefit categories successfully launching treatment market effect size category 10510^5$. define small benefit 1000, medium benefit 2000, large benefit 3000. effect size categories directly correspond treatment effect: example, treatment effect 1 0.95 (terms risk ratio) small treatment effect yielding expected benefit 100 000 000$. alpha specified significance level. set alpha = 0.025. 1 - beta minimal power require drug development program. set beta = 0.1, meaning require power 90%. setting normally distributed outcomes, treatment effect may fixed (example) may distributed respect prior distribution. Furthermore, options adapt program specific needs also available setting. Now defined parameters needed example, ready feed package. use function optimal_binary(), calculates optimal sample size optimal threshold value binary distributed outcome variable.","code":"res <- optimal_binary(p0 = 0.5, p11 =  0.3,               # probabilities of the unfavorable outcome    n2min = 20, n2max = 400, stepn2 = 4,                   # define optimization set for n2    rrgomin = 0.7, rrgomax = 0.9, steprrgo = 0.01,         # define optimization set for RRgo    alpha = 0.025, beta = 0.1,                              # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,               # define fixed and variable costs for phase II and III,    K = Inf, N = Inf, S = -Inf,                            # constraints    steps1 = 1, stepm1 = 0.95,  stepl1 = 0.85,             # treatment effect size categories as proposed by IQWiG (2016)    b1 = 1000, b2 = 2000, b3 = 3000,                       # expected benefit categories    w = 0.3, p12 = 0.5, in1 = 30, in2 = 60,                # prior (https://web.imbi.uni-heidelberg.de/prior/)    gamma = 0,                                             # population structures in phase II and III    fixed = TRUE,                                          # choose if true treatment effects are fixed or random    skipII = FALSE,                                        # choose if skipping phase II would be an option    num_cl = 1)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Binary outcome variables","text":"setting input parameters running function, let‚Äôs take look output program. program returns total thirteen values input values. now, look important ones: res$n2 optimal sample size phase II res$n3 resulting sample size phase III. see optimal scenario requires 260 participants phase II 346 participants phase III. res$RRgo optimal threshold value go/-go decision rule. see need risk ratio less 0.86 phase II order proceed phase III. res$u expected utility program optimal sample size threshold value. case amounts 1399.56, .e.¬†expected utility 139 956 000$.","code":"res #> Optimization result: #>  Utility: 1399.56 #>  Sample size: #>    phase II: 260, phase III: 346, total: 606 #>  Probability to go to phase III: 0.99 #>  Total cost: #>    phase II: 295, phase III: 494, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.83 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.06, medium: 0.18, large: 0.59 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.86 [RRgo]  #>  Assumed true effect: #>   rate in the control: 0.5, rate in the treatment group: 0.3 #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Binary_outcomes.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Binary outcome variables","text":"article introduced setting, outcome variable binary distributed. information use package, see: Introduction drugdevelopR: See package works basic normally distributed example. Different outcomes: Apply time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Fixed effect estimates and prior distributions","text":"setting introduction, .e.¬†suppose developing new tumor treatment, exper. patient variable want investigate difference tumor width one-year visit baseline. normally distributed outcome variable. parameters insert function optimum_normal parameters also inserted basic setting. However time, set fixed = \"FALSE\", hence assumed true treatment effect fixed follows prior distribution. , start loading drugdevelopR package.","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html","id":"parameters-of-the-prior-distribution","dir":"Articles","previous_headings":"The example setting","what":"Parameters of the prior distribution","title":"Fixed effect estimates and prior distributions","text":"Additionally parameters baseline scenario fixed treatment effects, now need input parameters: Differing baseline scenario now one treatment effect, two: Delta1 Delta2. input parameter Delta1 one got randomized controlled pilot trial team conducted earlier. value given standardized difference means (Œî=Œºcontro‚àíŒºexperœÉ\\Delta=\\frac{\\mu_{contro} - \\mu_{exper}}{\\sigma}) value determined 0.625. However, sure result, another research group conducted similar study got treatment effect 0.9, now value Delta2. course, choice Œî1\\Delta_1 Œî2\\Delta_2 need built two clinical studies, can also derived different sources forming prior belief, e.g.¬†clinical experience. now specify sure two prior beliefs Œî1\\Delta_1 Œî2\\Delta_2. done two additional parameters in1 in2. call parameters ‚Äúamount information‚Äù. refer sample sizes studies base prior beliefs. pilot study conducted 300 participants, value in1 set 300. Let‚Äôs assume study research group conducted 600 participants, parameter value in2 600. higher amount information, lower variance attribute prior belief. Now, weight parameter w defined, allows us weigh two treatment effects. want trust results , can set higher parameter value w. (Note w 0 1, parameter value 1 put weight results none results second study). think results group reliable reduce value w, thus putting weight Delta2. Note exchanging values Delta1 Delta2 (corresponding values in1 in2) setting wnew=1‚àíwoldw_{new} = 1 - w_{old} final results change. case, want put trust results thus set parameter w 0.6. Setting weight 11 effectively mean ignoring second treatment effect, also possible. prior distribution used package sum two truncated normal distributions. Hence, need truncation values lower boundary truncation b upper boundary. case set = 0.25 b = 0.75. prior distribution standardized true difference means given Œî‚àºw¬∑ùí©[0.25,0.75]t(0.625,4/300)+(1‚àíw)¬∑ùí©[0.25,0.75]t(0.9,4/600)\\Delta ‚àº w ¬∑ \\mathcal{N}^t_{[0.25,0.75]} (0.625, 4/300) + (1 ‚àí w) ¬∑ \\mathcal{N}^t_{[0.25,0.75]} (0.9, 4/600) N[,b]t(Œº,œÉ2)N^t_{[,b]} (\\mu, \\sigma^2) denotes truncated normal distribution mean Œº\\mu, variance œÉ2\\sigma^2, truncated b. see different input values change prior distribution refer Shiny app.","code":"res <- optimal_normal(Delta1 = 0.625, Delta2 = 0.8, fixed = FALSE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        w = 0.6, in1 = 300, in2 = 600, #weight and amount of information                        a = 0.25, b = 0.75) #truncation values"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"The example setting","what":"Interpreting the output","title":"Fixed effect estimates and prior distributions","text":"setting input parameters running function, let‚Äôs take look output program. program returns total thirteen values input values. , focus important ones: res$n2 optimal sample size phase II res$n3 resulting sample size phase III. see optimal scenario requires 80 participants phase II 188 participants phase III. number participants phases reduced compared setting fixed treatment effect. res$Kappa optimal threshold value go/-go decision rule. see need treatment effect 0.06 phase II order proceed phase III, baseline scenario. res$u expected utility program optimal sample size threshold value. case amounts 3147.32, .e.¬†expected utility 314 732 000$. 6.83% increase scenario without prior distribution. increase expected utility can attributed additional weight put second treatment effect Delta2, promising treatment effect. course, differences output values compared fixed setting heavily depend choice prior.","code":"res #> Optimization result: #>  Utility: 3147.32 #>  Sample size: #>    phase II: 80, phase III: 188, total: 268 #>  Probability to go to phase III: 0.99 #>  Total cost: #>    phase II: 69, phase III: 155, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.68, medium: 0.16, large: 0.01 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Parameters of the prior distribution:  #>    Delta1: 0.625, Delta2: 0.9, in1: 300, in2: 600, #>    a: 0.25, b: 0.75, w: 0.6 #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html","id":"prior-distributions-for-time-to-event-outcomes","dir":"Articles","previous_headings":"","what":"Prior distributions for time-to-event outcomes","title":"Fixed effect estimates and prior distributions","text":"Note setting time--event outcomes, following input parameters specified, differ setting normally distributed outcomes: Instead parameters in1 in2 ‚Äúamount information‚Äù, use parameters id1 id2 represent ‚Äúnumber events‚Äù. refer number events observed study determine treatment effect. study 210 events observed, value id1 set 210. assume assume study research group 420 events observed, parameter value id2 420. Moreover, need truncation values, .e.¬†values parameters b.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Fixed effect estimates and prior distributions","text":"tutorial explains use parameters needed prior distribution setting parameter fixed \"FALSE\". information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html","id":"the-example-setting-and-the-input-parameters","dir":"Articles","previous_headings":"","what":"The example setting and the input parameters","title":"Interpreting the rest of the output","text":"setting introduction, .e.¬†suppose developing new tumor treatment, exper. patient variable want investigate difference tumor width one-year visit baseline. normally distributed outcome variable. parameters insert function optimum_normal parameters also inserted basic setting. Thus, information input values refer Introduction. start loading drugdevelopR package. insert input values function optimal_normal:","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel res <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL) # setting all unneeded parameters to NULL"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"","what":"Interpreting the output","title":"Interpreting the rest of the output","text":"setting input parameters running function, let‚Äôs take look output program. program returns total thirteen values input values. now take closer look explain output values necessary detail: res$u expected utility program optimal sample size threshold value. case amounts 2946.07, .e.¬†expected utility 294 607 000$. function maximizes expected utility, highest expected utility one can receive given input parameters. res$Kappa optimal threshold value go/-go decision rule. see need treatment effect 0.06 phase II order proceed phase III. phase II get treatment effect 0.06, program deemed unsuccessful phase III trial conducted. threshold value, proceed phase III. res$n2 optimal sample size phase II res$n3 resulting sample size phase III. see optimal scenario requires 92 participants phase II 192 participants phase III. res$n sum res$n2 res$n3 refers total number participants. Note, one can set maximum number participants, leading constrained optimization. information, see article input parameters. res$pgo probability go phase III, coincides probability observed treatment effect optimal threshold value. case, get probability close one hence rounded 1. means can expect treatment effect 0.06 phase II hence, trial proceed phase III almost certainly. res$sProg probability whole program successful, .e.¬†proceed phase III observe positive treatment effect phase III. case probability successful program 0.85, trial input parameters successful 85% time. probability successful program subdivided probabilities small, medium large treatment effect. probability small treatment effect res$sProg1 0.72 case, medium treatment effect probability res$sProg2 0.12 large treatment effect probability res&$sProg3 0. treatment effects correspond benefit categories, probability 0.72 receive benefit 300,000,000$ . Due rounding, probabilities may add exactly overall probability successful program. Note one can set minimum probability successful program, leading constrained optimization. information, see article input parameters. final output parameters costs res$K2 phase II res$K3 phase III. costs phase II calculated c02+n2‚ãÖc2c_{02} + n_2\\cdot c_2 costs phase II calculated (c03+n3‚ãÖc3)‚ãÖpgo(c_{03} + n_3\\cdot c_3)\\cdot p_{go}, .e.¬†phase III expected costs returned. setting, costs 77 10^5$ (.e.¬†7,200,000$) phase II costs 158 10^5$(.e.¬†13,900,000) phase III. Note, one can set maximum cost limit K=K2+K3K=K_2+K_3 , leading constrained optimization. information, see article input parameters.","code":"res #> Optimization result: #>  Utility: 2946.07 #>  Sample size: #>    phase II: 92, phase III: 192, total: 284 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 77, phase III: 158, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.12, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Interpreting the rest of the output","text":"tutorial explains can interpret output generated program. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Introduction to planning phase II and phase III trials with drugdevelopR","text":"Suppose developing new tumor treatment, exper. patient variable want investigate difference tumor width one-year visit baseline. normally distributed outcome variable. Within drug development program, compare experimental treatment exper control treatment contro. Building available data, expect mean tumor difference amounts 20¬±1mm20¬±1 \\mathrm{mm} contro 15¬±1mm15¬±1 \\mathrm{mm} exper. Furthermore, variance assumed 8. treatment effect given standardized difference mean (Œî=Œºcontro‚àíŒºexperœÉ\\Delta=\\frac{\\mu_{contro} - \\mu_{exper}}{\\sigma}). Thus, obtain standardized treatment difference Œî1=0.625\\Delta_1 = 0.625.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Introduction to planning phase II and phase III trials with drugdevelopR","text":"installing package according installation instructions, can load using following code:","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html","id":"defining-all-necessary-parameters","dir":"Articles","previous_headings":"Applying the package to the example","what":"Defining all necessary parameters","title":"Introduction to planning phase II and phase III trials with drugdevelopR","text":"order apply package setting example, need specify following parameters: Delta1 assumed true treatment effect, defined standardized difference means treatment arm control arm. use value Œî1=0.625\\Delta_1 = 0.625 defined . now, assume treatment effects fixed independent prior distribution. Thus, set fixed = TRUE. n2min n2max specify minimal maximal number participants phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 400 participants. addition, tell program search region steps four participants time setting stepn2 = 4. kappamin kappamax specify minimal maximal threshold value go/-go decision rule. package search optimal threshold value within region. now, want program search interval 0.02 0.2 going steps stepkappa = 0.02. Note lower bound decision rule set represents smallest size treatment effect observed phase II allowing go phase III, can used model minimally clinically relevant effect size. c02 c03 fixed costs phase II phase III respectively. set phase II costs 15 phase III costs 20 (10510^5$), .e.¬†fixed costs 1 500 000$ phase II 2 000 000$ phase III. Note currency input values matter, input value c02 15 also interpreted fixed costs 1 500 000‚Ç¨ necessary. c2 c3 costs phase II phase III per patient. set 0.675 phase II 0.72 phase III. , values given 10510^5$, .e.¬†per patient costs 67 500$ phase II 72 000$ phase III. b1, b2 b3 expected small, medium large benefit categories successfully launching treatment market effect size category 10510^5$. define small benefit 3000, medium benefit 8000, large benefit 10000. effect size categories directly correspond treatment effect, .e.¬†treatment effect 0 0.5 (standardized differences mean) small treatment effect, hence yielding expected benefits drug development program 300 000 000$. alpha specified one-sided significance level. set alpha = 0.025. 1 - beta minimal power require drug development program. set beta = 0.1, meaning require power 90%. parameters: advanced settings, need pre-specify even parameters. now, can set remaining parameters NULL. use explained vignette parameters vigentte prior distributions. Now defined parameters needed example, ready feed package. use function optimal_normal(), calculates optimal sample size optimal threshold value normally distributed outcome variable.","code":"res <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # one-sided significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL) # setting all unneeded parameters to NULL"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Introduction to planning phase II and phase III trials with drugdevelopR","text":"setting input parameters running function, let‚Äôs take look output program. program returns total thirteen values input values. now, look important ones: res$n2 optimal sample size phase II res$n3 resulting sample size phase III. see optimal scenario requires 92 participants phase II 192 participants phase III. res$Kappa optimal threshold value go/-go decision rule. see need treatment effect 0.06 phase II order proceed phase III. res$u expected utility program optimal sample size threshold value. case amounts 2946.07, .e.¬†expected utility 294 607 000$.","code":"res #> Optimization result: #>  Utility: 2946.07 #>  Sample size: #>    phase II: 92, phase III: 192, total: 284 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 77, phase III: 158, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.12, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Introduction to planning phase II and phase III trials with drugdevelopR","text":"tutorial covered drugdevelopR‚Äôs basic setting. Luckily, package‚Äôs functionality extends multitude different settings. example doesn‚Äôt suit needs, can adapt specific setting: Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"the-example-setting-and-the-input-parameters","dir":"Articles","previous_headings":"","what":"The example setting and the input parameters","title":"More parameters to adapt to specific settings","text":"setting introduction, .e.¬†suppose developing new tumor treatment, exper. patient variable want investigate difference tumor width one-year visit baseline. normally distributed outcome variable. parameters insert function optimum_normal parameters also inserted basic setting. Thus, information input values refer introduction. start loading drugdevelopR package. Back , got following output: now want see different modifications, .e.¬†using parameters change outcome program.","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel res #> Optimization result: #>  Utility: 2946.07 #>  Sample size: #>    phase II: 92, phase III: 192, total: 284 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 77, phase III: 158, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.12, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"fixed-treatment-effect-estimates-or-prior-distributions","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Fixed treatment effect estimates or prior distributions","title":"More parameters to adapt to specific settings","text":"Setting parameter fixed FALSE models assumed true treatment effect using prior distribution. explained detail article Fixed effect estimates prior distributions.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"constrained-optimization","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Constrained optimization","title":"More parameters to adapt to specific settings","text":"three options include constrained optimization, setting maximum cost limits, setting maximum number participants demanding minimum probability successful program. options can applied separately combined, best suited specific needs.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"cost-constraint-maximum-total-costs","dir":"Articles","previous_headings":"The example setting and the input parameters > Constrained optimization","what":"Cost constraint ‚Äì maximum total costs","title":"More parameters to adapt to specific settings","text":"total costs given sum cost phase II phase III, .e.¬†K2K2 + K3K3. example get total costs 72+139=21172+139=211 (10^5 $). Let‚Äôs assume investor drug pharmaceutical company willing pay 20,000,000 $. can now set maximum cost constraint providing parameter value K = 200 optimum_normal function. default value K Inf. get following results: see due cost constraint cost phase II decreases 77 66 cost phase III decreases 158 133, overall constraint met. Moreover, expected utility optimum decreases 294 607 000 284 669 000 dollars.","code":"resK <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # one-sided significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL, # setting all unneeded parameters to NULL                        K = 200 # cost constraint                        ) resK #> Optimization result: #>  Utility: 2846.69 #>  Sample size: #>    phase II: 76, phase III: 158, total: 234 #>  Probability to go to phase III: 0.97 #>  Total cost: #>    phase II: 66, phase III: 133, cost constraint: 200 #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.82 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.7, medium: 0.11, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.18 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"sample-size-constraint-maximum-number-of-participants","dir":"Articles","previous_headings":"The example setting and the input parameters > Constrained optimization","what":"Sample size constraint ‚Äì maximum number of participants","title":"More parameters to adapt to specific settings","text":"similarly cost constraint, can set constraint maximum number participants trial. Without constraints, need total number 250 participants optimum. However, one can certainly imagine situation, 200 persons willing participate trial, example incidence illness high within target population. model , can easily set sample size constraint, case N = 200. allows optimal allocation participants phase II III. default value N Inf. get following results: Due sample size constraint optimal number participants phase II 48 150 phase III (92 192 respectively) within framework. expected utility optimum decreases 265 890 000$.","code":"resN <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL, # setting all unneeded parameters to NULL                        N = 200 # sample size constraint                        ) resN #> Optimization result: #>  Utility: 2658.9 #>  Sample size: #>    phase II: 48, phase III: 150, total: 198 #>  Probability to go to phase III: 0.93 #>  Total cost: #>    phase II: 47, phase III: 127, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.76 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.65, medium: 0.11, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.2 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"success-probability-constraint---minimum-probability-of-a-successful-program","dir":"Articles","previous_headings":"The example setting and the input parameters > Constrained optimization","what":"Success probability constraint - minimum probability of a successful program","title":"More parameters to adapt to specific settings","text":"last option provided constraint optimization minimum probability successful program. basic setting without constraints, probability program successful 0.85, .e.¬†probability 0.85 program proceed phase II phase III positive treatment effect detected phase III. Let‚Äôs say, willing higher costs return want probability 0.87. can include within framework, including parameter S setting S = 0.87. default value S -Inf. get following results: probability successful program now increased 0.85 0.87, mainly increasing number participants phase II. expected utility decreased 290 694 000 $.","code":"resS <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL, # setting all unneeded parameters to NULL                        S = 0.87 #minimum success probability                        ) resS #> Optimization result: #>  Utility: 2906.94 #>  Sample size: #>    phase II: 172, phase III: 138, total: 310 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 131, phase III: 119, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.87 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.76, medium: 0.11, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"customized-effect-size-categories","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Customized effect size categories","title":"More parameters to adapt to specific settings","text":"now, effect size categories small, medium large treatment effect predefined set 0‚àí0.50-0.5 small treatment effect, 0.5‚àí0.80.5-0.8 medium treatment effect ‚â•0.8\\geq 0.8 large treatment effect (standardized differences mean). parameter values taken Cohen (1988). However, one can easily customize effect size categories inserting threshold values effect size. Let‚Äôs say consider program successful treatment effect 0.1. Furthermore, want assign medium benefit treatment effect 0.6 1 large benefit treatment effect 1. Note one--one relation effect size categories benefit categories, .e.¬†large treatment effect corresponds large benefit . want implement scenario can defining parameters steps1, stepm1 stepl1. , set steps1 = 0.1, stepm1 = 0.6 stepl1 = 1.","code":"res <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL, # setting all unneeded parameters to NULL                        steps1 = 0.1, stepm1 = 0.6, stepl1 = 1 # step sizes for effect size categories                        )"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"differences-in-the-treatment-effect","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Differences in the treatment effect","title":"More parameters to adapt to specific settings","text":"Due different population structures phase II phase III, assumed true treatment effect Delta1 may phases. Phase III trials often conducted populations heterogeneous preceding phase II trials (Kirby et al., 2012), effect phase III may differ phase II. order model differences, one can use parameter gamma. treatment effect phase III calculated follows: Œî3=Œî2+Œ≥\\Delta_3 = \\Delta_2 + \\gamma. Values gamma zero indicate pessimistic view, values zero indicate optimistic view treatment effect confirmatory phase. default value gamma zero.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"skipping-phase-ii","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Skipping phase II","title":"More parameters to adapt to specific settings","text":"enough information available, one may decide skip phase II trial move directly confirmatory trial. can integrated framework using parameter skipII. set parameter TRUE, program calculates expected utility case phase II skipped compares situation phase II skipped. skipping phase II, assumed treatment effect used planning phase III trial calculated median prior distribution. results returned two-row data frame, res[1, ] results including phase II res[2, ] skipping phase II. default value skipII = FALSE. get following results: can seen case skipping phase II yields higher utility including phase II. Skipping phase II automatically sets n2 = O leads costs K2 = 0. Hence, overall costs smaller example. Furthermore, note optimal threshold value Kappa also automatically set -Inf probability go phase III pgo = 1, go phase III every time, skipping phase II.","code":"resII <- optimal_normal(Delta1 = 0.625, fixed = TRUE, # treatment effect                        n2min = 20, n2max = 400, # sample size region                        stepn2 = 4, # sample size step size                        kappamin = 0.02, kappamax = 0.2, # threshold region                        stepkappa = 0.02, # threshold step size                        c2 = 0.675, c3 = 0.72, # maximal total trial costs                        c02 = 15, c03 = 20, # maximal per-patient costs                        b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                        alpha = 0.025, # significance level                        beta = 0.1, # 1 - power                        Delta2 = NULL, w = NULL, in1 = NULL, in2 = NULL,                         a = NULL,b = NULL, # setting all unneeded parameters to NULL                        skipII = TRUE #skipping phase II                        ) resII #> Optimization result including phase II: #>  Utility: 2946.07 #>  Sample size: #>    phase II: 92, phase III: 192, total: 284 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 77, phase III: 158, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.12, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effect: 0.625 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  #> Result when skipping phase II: #>  Utility: 3080.46 #>  Sample size: #>    phase II: 0, phase III: 108, total: 108 #>  Probability to go to phase III: 1 #>  Total cost: #>    phase II: 0, phase III: 98, cost constraint: Inf #>  Fixed cost: #>    phase II: 0, phase III: 20 #>  Variable cost per patient: #>    phase II: 0, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.9 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.81, medium: 0.09, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: -Inf [Kappa]  #>  Assumed true effect: 0.62 [Delta]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  #> Skipping phase II is the optimal option with respect to the maximal expected utility."},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"parallel-computing","dir":"Articles","previous_headings":"The example setting and the input parameters","what":"Parallel computing","title":"More parameters to adapt to specific settings","text":"programs may long run-times, especial complex ones, faster computing enabled parallel programming. parameter num_cl allows set number cores parallel computing. advisable check number cores available using function detectCores(). default value num_cl = 1. Note using parameters change results, can decrease run-time.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"More parameters to adapt to specific settings","text":"tutorial presents parameters, can adapt program specific needs. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"More parameters to adapt to specific settings","text":"Cohen, J. (1988). Statistical power analysis behavioral sciences. Kirby, S., Burke, J., Chuang-Stein, C., Sin, C. (2012). Discounting phase 2 results planning phase 3 clinical trials. Pharmaceutical Statistics, 11(5):373‚Äì385.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Multiarm - methods for multi-arm programs","text":"Suppose developing new tumor treatment, exper. patient variable want investigate long patient survives without progression tumor (progression-free survival). time--event outcome variable. want test two different doses , exper1 exper2. Therefore, use function optimal_multiarm, calculates optimal sample sizes threshold decisions values time--event outcomes multi-arm trials conducted. Within drug development program, compare two experimental treatments exper1 exper2 control treatment contro. treatment effect measure given Œ∏=‚àílog(HR)\\theta = ‚àí\\log(HR), hazard ratio HRHR ratio hazards treatment control.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Multiarm - methods for multi-arm programs","text":"installing package according installation instructions, can load using following code:","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html","id":"defining-all-necessary-parameters","dir":"Articles","previous_headings":"Applying the package to the example","what":"Defining all necessary parameters","title":"Multiarm - methods for multi-arm programs","text":", parameters multi-arm setting differ slightly cases (bias adjustment multitrial), explain detail. Contrary basic setting, treatment effect always assumed fixed, option use prior distributions available. Nevertheless, options adapt program specific needs also available setting (see parameters), however, skipping phase II choosing different treatment effects phase II III possible. following parameters different basic setting, even names . hr1 hazard ratio first dose exper1. already explained , assume experimental treatment exper1 leads unfavorable events occurring 75% times compared control treatment contro. Therefore, set hr1 = 0.75. Analogously, hr2 hazard ratio second dose exper2. example, set hr2 = 0.8. ec control arm event rate phase II III, often unfavorable event occurs control group. assume 60% patients group contro unfavorable event, thus, set ec = 0.6. n2min n2max specify minimal maximal number participants phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 400 participants. addition, tell program search region steps ten participants time setting stepn2 = 10. different optimal_tte, region events (sample size region) searched. One parameter basic setting following parameter: parameter strategy allows user choose three strategies. One can select strategy = 1 best promising candidate two doses proceeds phase III, strategy = 2 promising candidates proceed phase III strategy = 3, strategies explored. example want explore settings, use strategy = 3. parameters identical basic setting. Let‚Äôs plug function:","code":"res <- optimal_multiarm(hr1 = 0.75, hr2 = 0.80, ec = 0.6, # define assumed true HRs and control arm event rate    n2min = 100, n2max = 200, stepn2 = 10,                 # define optimization set for n2    hrgomin = 0.76, hrgomax = 0.9, stephrgo = 0.02,        # define optimization set for HRgo    alpha = 0.025, beta = 0.1,                             # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,               # define fixed and variable costs for phase II and III    b1 = 1000, b2 = 2000, b3 = 3000,                       # gains for each effect size category    strategy = 3,                                              num_cl = 3)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Multiarm - methods for multi-arm programs","text":"setting input parameters running function, let‚Äôs take look output program. program returns data frame, output implemented strategies listed. strategy 1 (best promising proceeds phase III) get: res[1,]$n2 optimal number participants phase II res$n3 resulting number events phase III. see optimal scenario requires 140 participants phase II 393 participants phase III. res[1,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.82 phase II order proceed phase III. res[1,]$u expected utility program optimal sample size threshold value. case amounts 66.88, .e.¬†expected utility 6 688 000$. results strategy 2 (promising proceed phase III) : res[2,]$n2 optimal number participants phase II res$n3 resulting number events phase III. see optimal scenario requires 100 participants phase II 481 participants phase III. res[2,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.78 phase II order proceed phase III. res[2,]$u expected utility program optimal sample size threshold value. case amounts 56.6, .e.¬†expected utility 5 660 000$. Furthermore, consider return values sProg, sProg2 sProg3. Contrary basic setting, sProg2 probability successful program one treatment phase III (.e.¬†two arms) sProg3 probability successful program two treatments phase III (.e.¬†three arms). Hence, strategy 1 (promising treatment phase II proceeds phase III) sProg = sProg2 = 0.38. strategy 2 (promising treatments proceed phase III), success probability sProg sum probability treatments go phase III sProg3 = 0.22 probability one treatment proceeds phase III sProg2 = 0.18.","code":"res #> Optimization result where only the most promising candidate continues: #>  Utility: 66.88 #>  Sample size: #>    phase II: 140, phase III: 393, total: 533 #>  Probability to go to phase III: 0.75 #>  Total cost: #>    phase II: 205, phase III: 505, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.38 #>  Success probability for a trial with: #>    two arms in phase III: 0.38, three arms in phase III: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.82 [HRgo]  #>  Assumed true effects [HR]:  #>    treatment 1: 0.75,  treatment 2: 0.8 #>  Control arm event rate: 0.6 #>  #> Optimization result where all promising candidates continue: #>  Utility: 56.6 #>  Sample size: #>    phase II: 100, phase III: 481, total: 581 #>  Probability to go to phase III: 0.68 #>  Total cost: #>    phase II: 175, phase III: 583, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.4 #>  Success probability for a trial with: #>    two arms in phase III: 0.18, three arms in phase III: 0.22 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.78 [HRgo]  #>  Assumed true effects [HR]:  #>    treatment 1: 0.75,  treatment 2: 0.8 #>  Control arm event rate: 0.6"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Multiarm - methods for multi-arm programs","text":"article, presented example multi-arm trials conducted. Note example restricted time--event endpoints can also applied binary normally distributed endpoints using functions optimal_multiarm_binary optimal_multiarm_normal. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"only-one-endpoint-has-to-be-significant","dir":"Articles","previous_headings":"","what":"Only one endpoint has to be significant","title":"Multiple - methods for trials with multiple endpoints","text":"Suppose developing new tumor treatment, exper. two endpoints consider interesting overall survival (OS) progression-free survival (PFS). time--event outcome variables. Therefore, use function optimal_multiple_tte, calculates optimal sample sizes threshold decisions values time--event outcomes multiple endpoints investigated. Within drug development program, compare experimental treatment control treatment contro. treatment effect measure exper endpoint ‚àà{1,2}\\\\{1,2\\} given Œ∏i=‚àílog(HRi)\\theta_i = ‚àí\\log(HR_i), hazard ratio HRiHR_i ratio hazard rates experimental treatment control treatment, endpoint. information hazard ratio, see vignette time--event endpoints.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"defining-all-necessary-parameters","dir":"Articles","previous_headings":"Only one endpoint has to be significant","what":"Defining all necessary parameters","title":"Multiple - methods for trials with multiple endpoints","text":"parameters setting multiple endpoints differ slightly cases (bias adjustment multitrial). basic setting, treatment effect may fixed (example) may follow prior distribution (see Fixed Prior) Note case, contrary settings, second treatment effect describes effect second endpoint also relevant fixed = TRUE. Furthermore, options adapt program specific needs also available setting (see parameters), however skipping phase II choosing different treatment effects phase II III possible. hr1 assumed hazard ratio endpoint OS. hr2 assumed hazard ratio endpoint PFS. assume experimental treatment exper leads hazard reduction 80% compared control treatment contro endpoint OS reduction 75% PFS. Therefore, set hr1 = 0.8 hr2 = 0.75. n2min n2max specify minimal maximal number participants (events) phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 400 participants. addition, tell program search region steps ten participants time setting stepn2 = 10. Differing basis setting, one provide two sets benefits triples, one triple b11, b21, b31 case endpoint OS significant (independent PFS beiing significant ) one triple b12, b22, b32 case OS significant. intuition overall survival ‚Äúrelevant‚Äù endpoint, .e.¬†endpoints shows significant result, higher gains ‚Äúless important‚Äù endpoint PFS shows significant result. assign benefit triples {1000, 2000, 3000} case OS significant {1000, 1500, 2000} (units 10^5$). Finally, parameter rho determines correlation treatment effects two endpoints. case, set rho = 0.6, indicating correlation treatment effects OS PFS 0.6.","code":"set.seed(123) res1 <- optimal_multiple_tte(hr1 = 0.8, hr2 = 0.75,                   # define assumed true HRs                     id1 = NULL, id2 = NULL,                     n2min = 20, n2max = 400, stepn2 = 10,             # define optimization set for n2                     hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05,    # define optimization set for HRgo                     alpha = 0.025, beta = 0.1,                        # drug development planning parameters                     c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,          # define costs for phase II and III                     K = Inf, N = Inf, S = -Inf,                       # set constraints                     steps1 = 1,  stepm1 = 0.95,  stepl1 = 0.85,       # effect size categories                     b11 = 1000, b21 = 2000, b31 = 3000,                     b12 = 1000, b22 = 1500, b32 = 2000,               # define expected benefits (both categories)                     rho = 0.6, fixed = TRUE,                          # correlation and treatment effect                     num_cl = 2)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Only one endpoint has to be significant","what":"Interpreting the output","title":"Multiple - methods for trials with multiple endpoints","text":"setting input parameters running function, let‚Äôs take look output program. program returns data frame, following results: res1$n2 optimal number participants phase II res$n3 resulting number events phase III. see optimal scenario requires 90 participants phase II 301 participants phase III. res1$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.85 phase II order proceed phase III. res1$u expected utility program optimal sample size threshold value. case amounts 106.61, .e.¬†expected utility 10 661 000$. res1$OS probability endpoint OS significant, given program successful overall. probability successful program 0.4, thus, program successful probability endpoint OS significant obtain higher benefits 0.71.","code":"res1 #> Optimization result: #>  Utility: 106.61 #>  Sample size: #>    phase II: 90, phase III: 301, total: 391 #>  Probability to go to phase III: 0.79 #>  Total cost: #>    phase II: 168, phase III: 420, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories: #>   small: 1 medium: 0.95 large: 0.85 #>  Expected gains if endpoint 1 is significant: #>   small: 1000 medium: 2000 large: 3000 #>  Expected gains if only endpoint 2 is significant: #>   small: 1000 medium: 1500 large: 2000 #>  Success probability: 0.4 #>  Joint probability of success and observed effect of size ... in phase III: #>    medium: 0.21, large: 0.07 #>  Probability of endpoint 1 being significant in phase III: 0.71 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [HRgo]  #>  Assumed true effects [HR]:  #>    endpoint 1: 0.8,  endpoint2 2: 0.75 #>  Correlation between endpoints: 0.6"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"both-endpoints-have-to-be-significant","dir":"Articles","previous_headings":"","what":"Both endpoints have to be significant","title":"Multiple - methods for trials with multiple endpoints","text":"scenario, suppose developing new Alzheimer medication, exper. two endpoints consider interesting improving cognition (cognitive endpoint) improving activities daily living (functional endpoint). want outcomes show statistically significant differences trial successful. normally distributed outcome variables. Therefore, use function optimal_multiple_normal, calculates optimal sample sizes threshold decisions values normally distributed outcomes multiple endpoints investigated. Within drug development program, compare experimental treatment control treatment contro. treatment effect measure exper endpoint ‚àà{1,2}\\\\{1,2\\} given Œîi=Œºexper‚àíŒºcontro\\Delta_i = \\mu_{exper} - \\mu_{contro}, difference mean experimental treatment control treatment, endpoints. Note divided standard deviation, hence standardized. information, see vignette normally distributed outcomes.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"defining-all-necessary-parameters-1","dir":"Articles","previous_headings":"Both endpoints have to be significant","what":"Defining all necessary parameters","title":"Multiple - methods for trials with multiple endpoints","text":", parameters setting multiple endpoints differ slightly cases (bias adjustment multitrial). basic setting, treatment effect may fixed (example) may follow prior distribution (see Fixed Prior) Note, case, contrary settings, second treatment effect describes effect second endpoint also relevant fixed = TRUE. Furthermore, options adapt program specific needs also available setting (see parameters), however skipping phase II choosing different treatment effects phase II III possible. Delta1 assumed true treatment effect given difference means exper contro cognitive endpoint Delta2 assumed true treatment effect given difference means exper contro functional endpoint. assume true treatment effects 0.8 0.5 endpoint respectively, hence Delta1 = 0.8 Delta2 = 0.5. n2min n2max specify minimal maximal number participants phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 200 participants. addition, tell program search region steps ten participants time setting stepn2 = 10. include two parameters amount standard deviations œÉi\\sigma_i ‚àà{1,2}\\\\{1,2\\}. set sigma1 = 2 sigma2 = 1 example. parameter relaxed decides effect sizes two endpoints combined one overall effect size (large, medium small overall treatment effect). relaxed = FALSE , consider strict rule assigning large overall effect endpoints show effect large size, small overall effect least one endpoints shows small effect, medium overall effect otherwise. relaxed = TRUE, investigate characteristics relaxed rule assigning large overall effect least one endpoints shows large effect, small effect endpoints show small effect, medium overall effect otherwise. example, set relaxed = TRUE Finally, parameter rho determines correlation treatment effects two endpoints. case, set rho = 0.5, indicating correlation treatment effects 0.5.","code":"set.seed(123) res2 <- optimal_multiple_normal(Delta1 = 0.8, Delta2 = 0.5,  # define assumed true treatment effects    in1= NULL, in2= NULL, sigma1 = 2, sigma2= 1,              # standard deviations    n2min = 20, n2max = 200, stepn2 = 10,                     # define optimization set for n2    kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02,        # define optimization set for HRgo    alpha = 0.025, beta = 0.1,                                # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                  # define fixed and variable costs for phase II and III    K = Inf, N = Inf, S = -Inf,                               # set constraints    steps1 = 0,  stepm1 = 0.5, stepl1 = 0.8,                  # benefit categories    b1 = 1000, b2 = 2000, b3 = 3000,                          # define expected benefits     rho = 0.5, relaxed = TRUE,                                # relaxed \"TRUE\"    fixed = TRUE,                                             # fixed treatment effect     num_cl = 2)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"interpreting-the-output-1","dir":"Articles","previous_headings":"Both endpoints have to be significant","what":"Interpreting the output","title":"Multiple - methods for trials with multiple endpoints","text":"setting input parameters running function, let‚Äôs take look output program. program returns data frame, following results: res$n2 optimal number participants phase II res$n3 resulting number events phase III. see optimal scenario requires 120 participants phase II 171 participants phase III. res$Kappa optimal threshold value go/-go decision rule. see need hazard ratio less 0.02 phase II order proceed phase III. res$u expected utility program optimal sample size threshold value. case amounts 342.07, .e.¬†expected utility 34 207 000$.","code":"res2 #> Optimization result: #>  Utility: 342.07 #>  Sample size: #>    phase II: 120, phase III: 171, total: 291 #>  Probability to go to phase III: 0.98 #>  Total cost: #>    phase II: 190, phase III: 318, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 0 (1000), medium: 0.5 (2000), large: 0.8 (3000) #>  Success probability: 0.824 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.798, medium: 0.026, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.02 [Kappa]  #>  Assumed true effects [Delta]:  #>    endpoint 1: 0.8, endpoint 2: 0.5 #>  Correlation between endpoints: 0.5"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Multiple - methods for trials with multiple endpoints","text":"article presented examples multiple endpoints interest. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials multi-arm trials. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Multitrial - methods for programs with several phase III trials","text":"Suppose developing new tumor treatment, exper. patient variable want investigate long patient survives without progression disease (progression-free survival). time--event outcome variable. Therefore, use function optimal_multitrial, calculates optimal sample sizes threshold decisions values time--event outcomes several phase III trials performed. Within drug development program, compare experimental treatment exper control treatment contro. treatment effect measure given Œ∏=‚àílog(HR)\\theta = ‚àí\\log(HR), hazard ratio HRHR ratio hazard rates two groups. assume hazard experiencing progression reduced 75% treatment group compared control group, hazard ratio 0.75.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Multitrial - methods for programs with several phase III trials","text":"installing package according installation instructions, can load using following code: insert input values example time--event endpoints. basic setting, treatment effect may fixed follow prior distribution. Furthermore, options adapt program specific needs also available setting, however skipping phase II, setting predefined benefit categories choosing different treatment effects phase II III possible. package implements framework developed phase II/III drug development programs several phase III trials performed. particular relevance regulatory agencies often require statistical significance two phase III trials. Different cases, defined number significant trials needed approval, possible. case, different strategies possible. defined number phase III trials conducted order reach goal case. success drug development program, necessary treatment effects phase III trials point direction. example, select case 3 strategy 4, require four phase III trials, three need significant level Œ±\\alpha treatment effect fourth must point direction. following cases possible strategies implemented package. Note setting case = 1 strategy = 1 lead results basic setting. two special strategies marked * table: using strategy 23 (‚Äútwo+one‚Äù strategy) case 2, two phase III trials conducted. one shows significant positive treatment effect (trial‚Äôs treatment effect points least direction), third trial conducted. Setting strategy = 1 cases 2 3 leads situation one large phase III trial conducted adjusted significance level, .e.¬†Œ±new=Œ±2\\alpha_{new} = \\alpha^2 case 2 Œ±new=Œ±3\\alpha_{new} = \\alpha^3 case 3. feature implemented discussion larger trial adjusted significance level may also may serve evidence efficacy (see Koch (2005)). , addition parameters basic setting, provide following parameters: parameter case allows us chose number trials phase III show significant positive treatment effect whole program deemed successful. following example set parameter case = 3, indicating least two trials phase III show significant treatment effect phase III. parameter strategy defines number trials conducted phase III. strategies 1, 2, 3, 4 (23) implemented. Setting strategy = TRUE returns results optimization implemented strategies specific case. Note strategies implemented case (see table ). following example set strategy = TRUE. Note following example, input parameters changed compared basic setting order reduce computation time.","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel res <- optimal_multitrial(w = 0.3,                        # define parameters for prior    hr1 = 0.7, hr2 = 0.8, id1 = 210, id2 = 420,            # (https://web.imbi.uni-heidelberg.de/prior/)    d2min = 20, d2max = 200, stepd2 = 5,                   # define optimization set for d2    hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.02,         # define optimization set for HRgo    alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,       # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,               # define fixed and variable costs    K = Inf, N = Inf, S = -Inf,                            # set constraints    b1 = 1000, b2 = 2000, b3 = 3000,                       # define expected benefits    fixed = TRUE,                                          # choose if  effects are fixed or random    case = 3, strategy = TRUE                              # choose case and strategy    num_cl = 3)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Multitrial - methods for programs with several phase III trials","text":"setting input parameters running function, let‚Äôs take look output program. program returns data frame output implemented strategies listed. strategy 1 get: res[1,]$d2 optimal number events phase II res[1,]$d3 resulting number events phase III. see optimal scenario requires 20 events phase II 258 events phase III, correspond 30 participants phase II 368 phase III. res[1,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.76 phase II order proceed phase III. res[1,]$u expected utility program optimal sample size threshold value. case amounts -231.07, .e.¬†expected utility -23 107 000$. Note input parameter alpha returned value 0.000016, corresponds adjusted significance level Œ±3\\alpha^3. results strategy 3 : res[2,]$d2 optimal number events phase II res[2,]$d3 resulting number events phase III. see optimal scenario requires 20 events phase II 180 events phase III, leads 30 participants phase II 258 phase III. corresponds three trials phase III trial 86 participants. res[2,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.7 phase II order proceed phase III. res[2,]$u expected utility program optimal sample size threshold value. case amounts -411.1, .e.¬†expected utility -41 110 000$. Strategy 4 yields following results: res[3,]$d2 optimal number events phase II res[3,]$d3 resulting number events phase III. see optimal scenario requires 40 events phase II 292 events phase III, leads 58 participants phase II 416 phase III. corresponds four trials phase III trial 104 participants. res[3,]$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.70 phase II order proceed phase III. res[3,]$u expected utility program optimal sample size threshold value. case amounts -436.79, .e.¬†expected utility -43 679 000$.","code":"res #> Optimization result with 3 significant trial(s) needed, strategy 1: #>  Utility: -231.07 #>  Sample size: #>    phase II: 30, phase III: 368, total: 398 #>  Expected number of events: #>    phase II: 20, phase III: 258, total: 278 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.57 #>  Total cost: #>    phase II: 122, phase III: 454, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.19 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.06, medium: 0.11, large: 0.02 #>  Significance level: 1.5625e-05 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.76 [HRgo]  #>  Assumed true effect: 0.7 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  #> Optimization result with 3 significant trial(s) needed, strategy 3: #>  Utility: -411.1 #>  Sample size: #>    phase II: 30, phase III: 258, total: 288 #>  Expected number of events: #>    phase II: 20, phase III: 180, total: 200 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.5 #>  Total cost: #>    phase II: 122, phase III: 483, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.08 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0, medium: 0.05, large: 0.03 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.7 [HRgo]  #>  Assumed true effect: 0.7 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  #> Optimization result with 3 significant trial(s) needed, strategy 4: #>  Utility: -436.79 #>  Sample size: #>    phase II: 58, phase III: 416, total: 474 #>  Expected number of events: #>    phase II: 40, phase III: 292, total: 332 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.5 #>  Total cost: #>    phase II: 144, phase III: 716, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.2 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0, medium: 0.17, large: 0.02 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.7 [HRgo]  #>  Assumed true effect: 0.7 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Multitrial - methods for programs with several phase III trials","text":"article presented example several phase III trials conducted. Note example restricted time--event endpoints can also applied binary normally distributed endpoints using functions optimal_multitrial_binary optimal_multitrial_normal. information use package, see: Introduction drugdevelopR: See package works basic example. Different outcomes: Apply binary endpoints time--event endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"Multitrial - methods for programs with several phase III trials","text":"Koch, G. G. (2005). Statistical consideration strategy demonstrating clinical evidence effectiveness one larger vs two smaller pivotal studies z. shun, e. chi, s. durrleman l. fisher, statistics medicine 2005; 24: 1619‚Äì1637. Statistics Medicine, 24(11):1639‚Äì1646.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Package_validation.html","id":"guide-to-running-the-validation-suite","dir":"Articles","previous_headings":"","what":"Guide to running the validation suite","title":"Package validation","text":"validation report compiled using fork PHUSE‚Äôs valtools package. recommend using fork bugs fixed features added. changes yet merged package‚Äôs main repository. can installed running following command: next step, download source files current drugdevelopR project. Extract folder navigate using RStudio. Install package source using following command: , open file ./validation/validation.Rmd RStudio use Knit button compiling report. may take long time due long runtime test codes. used 12 cores RStudio server, took 93.5 hours (.e.¬†almost four days) complete.","code":"devtools::install_github(\"LukasDSauer/valtools\") devtools::install()"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Package_validation.html","id":"adding-a-signature-page","dir":"Articles","previous_headings":"","what":"Adding a signature page","title":"Package validation","text":"need signature page within report, proceed follows: Open file ./validation/validation.yml replace names names responsible persons facility. Open file ./validation/validation.Rmd uncomment section ## Certifications {-} subsection (approx. 20 lines code). Knit document explained .","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Package_validation.html","id":"references","dir":"Articles","previous_headings":"","what":"References","title":"Package validation","text":"FDA, US Food Drug Administration (2003): Guidance Industry Part 11. https://www.fda.gov/media/75414/download. Ellis Hughes PHUSE Data Visualisation & Open Source Technology Working Group (2021): White Paper 059. R Package Validation Framework. https://advance.phuse.global/display/WEL/R+Package+Validation+Framework.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html","id":"the-example-setting","dir":"Articles","previous_headings":"","what":"The example setting","title":"Time-to-event outcome variables","text":"Suppose developing new tumor treatment, exper. patient variable want investigate long patient survives without progression tumor (progression-free survival). time--event outcome variable. Within drug development program, compare experimental treatment exper control treatment contro. treatment effect measure given Œ∏=‚àílog(HR)\\theta = ‚àí\\log(HR), negative logarithm hazard ratio HRHR, turn ratio hazard rates. hazard ratio little difficult understand. hazard ratio 0.75 mean momentary rate experiencing (‚Äúhazard‚Äù) point time reduced 75% experimental group.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html","id":"applying-the-package-to-the-example","dir":"Articles","previous_headings":"","what":"Applying the package to the example","title":"Time-to-event outcome variables","text":"installing package according installation instructions, can load using following code:","code":"library(drugdevelopR) #> Loading required package: doParallel #> Loading required package: foreach #> Loading required package: iterators #> Loading required package: parallel"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html","id":"defining-all-necessary-parameters","dir":"Articles","previous_headings":"Applying the package to the example","what":"Defining all necessary parameters","title":"Time-to-event outcome variables","text":"order apply package setting example, need specify following parameters: hr1 hazard ratio. already explained , assume experimental treatment exper leads hazard reduced 75% compared control treatment contro. Therefore, set hr1 = 0.75. now, model hazard ratio prior distribution. Thus, set fixed = TRUE. d2min d2max specify minimal maximal number events phase II trial. package search optimal sample size within region. now, want program search optimal sample size interval 20 400 events. addition, tell program search region steps four participants time setting stepd2 = 4. hrgomin hrgomax specify minimal maximal threshold value go/-go decision rule terms negative logarithm hazard ratio. package search optimal threshold value within region. now, want program search interval 0.7 0.9 going steps stephrgo = 0.01. Note lower bound decision rule set represents smallest size treatment effect observed phase II allowing go phase III, can used model minimally clinically relevant effect size. Moreover, note interval specified corresponds set {‚àílog(0.9),...,‚àílog(0.7)}\\{-\\log(0.9), ..., -\\log(0.7)\\}. xi2 xi3 correspond event rates phase II phase III. calculating optimal number events d2 d3, event rates used calculate optimal sample sizes phase II III. assume event rates 0.7 phase, indicating 70 events correspond optimal sample size 100, respectively. c02 c03 fixed costs phase II phase III respectively. set phase II costs 100 phase III costs 150 (10510^5$), .e.¬†fixed costs 10 000 000$ phase II 15 000 000$ phase III. Note currency input values matter, input value c02 15 also interpreted fixed costs 1 500 000‚Ç¨ necessary. c2 c3 costs phase II phase III per patient. set 0.75 phase II 0.1 phase III. , values given 10510^5$, .e.¬†per patient costs 75 000$ phase II 100 000$ phase III. b1, b2 b3 expected small, medium large benefit categories successfully launching treatment market effect size category 10510^5$. define small benefit 1000, medium benefit 2000, large benefit 3000. effect size categories directly correspond treatment effect: example, treatment effect 1 0.95 (terms risk ratio) small treatment effect yielding expected benefit 100 000 000$. alpha specified one-sided significance level. set alpha = 0.025. 1 - beta minimal power require drug development program. set beta = 0.1, meaning require power 90%. setting normally distributed outcomes, treatment effect may fixed (example) may distributed respect prior distribution. Furthermore, options adapt program specific needs also available setting. Now defined parameters needed example, ready feed package. use function optimal_tte(), calculates optimal sample size optimal threshold value time--event outcome variable.","code":"res <- optimal_tte(w = 0.3,                               # define parameters for prior    hr1 = 0.75, hr2 = 0.8, id1 = 210, id2 = 420,           # (https://web.imbi.uni-heidelberg.de/prior/)    d2min = 20, d2max = 400, stepd2 = 5,                   # define optimization set for d2    hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.01,         # define optimization set for HRgo    alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,        # drug development planning parameters    c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,               # define fixed and variable costs    K = Inf, N = Inf, S = -Inf,                            # set constraints    steps1 = 1,  stepm1 = 0.95, stepl1 = 0.85,             # define boundary for  effect size categories    b1 = 1000, b2 = 2000, b3 = 3000,                       # define expected benefits    gamma = 0,                                             # assume different/same population structures     fixed = TRUE,                                          # choose if  effects are fixed or random    skipII = FALSE,                                        # more parameters    num_cl = 1)"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html","id":"interpreting-the-output","dir":"Articles","previous_headings":"Applying the package to the example","what":"Interpreting the output","title":"Time-to-event outcome variables","text":"setting input parameters running function, let‚Äôs take look output program. program returns total sixteen output values input parameters. now, look important ones: res$d2 optimal number events phase II res$d3 resulting number events phase III. see optimal scenario requires 165 events phase II 430 events phase III, correspond 236 participants phase II 614 phase III. res$HRgo optimal threshold value go/-go decision rule. see need hazard ratio less 0.86 phase II order proceed phase III. res$u expected utility program optimal sample size threshold value. case amounts 377.1, .e.¬†expected utility 37 710 000$.","code":"res #> Optimization result: #>  Utility: 377.1 #>  Sample size: #>    phase II: 236, phase III: 614, total: 850 #>  Expected number of events: #>    phase II: 165, phase III: 430, total: 595 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.81 #>  Total cost: #>    phase II: 277, phase III: 736, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.62 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.09, medium: 0.29, large: 0.24 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.86 [HRgo]  #>  Assumed true effect: 0.75 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html","id":"where-to-go-from-here","dir":"Articles","previous_headings":"","what":"Where to go from here","title":"Time-to-event outcome variables","text":"article introduced setting, outcome time--event variable. information use package, see: Introduction drugdevelopR: See package works basic normally distributed example. Different outcomes: Apply binary endpoints. Interpreting rest output: Obtain details drug development program. Fixed prior: Model assumed treatment effect prior distribution. parameters: Define custom effect size categories. Put constraints optimization defining maximum costs, total expected sample size program minimum expected probability successful program. Define expected difference treatment effect phase II III. Skip phase II. Complex drug development programs: Adapt situations biased effect estimators, multiple phase III trials, multi-arm trials, multiple endpoints. Parallel computing: faster calculating optimum using parallel computing.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Stella Erdmann. Author. Johannes Cepicka. Author. Marietta Kirchner. Author. Meinhard Kieser. Author. Lukas D. Sauer. Author, maintainer.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Erdmann S, Cepicka J, Kirchner M, Kieser M, Sauer L (2025). drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning. R package version 1.0.2, https://sterniii3.github.io/drugdevelopR/, https://github.com/Sterniii3/drugdevelopR.","code":"@Manual{,   title = {drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning},   author = {Stella Erdmann and Johannes Cepicka and Marietta Kirchner and Meinhard Kieser and Lukas D. Sauer},   year = {2025},   note = {R package version 1.0.2,     https://sterniii3.github.io/drugdevelopR/},   url = {https://github.com/Sterniii3/drugdevelopR}, }"},{"path":"https://sterniii3.github.io/drugdevelopR/index.html","id":"drugdevelopr-utility-based-optimal-phase-iiiii-drug-development-planning","dir":"","previous_headings":"","what":"Utility-Based Optimal Phase II/III Drug Development Planning","title":"Utility-Based Optimal Phase II/III Drug Development Planning","text":"drugdevelopR package enables plan phase II/III drug development programs optimal sample size allocation go/-go decision rules. assumed true treatment effects can fixed modelled prior distribution. corresponding R Shiny application graphic user interface thus makes accessible users without prior knowledge R. Fast computing made possible parallel programming. Theoretical foundations package laid dissertation ‚ÄúIntegrated Planning Pilot Subsequent Confirmatory Study Clinical Research ‚Äì Finding Optimal Designs Utility-Based Framework‚Äù Stella Erdmann Institute Medical Biometry University Heidelberg. package webpage, supply full documentation functions well tutorial getting started drugdevelopR.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Utility-Based Optimal Phase II/III Drug Development Planning","text":"Install development version package directly GitHub using following code: access drugdevelopR App via https://web.imbi.uni-heidelberg.de/drugdevelopR/.","code":"if(!require(devtools)) { install.packages(\"devtools\"); require(devtools)}  devtools::install_github(\"Sterniii3/drugdevelopR\")"},{"path":"https://sterniii3.github.io/drugdevelopR/index.html","id":"usage","dir":"","previous_headings":"","what":"Usage","title":"Utility-Based Optimal Phase II/III Drug Development Planning","text":"basic example applying drugdevelopR drug development program normally distributed outcome:","code":"library(drugdevelopR) #> Lade n√∂tiges Paket: doParallel #> Lade n√∂tiges Paket: foreach #> Lade n√∂tiges Paket: iterators #> Lade n√∂tiges Paket: parallel #> Lade n√∂tiges Paket: progressr # Optimize optimal_normal(Delta1 = 0.625, Delta2 = 0.8, fixed = FALSE, # treatment effect                n2min = 20, n2max = 400, # sample size region                stepn2 = 4, # sample size step size                kappamin = 0.02, kappamax = 0.2, # threshold region                stepkappa = 0.02, # threshold step size                c2 = 0.675, c3 = 0.72, # maximal total trial costs                c02 = 15, c03 = 20, # maximal per-patient costs                b1 = 3000, b2 = 8000, b3 = 10000, # gains for patients                alpha = 0.025, # one-sided significance level                beta = 0.1, # 1 - power                w = 0.6, in1 = 300, in2 = 600, # weight and amount of information                a = 0.25, b = 0.75) # truncation values #> Optimization result: #>  Utility: 3073.85 #>  Sample size: #>    phase II: 84, phase III: 194, total: 278 #>  Probability to go to phase III: 0.99 #>  Total cost: #>    phase II: 72, phase III: 160, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.85 #>  Success probability by effect size: #>    small: 0.69, medium: 0.15, large: 0.01 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Parameters of the prior distribution:  #>    Delta1: 0.625, Delta2: 0.8, in1: 300, in2: 600, #>    a: 0.25, b: 0.75, w: 0.6 #>  Treatment effect offset between phase II and III: 0 [gamma]"},{"path":"https://sterniii3.github.io/drugdevelopR/index.html","id":"drugdevelopr-functions","dir":"","previous_headings":"","what":"drugdevelopR functions","title":"Utility-Based Optimal Phase II/III Drug Development Planning","text":"drugdevelopR package provides functions optimal_tte, optimal_binary, optimal_normal plan optimal phase II/III drug development programs time--event (treatment effect measured hazard ratio, HR), binary (treatment effect measured risk ratio, RR), normally distributed (treatment effect measured standardized difference means, Delta) endpoints, treatment effect modelled prior distribution. Optimal phase II/III drug development planning fixed treatment effects can done help R Shiny application basic. Extensions basic setting : optimal planning programs including methods discounting phase II results (function: optimal_bias, App: bias), optimal planning programs several phase III trials (function: optimal_multitrial, App: multitrial) optimal planning programs multiple arms (function: optimal_multiarm, App: multiarm).","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","title":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","text":"function EPsProg23() calculates expected probability successful program time--event setting. function follows special decision rule order determine whether two three phase III trials conducted. First, two phase III trials performed. Depending success, decision third phase III trial made: trials successful, third phase III trial conducted. one two trials successful trial treatment effect points direction, third phase III trial conducted sample size N3 = N3(ymin), depends assumed minimal clinical relevant effect (ymin). third trial significant level alpha one two trials successful treatment effect points opposite direction none two trials successful, third trial performed drug development development program successful. utility function, lead utility -9999.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","text":"","code":"EPsProg23(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2, case, size, ymin)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","text":"HRgo threshold value go/-go decision rule d2 total number events phase II alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events case choose case: \"least 1, 2 3 significant trials needed approval\" size size category \"small\", \"medium\" \"large\" ymin assumed minimal clinical relevant effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","text":"output function EPsProg23() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program deciding between two or three phase III trials in a time-to-event setting ‚Äî EPsProg23","text":"","code":"res <- EPsProg23(HRgo = 0.8, d2 = 50,  alpha = 0.025, beta = 0.1,                                    w = 0.3, hr1 =  0.69, hr2 = 0.81,                                    id1 = 280, id2 = 420, case = 2, size = \"small\",                                   ymin = 0.5)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","title":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","text":"function EPsProg23_binary() calculates expected probability successful program normally distributed outcome. function follows special decision rule order determine whether two three phase III trials conducted. First, two phase III trials performed. Depending success, decision third phase III trial made: trials successful, third phase III trial conducted. one two trials successful trial treatment effect points direction, third phase III trial conducted sample size N3 = N3(ymin), depends assumed minimal clinical relevant effect (ymin). third trial significant level alpha one two trials successful treatment effect points opposite direction none two trials successful, third trial performed drug development development program successful. utility function, lead utility -9999.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","text":"","code":"EPsProg23_binary(   RRgo,   n2,   alpha,   beta,   w,   p0,   p11,   p12,   in1,   in2,   case,   size,   ymin )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size case choose case: \"least 1, 2 3 significant trials needed approval\" size size category \"small\", \"medium\" \"large\" ymin assumed minimal clinical relevant effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","text":"output function EPsProg23_binary() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program deciding between two or three phase III trials for a binary distributed outcome ‚Äî EPsProg23_binary","text":"","code":"res <- EPsProg23_binary(RRgo = 0.8, n2 = 50,  alpha = 0.025, beta = 0.1,                                   w = 0.6,  p0 = 0.3, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, case = 2, size = \"small\",                                  ymin = 0.5)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","title":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","text":"function EPsProg23_normal() calculates expected probability successful program normally distributed outcome. function follows special decision rule order determine whether two three phase III trials conducted. First, two phase III trials performed. Depending success, decision third phase III trial made: trials successful, third phase III trial conducted. one two trials successful trial treatment effect points direction, third phase III trial conducted sample size N3 = N3(ymin), depends assumed minimal clinical relevant effect (ymin). third trial significant level alpha one two trials successful treatment effect points opposite direction none two trials successful, third trial performed drug development development program successful. utility function, lead utility -9999.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","text":"","code":"EPsProg23_normal(   kappa,   n2,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   case,   size,   ymin )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta type II error rate; means 1 - beta power calculating sample size phase III w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation case number significant trials needed approval; possible values 2 3 function size effect size category; possible values \"small\", \"medium\", \"large\" \"\" ymin assumed minimal clinical relevant effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","text":"output function EPsProg23_normal() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg23_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program deciding between two or three phase III trials for a normally distributed outcome ‚Äî EPsProg23_normal","text":"","code":"EPsProg23_normal(kappa = 0.1, n2 = 50, alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   case = 2, size = \"small\", ymin = 0.5) #> [1] 0.5443622"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","title":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use following functions, describe specific case: EPsProg_L(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment EPsProg_L2(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment EPsProg_R(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment EPsProg_R2(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","text":"","code":"EPsProg_L(   HRgo,   d2,   Adj,   alpha,   beta,   step1,   step2,   w,   hr1,   hr2,   id1,   id2,   fixed )  EPsProg_L2(   HRgo,   d2,   Adj,   alpha,   beta,   step1,   step2,   w,   hr1,   hr2,   id1,   id2,   fixed )  EPsProg_R(   HRgo,   d2,   Adj,   alpha,   beta,   step1,   step2,   w,   hr1,   hr2,   id1,   id2,   fixed )  EPsProg_R2(   HRgo,   d2,   Adj,   alpha,   beta,   step1,   step2,   w,   hr1,   hr2,   id1,   id2,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","text":"HRgo threshold value go/-go decision rule d2 total events phase II; must even number Adj adjustment parameter alpha significance level beta 1-beta power calculation sample size phase III step1 lower boundary effect size step2 upper boundary effect size w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","text":"output functions EPsProg_L(), EPsProg_L2(), EPsProg_R() EPsProg_R2() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for bias adjustment programs with time-to-event outcomes ‚Äî EPsProg_bias","text":"","code":"res <- EPsProg_L(HRgo = 0.8, d2 = 50, Adj = 0.4,                             alpha = 0.025, beta = 0.1,                             step1 = 1, step2 = 0.95,                             w = 0.3, hr1 = 0.69, hr2 = 0.81,                            id1 = 280, id2 = 420, fixed = FALSE)           res <- EPsProg_L2(HRgo = 0.8, d2 = 50, Adj = 0.4,                             alpha = 0.025, beta = 0.1,                             step1 = 1, step2 = 0.95,                             w = 0.3, hr1 = 0.69, hr2 = 0.81,                            id1 = 280, id2 = 420, fixed = FALSE)           res <- EPsProg_R(HRgo = 0.8, d2 = 50, Adj = 0.9,                             alpha = 0.025, beta = 0.1,                             step1 = 1, step2 = 0.95,                             w = 0.3, hr1 = 0.69, hr2 = 0.81,                            id1 = 280, id2 = 420, fixed = FALSE)           res <- EPsProg_R2(HRgo = 0.8, d2 = 50, Adj = 0.9,                             alpha = 0.025, beta = 0.1,                             step1 = 1, step2 = 0.95,                             w = 0.3, hr1 = 0.69, hr2 = 0.81,                            id1 = 280, id2 = 420, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","title":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use following functions, describe specific case: EPsProg_binary_L(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment EPsProg_binary_L2(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment EPsProg_binary_R(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment EPsProg_binary_R2(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","text":"","code":"EPsProg_binary_L(   RRgo,   n2,   Adj,   alpha,   beta,   step1,   step2,   p0,   w,   p11,   p12,   in1,   in2,   fixed )  EPsProg_binary_L2(   RRgo,   n2,   Adj,   alpha,   beta,   step1,   step2,   p0,   w,   p11,   p12,   in1,   in2,   fixed )  EPsProg_binary_R(   RRgo,   n2,   Adj,   alpha,   beta,   step1,   step2,   p0,   w,   p11,   p12,   in1,   in2,   fixed )  EPsProg_binary_R2(   RRgo,   n2,   Adj,   alpha,   beta,   step1,   step2,   p0,   w,   p11,   p12,   in1,   in2,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter alpha significance level beta 1-beta power calculation sample size phase III step1 lower boundary effect size step2 upper boundary effect size p0 assumed true rate control group w weight mixture prior distribution p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size fixed choose true treatment effects fixed random, TRUE p11 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","text":"output functions EPsProg_binary_L(), EPsProg_binary_L2(), EPsProg_binary_R() EPsProg_binary_R2() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for bias adjustment programs with binary distributed outcomes ‚Äî EPsProg_bias_binary","text":"","code":"res <- EPsProg_binary_L(RRgo = 0.8, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1,                                   step1 = 1, step2 = 0.95, p0 = 0.6,  w = 0.3,                                  p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                   fixed = FALSE)           res <- EPsProg_binary_L2(RRgo = 0.8, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1,                                   step1 = 1, step2 = 0.95, p0 = 0.6,  w = 0.3,                                  p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                   fixed = FALSE)           res <- EPsProg_binary_R(RRgo = 0.8, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1,                                   step1 = 1, step2 = 0.95, p0 = 0.6,  w = 0.3,                                  p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                   fixed = FALSE)           res <- EPsProg_binary_R2(RRgo = 0.8, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1,                                   step1 = 1, step2 = 0.95, p0 = 0.6,  w = 0.3,                                  p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                   fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","title":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use following functions, describe specific case: EPsProg_normal_L(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment EPsProg_normal_L2(): calculates expected probability successful additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment EPsProg_normal_R(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment EPsProg_normal_R2(): calculates expected probability successful multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","text":"","code":"EPsProg_normal_L(   kappa,   n2,   Adj,   alpha,   beta,   step1,   step2,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  EPsProg_normal_L2(   kappa,   n2,   Adj,   alpha,   beta,   step1,   step2,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  EPsProg_normal_R(   kappa,   n2,   Adj,   alpha,   beta,   step1,   step2,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  EPsProg_normal_R2(   kappa,   n2,   Adj,   alpha,   beta,   step1,   step2,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter alpha significance level beta 1-beta power calculation sample size phase III step1 lower boundary effect size step2 upper boundary effect size w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","text":"output functions EPsProg_normal_L(), EPsProg_normal_L2(), EPsProg_normal_R() EPsProg_normal_R2() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_bias_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for bias adjustment programs with normally distributed outcomes ‚Äî EPsProg_bias_normal","text":"","code":"res <- EPsProg_normal_L(kappa = 0.1, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  step1 = 0, step2 = 0.5,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75, fixed = FALSE)           res <- EPsProg_normal_L2(kappa = 0.1, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  step1 = 0, step2 = 0.5,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75, fixed = FALSE)           res <- EPsProg_normal_R(kappa = 0.1, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  step1 = 0, step2 = 0.5,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75, fixed = FALSE)           res <- EPsProg_normal_R2(kappa = 0.1, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  step1 = 0, step2 = 0.5,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for multiple endpoints and normally distributed outcomes ‚Äî EPsProg_multiple_normal","title":"Expected probability of a successful program for multiple endpoints and normally distributed outcomes ‚Äî EPsProg_multiple_normal","text":"function calculates probability drug development program successful. Successful defined endpoints showing statistically significant positive treatment effect phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for multiple endpoints and normally distributed outcomes ‚Äî EPsProg_multiple_normal","text":"","code":"EPsProg_multiple_normal(   kappa,   n2,   alpha,   beta,   Delta1,   Delta2,   sigma1,   sigma2,   step11,   step12,   step21,   step22,   in1,   in2,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for multiple endpoints and normally distributed outcomes ‚Äî EPsProg_multiple_normal","text":"kappa threshold value go/-go decision rule; n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint step11 lower boundary effect size first endpoint step12 lower boundary effect size second endpoint step21 upper boundary effect size first endpoint step22 upper boundary effect size second endpoint in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for multiple endpoints and normally distributed outcomes ‚Äî EPsProg_multiple_normal","text":"output function EPsProg_multiple_normal() expected probability successfull program, going phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for multiple endpoints in a time-to-event setting ‚Äî EPsProg_multiple_tte","title":"Expected probability of a successful program for multiple endpoints in a time-to-event setting ‚Äî EPsProg_multiple_tte","text":"function calculates probability drug development program successful. Successful defined least one endpoint showing statistically significant positive treatment effect phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for multiple endpoints in a time-to-event setting ‚Äî EPsProg_multiple_tte","text":"","code":"EPsProg_multiple_tte(   HRgo,   n2,   alpha,   beta,   ec,   hr1,   hr2,   id1,   id2,   step1,   step2,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for multiple endpoints in a time-to-event setting ‚Äî EPsProg_multiple_tte","text":"HRgo threshold value go/-go decision rule; n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III ec control arm event rate phase II III hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms sample size id2 amount information hr2 terms sample size step1 lower boundary effect size step2 upper boundary effect size fixed choose true treatment effects fixed random rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for multiple endpoints in a time-to-event setting ‚Äî EPsProg_multiple_tte","text":"output function EPsProg_multiple_tte() expected probability successful program, going phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"functions calculate expected probability successful program given parameters. function represents specific strategy, e.g. function EpsProg3() calculates expected probability three phase III trials performed. parameter case specifies many trials successful, .e. many trials show significantly relevant positive treatment effect.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"","code":"EPsProg2(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2, case, size, fixed)  EPsProg3(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2, case, size, fixed)  EPsProg4(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2, case, size, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"HRgo threshold value go/-go decision rule d2 total number events phase II alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events case choose case: \"least 1, 2 3 significant trials needed approval\" size size category \"small\", \"medium\" \"large\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"output function EPsProg2(), EPsProg3() EPsProg4() expected probability successful program performing several phase III trials (2, 3 4 respectively)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"following cases can investigated software: Two phase III trials Case 1: Strategy 1/2; least one trial significant, treatment effect one least showing direction Case 2: Strategy 2/2; trials significant Three phase III trials Case 2: Strategy 2/3; least two trials significant, treatment effect one least showing direction Case 3: Strategy 3/3; trials significant Four phase III trials Case 3: Strategy 3/4; least three trials significant, treatment effect one least showing direction","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for multitrial programs in a time-to-event setting ‚Äî EPsProg_multitrial","text":"","code":"EPsProg2(HRgo = 0.8, d2 = 50,  alpha = 0.025, beta = 0.1,                                   w = 0.3, hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420, case = 2, size = \"small\",                                  fixed = FALSE) #> [1] 0.03607598           EPsProg3(HRgo = 0.8, d2 = 50,  alpha = 0.025, beta = 0.1,                                   w = 0.3, hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420, case = 2, size = \"small\",                                  fixed = TRUE) #> [1] 0.02454443           EPsProg4(HRgo = 0.8, d2 = 50,  alpha = 0.025, beta = 0.1,                                   w = 0.3, hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420, case = 3, size = \"small\",                                  fixed = TRUE) #> [1] 0.003566271"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"functions calculate expected probability successful program given parameters. function represents specific strategy, e.g. function EpsProg3_binary() calculates expected probability three phase III trials performed. parameter case specifies many trials successful, .e. many trials show significantly relevant positive treatment effect.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"","code":"EPsProg2_binary(   RRgo,   n2,   alpha,   beta,   p0,   w,   p11,   p12,   in1,   in2,   case,   size,   fixed )  EPsProg3_binary(   RRgo,   n2,   alpha,   beta,   p0,   w,   p11,   p12,   in1,   in2,   case,   size,   fixed )  EPsProg4_binary(   RRgo,   n2,   alpha,   beta,   p0,   w,   p11,   p12,   in1,   in2,   case,   size,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group w weight mixture prior distribution p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size case choose case: \"least 1, 2 3 significant trials needed approval\" size size category \"small\", \"medium\" \"large\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"output function EPsProg2_binary(), EPsProg3_binary() EPsProg4_binary() expected probability successful program performing several phase III trials (2, 3 4 respectively)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"following cases can investigated software: Two phase III trials Case 1: Strategy 1/2; least one trial significant, treatment effect one least showing direction Case 2: Strategy 2/2; trials significant Three phase III trials Case 2: Strategy 2/3; least two trials significant, treatment effect one least showing direction Case 3: Strategy 3/3; trials significant Four phase III trials Case 3: Strategy 3/4; least three trials significant, treatment effect one least showing direction","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for multitrial programs with binary distributed outcomes ‚Äî EPsProg_multitrial_binary","text":"","code":"EPsProg2_binary(RRgo = 0.8, n2 = 50,  alpha = 0.025, beta = 0.1,                                   p0 = 0.6,  w = 0.3, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, case = 2, size = \"small\",                                  fixed = FALSE) #> [1] 0.02947054           EPsProg3_binary(RRgo = 0.8, n2 = 50,  alpha = 0.025, beta = 0.1,                                   p0 = 0.6,  w = 0.3, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, case = 2, size = \"small\",                                  fixed = FALSE) #> [1] 0.01901078           EPsProg4_binary(RRgo = 0.8, n2 = 50,  alpha = 0.025, beta = 0.1,                                   p0 = 0.6,  w = 0.3, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, case = 3, size = \"small\",                                  fixed = FALSE) #> [1] 0.002690347"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"functions calculate expected probability successful program given parameters. function represents specific strategy, e.g. function EpsProg3_normal() calculates expected probability three phase III trials performed. parameter case specifies many trials successful, .e. many trials show significantly relevant positive treatment effect.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"","code":"EPsProg2_normal(   kappa,   n2,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   case,   size,   fixed )  EPsProg3_normal(   kappa,   n2,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   case,   size,   fixed )  EPsProg4_normal(   kappa,   n2,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   case,   size,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation case choose case: \"least 1, 2 3 significant trials needed approval\" size size category \"small\", \"medium\" \"large\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"output function EPsProg2_normal(), EPsProg3_normal() EPsProg4_normal() expected probability successful program performing several phase III trials (2, 3 4 respectively).","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"following cases can investigated software: Two phase III trials Case 1: Strategy 1/2; least one trial significant, treatment effect one least showing direction Case 2: Strategy 2/2; trials significant Three phase III trials Case 2: Strategy 2/3; least two trials significant, treatment effect one least showing direction Case 3: Strategy 3/3; trials significant Four phase III trials Case 3: Strategy 3/4; least three trials significant, treatment effect one least showing direction","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_multitrial_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for multitrial programs with normally distributed outcomes ‚Äî EPsProg_multitrial_normal","text":"","code":"EPsProg2_normal(kappa = 0.1, n2 = 50, alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   case = 2, size = \"small\", fixed = FALSE) #> [1] 0.5443622           EPsProg3_normal(kappa = 0.1, n2 = 50, alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   case = 2, size = \"small\", fixed = TRUE) #> [1] 0.6219163           EPsProg4_normal(kappa = 0.1, n2 = 50, alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   case = 3, size = \"small\", fixed = TRUE)                       #> [1] 0.5562962"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","title":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","text":"Expected probability successful program time--event outcomes","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","text":"","code":"EPsProg_tte(   HRgo,   d2,   alpha,   beta,   step1,   step2,   w,   hr1,   hr2,   id1,   id2,   gamma,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","text":"HRgo threshold value go/-go decision rule d2 total events phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III step1 lower boundary effect size step2 upper boundary effect size w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events gamma difference treatment effect due different population structures phase II III fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","text":"output functions EPsProg_tte() expected probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/EPsProg_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability of a successful program for time-to-event outcomes ‚Äî EPsProg_tte","text":"","code":"res <- EPsProg_tte(HRgo = 0.8, d2 = 50,                             alpha = 0.025, beta = 0.1,                             step1 = 1, step2 = 0.95,                             w = 0.3, hr1 = 0.69, hr2 = 0.81,                            id1 = 280, id2 = 420,                            gamma = 0, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_bias.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","title":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use functions Ed3_L(), Ed3_L2(), Ed3_R() Ed3_R2(). function describes specific case: Ed3_L(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment Ed3_L2(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment Ed3_R(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment Ed3_R2(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_bias.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","text":"","code":"Ed3_L(HRgo, d2, Adj, alpha, beta, w, hr1, hr2, id1, id2, fixed)  Ed3_L2(HRgo, d2, Adj, alpha, beta, w, hr1, hr2, id1, id2, fixed)  Ed3_R(HRgo, d2, Adj, alpha, beta, w, hr1, hr2, id1, id2, fixed)  Ed3_R2(HRgo, d2, Adj, alpha, beta, w, hr1, hr2, id1, id2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_bias.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","text":"HRgo threshold value go/-go decision rule d2 total events phase II; must even number Adj adjustment parameter alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_bias.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","text":"output functions Ed3_L, Ed3_L2, Ed3_R Ed3_R2 expected number participants phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_bias.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for bias adjustment programs and time-to-event outcomes ‚Äî Ed3_bias","text":"","code":"res <-  Ed3_L(HRgo = 0.8, d2 = 50, Adj = 0.4,                         alpha = 0.025, beta = 0.1, w = 0.3,                          hr1 =  0.69, hr2 = 0.81,                          id1 = 280, id2 = 420, fixed = FALSE)           res <-  Ed3_L2(HRgo = 0.8, d2 = 50, Adj = 0.4,                         alpha = 0.025, beta = 0.1, w = 0.3,                          hr1 =  0.69, hr2 = 0.81,                          id1 = 280, id2 = 420, fixed = FALSE)           res <- Ed3_R(HRgo = 0.8, d2 = 50, Adj = 0.9,                         alpha = 0.025, beta = 0.1, w = 0.3,                          hr1 =  0.69, hr2 = 0.81,                          id1 = 280, id2 = 420, fixed = FALSE)           res <- Ed3_R2(HRgo = 0.8, d2 = 50, Adj = 0.9,                         alpha = 0.025, beta = 0.1, w = 0.3,                          hr1 =  0.69, hr2 = 0.81,                          id1 = 280, id2 = 420, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","title":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","text":"Expected sample size phase III time--event outcomes","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","text":"","code":"Ed3_tte(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","text":"HRgo threshold value go/-go decision rule d2 total events phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","text":"output functions Ed3_tte expected number events phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ed3_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for time-to-event outcomes ‚Äî Ed3_tte","text":"","code":"res <-  Ed3_tte(HRgo = 0.8, d2 = 50,                         alpha = 0.025, beta = 0.1, w = 0.3,                          hr1 =  0.69, hr2 = 0.81,                          id1 = 280, id2 = 420, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","title":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use functions En3_binary_L(), En3_binary_L2(), En3_binary_R() En3_binary_R2(). function describes specific case: En3_binary_L(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment En3_binary_L2(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment En3_binary_R(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment En3_binary_R2(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","text":"","code":"En3_binary_L(RRgo, n2, Adj, alpha, beta, p0, w, p11, p12, in1, in2, fixed)  En3_binary_L2(RRgo, n2, Adj, alpha, beta, p0, w, p11, p12, in1, in2, fixed)  En3_binary_R(RRgo, n2, Adj, alpha, beta, p0, w, p11, p12, in1, in2, fixed)  En3_binary_R2(RRgo, n2, Adj, alpha, beta, p0, w, p11, p12, in1, in2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group w weight mixture prior distribution p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size fixed choose true treatment effects fixed random, TRUE p11 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","text":"output functions En3_binary_L, En3_binary_L2, En3_binary_R En3_binary_R2 expected number participants phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for bias adjustment programs and binary distributed outcomes ‚Äî En3_bias_binary","text":"","code":"res <- En3_binary_L(RRgo = 0.8, n2 = 50, Adj = 0,                                alpha = 0.025, beta = 0.1, p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)           res <-  En3_binary_L2(RRgo = 0.8, n2 = 50, Adj = 0,                                alpha = 0.025, beta = 0.1, p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)           res <- En3_binary_R(RRgo = 0.8, n2 = 50, Adj = 1,                                alpha = 0.025, beta = 0.1, p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)           res <- En3_binary_R2(RRgo = 0.8, n2 = 50, Adj = 1,                                alpha = 0.025, beta = 0.1, p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","title":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","text":"discount overoptimistic results phase II calculating optimal sample size phase III, necessary use functions En3_normal_L(), En3_normal_L2(), En3_normal_R() En3_normal_R2(). function describes specific case: En3_normal_L(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval), however go-decision affected bias adjustment En3_normal_L2(): calculates optimal sample size additive adjustment factor (.e. adjust lower bound one-sided confidence interval) go-decision also affected bias adjustment En3_normal_R(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor), however go-decision affected bias adjustment En3_normal_R2(): calculates optimal sample size multiplicative adjustment factor (.e. use estimate retention factor) go-decision also affected bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","text":"","code":"En3_normal_L(   kappa,   n2,   Adj,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  En3_normal_L2(   kappa,   n2,   Adj,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  En3_normal_R(   kappa,   n2,   Adj,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )  En3_normal_R2(   kappa,   n2,   Adj,   alpha,   beta,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter alpha significance level beta 1 - beta power calculation sample size phase III w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","text":"output functions En3_normal_L, En3_normal_L2, En3_normal_R En3_normal_R2 expected number participants phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/En3_bias_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for bias adjustment programs and normally distributed outcomes ‚Äî En3_bias_normal","text":"","code":"res <- En3_normal_L(kappa = 0.1, n2 = 50, Adj = 0,                                alpha = 0.025, beta = 0.1, w = 0.3,                               Delta1 = 0.375, Delta2 = 0.625,                                in1 = 300, in2 = 600,                                a = 0.25, b = 0.75, fixed = FALSE)           res <- En3_normal_L2(kappa = 0.1, n2 = 50, Adj = 0,                                alpha = 0.025, beta = 0.1, w = 0.3,                               Delta1 = 0.375, Delta2 = 0.625,                                in1 = 300, in2 = 600,                                a = 0.25, b = 0.75, fixed = TRUE)           res <- En3_normal_R(kappa = 0.1, n2 = 50, Adj = 1,                                alpha = 0.025, beta = 0.1, w = 0.3,                               Delta1 = 0.375, Delta2 = 0.625,                                in1 = 300, in2 = 600,                                a = 0.25, b = 0.75, fixed = FALSE)           res <- En3_normal_R2(kappa = 0.1, n2 = 50, Adj = 1,                                alpha = 0.025, beta = 0.1, w = 0.3,                               Delta1 = 0.375, Delta2 = 0.625,                                in1 = 300, in2 = 600,                                a = 0.25, b = 0.75, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to do third phase III trial ‚Äî Epgo23","title":"Expected probability to do third phase III trial ‚Äî Epgo23","text":"setting Case 2: Strategy 2/2( + 1); least two trials significant (treatment effect one least showing direction) function calculates probability third phase III trial necessary.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to do third phase III trial ‚Äî Epgo23","text":"","code":"Epgo23(HRgo, d2, alpha, beta, w, hr1, hr2, id1, id2)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to do third phase III trial ‚Äî Epgo23","text":"HRgo threshold value go/-go decision rule d2 total number events phase II alpha significance level beta 1-beta power calculation sample size phase III w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to do third phase III trial ‚Äî Epgo23","text":"output function Epgo23() probability third phase III trial.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to do third phase III trial ‚Äî Epgo23","text":"","code":"res <- Epgo23(HRgo = 0.8, d2 = 50,  w = 0.3, alpha = 0.025, beta = 0.1,                                hr1 =  0.69, hr2 = 0.81, id1 = 280, id2 = 420)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","title":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","text":"setting Case 2: Strategy 2/2( + 1); least two trials significant (treatment effect one least showing direction) function calculates probability third phase III trial necessary.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","text":"","code":"Epgo23_binary(RRgo, n2, alpha, beta, p0, w, p11, p12, in1, in2)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group w weight mixture prior distribution p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","text":"output function Epgo23_binary() probability third phase III trial.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to do third phase III trial ‚Äî Epgo23_binary","text":"","code":"res <- Epgo23_binary(RRgo = 0.8, n2 = 50,  p0 = 0.3, w = 0.3, alpha = 0.025, beta = 0.1,                                p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","title":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","text":"setting Case 2: Strategy 2/2( + 1); least two trials significant (treatment effect one least showing direction) function calculates probability third phase III trial necessary.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","text":"","code":"Epgo23_normal(kappa, n2, alpha, beta, a, b, w, Delta1, Delta2, in1, in2)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III lower boundary truncation b upper boundary truncation w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","text":"output function Epgo23_normal() probability third phase III trial.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo23_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to do third phase III trial ‚Äî Epgo23_normal","text":"","code":"Epgo23_normal(kappa = 0.1, n2 = 50, w = 0.3, alpha = 0.025, beta = 0.1, a = 0.25, b=0.75,                                Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600) #> [1] 0.2066215"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","title":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","text":"case want discount overoptimistic results phase II calculating sample size phase III, also deciding whether go phase III functions Epgo_L2 Epgo_R2 necessary. function Epgo_L2 uses additive adjustment parameter (.e. adjust lower bound one-sided confidence interval), function Epgo_R2 uses multiplicative adjustment parameter (.e. use estimate retention factor)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","text":"","code":"Epgo_L2(HRgo, d2, Adj, w, hr1, hr2, id1, id2, fixed)  Epgo_R2(HRgo, d2, Adj, w, hr1, hr2, id1, id2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","text":"HRgo threshold value go/-go decision rule d2 total number events phase II; must even number Adj adjustment parameter w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","text":"output functions Epgo_L2 Epgo_R2 expected probability go phase III conservative decision rule sample size calculation.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to go to phase III for bias adjustment programs with time-to-event outcomes ‚Äî Epgo_bias","text":"","code":"res <- Epgo_L2(HRgo = 0.8, d2 = 50, Adj = 0.4,                                   w = 0.3, hr1 = 0.69, hr2 = 0.81,                                  id1 = 280, id2 = 420, fixed = FALSE)           res <- Epgo_R2(HRgo = 0.8, d2 = 50, Adj = 0.9,                                   w = 0.3, hr1 = 0.69, hr2 = 0.81,                                  id1 = 280, id2 = 420, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","title":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","text":"case want discount overoptimistic results phase II calculating sample size phase III, also deciding whether go phase III functions Epgo_binary_L2 Epgo_binary_R2 necessary. function Epgo_binary_L2 uses additive adjustment parameter (.e. adjust lower bound one-sided confidence interval), function Epgo_binary_R2 uses multiplicative adjustment parameter (.e. use estimate retention factor)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","text":"","code":"Epgo_binary_L2(RRgo, n2, Adj, p0, w, p11, p12, in1, in2, fixed)  Epgo_binary_R2(RRgo, n2, Adj, p0, w, p11, p12, in1, in2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter p0 assumed true rate control group w weight mixture prior distribution p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size fixed choose true treatment effects fixed random, TRUE p11 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","text":"output functions Epgo_binary_L2 Epgo_binary_R2 expected number participants phase III conservative decision rule sample size calculation.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to go to phase III for bias adjustment programs with binary distributed outcomes ‚Äî Epgo_bias_binary","text":"","code":"res <- Epgo_binary_L2(RRgo = 0.8, n2 = 50, Adj = 0,  p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)           res <- Epgo_binary_R2(RRgo = 0.8, n2 = 50, Adj = 1,  p0 = 0.6,  w = 0.3,                               p11 =  0.3, p12 = 0.5, in1 = 300, in2 = 600,                                fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","title":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","text":"case want discount overoptimistic results phase II calculating sample size phase III, also deciding whether go phase III functions Epgo_normal_L2 Epgo_normal_R2 necessary. function Epgo_normal_L2 uses additive adjustment parameter (.e. adjust lower bound one-sided confidence interval), function Epgo_normal_R2 uses multiplicative adjustment parameter (.e. use estimate retention factor)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","text":"","code":"Epgo_normal_L2(kappa, n2, Adj, w, Delta1, Delta2, in1, in2, a, b, fixed)  Epgo_normal_R2(kappa, n2, Adj, w, Delta1, Delta2, in1, in2, a, b, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number Adj adjustment parameter w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","text":"output functions Epgo_normal_L2 Epgo_normal_R2 expected number participants phase III conservative decision rule sample size calculation.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_bias_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to go to phase III for bias adjustment programs with normally distributed outcomes ‚Äî Epgo_bias_normal","text":"","code":"res <- Epgo_normal_L2(kappa = 0.1, n2 = 50, Adj = 0, w = 0.3,                                Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                 a = 0.25, b = 0.75, fixed = FALSE)           res <- Epgo_normal_R2(kappa = 0.1, n2 = 50, Adj = 1, w = 0.3,                                Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                 a = 0.25, b = 0.75, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","text":"Expected probability go phase III time--event outcomes","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","text":"","code":"Epgo_tte(HRgo, d2, w, hr1, hr2, id1, id2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","text":"HRgo threshold value go/-go decision rule d2 total number events phase II; must even number w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","text":"output functions Epgo_tte() expected probability go phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Epgo_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî Epgo_tte","text":"","code":"res <- Epgo_tte(HRgo = 0.8, d2 = 50,                                   w = 0.3, hr1 = 0.69, hr2 = 0.81,                                  id1 = 280, id2 = 420, fixed = FALSE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","title":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","text":"Given phase II results promising enough get \"go\"-decision go phase III function now calculates expected sample size phase III given cases strategies listed . results function necessary calculating utility program, step maximized optimal_multiarm_binary() function","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","text":"","code":"Ess_binary(RRgo, n2, alpha, beta, p0, p11, p12, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","text":"function Ess_binary() returns expected sample size phase III going phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for multiarm programs with binary distributed outcomes ‚Äî Ess_binary","text":"","code":"res <- Ess_binary(RRgo = 0.8 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             p0 = 0.6, p11 =  0.3, p12 = 0.5,strategy = 3, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_normal","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_normal","text":"Given phase II results promising enough get \"go\"-decision go phase III function now calculates expected sample size phase III. results function necessary calculating utility program, step maximized optimal_multiple_normal() function","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_normal","text":"","code":"Ess_multiple_normal(   kappa,   n2,   alpha,   beta,   Delta1,   Delta2,   in1,   in2,   sigma1,   sigma2,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_normal","text":"kappa threshold value go/-go decision rule; vector endpoints n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_normal","text":"output function Ess_multiple_normal expected number participants phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_tte","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_tte","text":"Given phase II results promising enough get \"go\"-decision go phase III function now calculates expected sample size phase III. results function necessary calculating utility program, step maximized optimal_multiple_tte() function","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_tte","text":"","code":"Ess_multiple_tte(HRgo, n2, alpha, beta, hr1, hr2, id1, id2, fixed, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_tte","text":"HRgo threshold value go/-go decision rule; n2 total sample size phase II; must even number alpha one- sided significance level beta 1-beta power calculation number events phase III Schoenfeld (1981) formula hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for multiple endpoints with normally distributed outcomes ‚Äî Ess_multiple_tte","text":"output function Ess_multiple_tte() expected number participants phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","title":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","text":"Given phase II results promising enough get \"go\"-decision go phase III function now calculates expected sample size phase III given cases strategies listed . results function necessary calculating utility program, step maximized optimal_multiarm_normal() function","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","text":"","code":"Ess_normal(kappa, n2, alpha, beta, Delta1, Delta2, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","text":"function Ess_normal() returns expected sample size phase III going phase III outcomes normally distributed consider multiarm programs, .e. several phase III trials different doses different treatments performed","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for multiarm programs with normally distributed outcomes ‚Äî Ess_normal","text":"","code":"res <- Ess_normal(kappa = 0.1 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             Delta1 = 0.375, Delta2 = 0.625, strategy = 3, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","title":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","text":"Given phase II results promising enough get \"go\"-decision go phase III function now calculates expected sample size phase III given cases strategies listed . results function necessary calculating utility program, step maximized optimal_multiarm() function","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","text":"","code":"Ess_tte(HRgo, n2, alpha, beta, ec, hr1, hr2, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","text":"HRgo threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III ec control arm event rate phase II III hr1 assumed true treatment effect HR scale treatment 1 hr2 assumed true treatment effect HR scale treatment 2 strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","text":"function Ess_tte() returns expected sample size phase III going phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/Ess_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected sample size for phase III for multiarm programs with time-to-event outcomes ‚Äî Ess_tte","text":"","code":"res <- Ess_tte(HRgo = 0.8 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             ec = 0.6, hr1 = 0.7, hr2 = 0.8, strategy = 2, case = 21)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","title":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","text":"Given get \"go\"-decision phase II, functions now calculates probability results confirmatory trial (phase III) significant, .e. statistically relevant positive effect treatment.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","text":"","code":"PsProg_binary(   RRgo,   n2,   alpha,   beta,   p0,   p11,   p12,   step1,   step2,   strategy,   case )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must divisible three alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group step1 lower boundary effect size step2 upper boundary effect size strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","text":"function PsProg_binary() returns probability successful program","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability of a successful program for multiarm programs with binary distributed outcomes ‚Äî PsProg_binary","text":"","code":"res <- PsProg_binary(RRgo = 0.8 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             p0 = 0.6, p11 =  0.3, p12 = 0.5, step1 = 1, step2 = 0.95,                             strategy = 3, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","title":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","text":"Given get \"go\"-decision phase II, functions now calculates probability results confirmatory trial (phase III) significant, .e. statistically relevant positive effect treatment.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","text":"","code":"PsProg_normal(   kappa,   n2,   alpha,   beta,   Delta1,   Delta2,   step1,   step2,   strategy,   case )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means step1 lower boundary effect size step2 upper boundary effect size strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","text":"function PsProg_normal() returns probability successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability of a successful program for multiarm programs with normally distributed outcomes ‚Äî PsProg_normal","text":"","code":"res <- PsProg_normal(kappa = 0.1 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             Delta1 = 0.375, Delta2 = 0.625,  step1 = 0, step2 = 0.5,                             strategy = 3, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","title":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","text":"Given get \"go\"-decision phase II, functions now calculates probability results confirmatory trial (phase III) significant, .e. statistically relevant positive effect treatment.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","text":"","code":"PsProg_tte(HRgo, n2, alpha, beta, ec, hr1, hr2, step1, step2, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","text":"HRgo threshold value go/-go decision rule n2 total sample size phase II; must divisible three alpha significance level beta 1-beta power calculation sample size phase III ec control arm event rate phase II III hr1 assumed true treatment effect HR scale treatment 1 hr2 assumed true treatment effect HR scale treatment 2 step1 lower boundary effect size step2 upper boundary effect size strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") 3 () case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","text":"function PsProg_tte() returns probability successful program","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/PsProg_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability of a successful program for multiarm programs with time-to-event outcomes ‚Äî PsProg_tte","text":"","code":"res <- PsProg_tte(HRgo = 0.8 ,n2 = 50 ,alpha = 0.05, beta = 0.1,                             ec = 0.6, hr1 = 0.7, hr2 = 0.8, step1 = 1, step2 = 0.95,                             strategy = 2, case = 21)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/d3_skipII_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","text":"choosing skipII = TRUE, program calculates expected utility case phase II skipped compares situation phase II skipped. function calculates expected sample size phase III time--event outcomes using median prior.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/d3_skipII_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","text":"","code":"d3_skipII_tte(alpha, beta, median_prior)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/d3_skipII_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","text":"alpha significance level beta 1-beta power calculation sample size phase III median_prior median_prior given -log(hr1), assumed true treatment effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/d3_skipII_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","text":"output functions d3_skipII_tte() expected number events phase III skipping phase II.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/d3_skipII_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Expected probability to go to phase III for time-to-event outcomes ‚Äî d3_skipII_tte","text":"","code":"res <- d3_skipII_tte(alpha = 0.05, beta = 0.1, median_prior = 0.35)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/dbivanorm.html","id":null,"dir":"Reference","previous_headings":"","what":"Density of the bivariate normal distribution ‚Äî dbivanorm","title":"Density of the bivariate normal distribution ‚Äî dbivanorm","text":"Density bivariate normal distribution","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/dbivanorm.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Density of the bivariate normal distribution ‚Äî dbivanorm","text":"","code":"dbivanorm(x, y, mu1, mu2, sigma1, sigma2, rho)  dbivanorm(x, y, mu1, mu2, sigma1, sigma2, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/dbivanorm.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Density of the bivariate normal distribution ‚Äî dbivanorm","text":"x integral variable y integral variable mu1 mean second endpoint mu2 mean first endpoint sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/dbivanorm.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Density of the bivariate normal distribution ‚Äî dbivanorm","text":"Function dbivanorm() return density bivariate normal distribution.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR-package.html","id":null,"dir":"Reference","previous_headings":"","what":"drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning ‚Äî drugdevelopR-package","title":"drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning ‚Äî drugdevelopR-package","text":"Plan optimal sample size allocation go/-go decision rules phase II/III drug development programs time--event, binary normally distributed endpoints assuming fixed treatment effects prior distribution treatment effect, using methods Kirchner et al. (2016) doi:10.1002/sim.6624  Preussler (2020). Optimal sense maximal expected utility, utility function taking account expected cost benefit program. possible extend complex settings bias correction (Preussler S et al. (2020) doi:10.1186/s12874-020-01093-w ), multiple phase III trials (Preussler et al. (2019) doi:10.1002/bimj.201700241 ), multi-arm trials (Preussler et al. (2019) doi:10.1080/19466315.2019.1702092 ), multiple endpoints (Kieser et al. (2018) doi:10.1002/pst.1861 ).","code":""},{"path":[]},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning ‚Äî drugdevelopR-package","text":"Maintainer: Lukas D. Sauer sauer@imbi.uni-heidelberg.de (ORCID) Authors: Stella Erdmann erdmann@imbi.uni-heidelberg.de Johannes Cepicka Marietta Kirchner Meinhard Kieser","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility based optimal phase II/III drug development planning ‚Äî drugdevelopR","title":"Utility based optimal phase II/III drug development planning ‚Äî drugdevelopR","text":"drugdevelopR package enables utility based planning phase II/III drug development programs optimal sample size allocation go/-go decision rules. assumed true treatment effects can assumed fixed (planning also possible via user friendly R Shiny App: drugdevelopR) modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility based optimal phase II/III drug development planning ‚Äî drugdevelopR","text":"","code":"drugdevelopR()"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR.html","id":"drugdevelopr-package-and-r-shiny-app","dir":"Reference","previous_headings":"","what":"drugdevelopR package and R Shiny App","title":"Utility based optimal phase II/III drug development planning ‚Äî drugdevelopR","text":"drugdevelopR package provides functions plan optimal phase II/III drug development programs time--event endpoint (optimal_tte), binary endpoint (optimal_binary) normally distributed endpoint (optimal_normal), treatment effect assumed fixed modelled prior. settings, optimal phase II/III drug development planning fixed assumed treatment effects can also done help R Shiny application basic. Extensions basic setting optimal planning programs including methods discounting phase II results (function: optimal_bias, App: bias), optimal planning programs several phase III trials (function: optimal_multitrial, App: multitrial) optimal planning programs multiple arms (function: optimal_multiarm, App: multiarm). R Shiny App drugdevelopR serves homepage, navigating different parts drugdevelopR via links.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopR.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Utility based optimal phase II/III drug development planning ‚Äî drugdevelopR","text":"Kirchner, M., Kieser, M., Goette, H., & Schueler, . (2016). Utility-based optimization phase II/III programs. Statistics Medicine, 35(2), 305-316. Preussler, S., Kieser, M., Kirchner, M. (2019). Optimal sample size allocation go/-go decision rules phase II/III programs several phase III trials performed. Biometrical Journal, 61(2), 357-378. Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal designs phase II/III drug development programs including methods discounting phase II results. Submitted peer-review journal. Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal designs multi-arm Phase II/III drug development programs. Submitted peer-review journal.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopResult.html","id":null,"dir":"Reference","previous_headings":"","what":"Construct a drugdevelopResult object from a data frame ‚Äî drugdevelopResult","title":"Construct a drugdevelopResult object from a data frame ‚Äî drugdevelopResult","text":"short wrapper adding \"drugdevelopR\" string list S3 classes data frame.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopResult.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Construct a drugdevelopResult object from a data frame ‚Äî drugdevelopResult","text":"","code":"drugdevelopResult(x, ...)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopResult.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Construct a drugdevelopResult object from a data frame ‚Äî drugdevelopResult","text":"x data frame","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/drugdevelopResult.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Construct a drugdevelopResult object from a data frame ‚Äî drugdevelopResult","text":"data frame, equipped class \"drugdevelopResult\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmax.html","id":null,"dir":"Reference","previous_headings":"","what":"Density for the maximum of two normally distributed random variables ‚Äî fmax","title":"Density for the maximum of two normally distributed random variables ‚Äî fmax","text":"function fmax() return value f(z), value density function maximum two normally distributed random variables.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmax.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Density for the maximum of two normally distributed random variables ‚Äî fmax","text":"","code":"fmax(z, mu1, mu2, sigma1, sigma2, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmax.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Density for the maximum of two normally distributed random variables ‚Äî fmax","text":"z integral variable mu1 mean second endpoint mu2 mean first endpoint sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmax.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Density for the maximum of two normally distributed random variables ‚Äî fmax","text":"function fmax() return value f(z), value density function maximum two normally distributed random variables.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmax.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Density for the maximum of two normally distributed random variables ‚Äî fmax","text":"Z = max(X,Y) X ~ N(mu1,sigma1^2), Y ~ N(mu2,sigma2^2) f(z)=f1(-z)+f2(-z)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmin.html","id":null,"dir":"Reference","previous_headings":"","what":"Density for the minimum of two normally distributed random variables ‚Äî fmin","title":"Density for the minimum of two normally distributed random variables ‚Äî fmin","text":"function fmin() return value f(z), value density function minimum two normally distributed random variables.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmin.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Density for the minimum of two normally distributed random variables ‚Äî fmin","text":"","code":"fmin(y, mu1, mu2, sigma1, sigma2, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmin.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Density for the minimum of two normally distributed random variables ‚Äî fmin","text":"y integral variable mu1 mean second endpoint mu2 mean first endpoint sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmin.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Density for the minimum of two normally distributed random variables ‚Äî fmin","text":"function fmin() return value f(z), value density function minimum two normally distributed random variables.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/fmin.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Density for the minimum of two normally distributed random variables ‚Äî fmin","text":"Z= min(X,Y) X ~ N(mu1,sigma1^2), Y ~ N(mu2,sigma2^2) f(z)=f1(z)+f2(z)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_normal","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_normal","text":"Generate sample Monte Carlo integration multiple setting","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_normal","text":"","code":"get_sample_multiple_normal(Delta1, Delta2, in1, in2, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_normal","text":"Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_normal","text":"randomly generated data frame","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_tte","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_tte","text":"Generate sample Monte Carlo integration multiple setting","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_tte","text":"","code":"get_sample_multiple_tte(hr1, hr2, id1, id2, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_tte","text":"hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms sample size id2 amount information hr2 terms sample size rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/get_sample_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generate sample for Monte Carlo integration in the multiple setting ‚Äî get_sample_multiple_tte","text":"randomly generated data frame","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"function optimal_bias drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules including methods discounting phase II results time--event endpoints (Preussler et. al, 2020). discounting may necessary programs proceed phase III can overoptimistic treatment effect (.e. biased). assumed true treatment effects can assumed fixed (planning also possible via user friendly R Shiny App: bias) modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"","code":"optimal_bias(   w,   hr1,   hr2,   id1,   id2,   d2min,   d2max,   stepd2,   hrgomin,   hrgomax,   stephrgo,   adj = \"both\",   lambdamin = NULL,   lambdamax = NULL,   steplambda = NULL,   alphaCImin = NULL,   alphaCImax = NULL,   stepalphaCI = NULL,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution, see vignette priors well Shiny app details concerning definition prior distribution. hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events d2min minimal number events phase II d2max maximal number events phase II stepd2 stepsize optimization d2 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo stepsize optimization HRgo adj choose type adjustment: \"multiplicative\", \"additive\", \"\" \"\". using \"\", res[1,] contains results using multiplicative method res[2,] contains results using additive method. using \"\", also res[3,] res[4,], containing results multiplicative additive method adjust treatment effect also threshold value decision rule. lambdamin minimal multiplicative adjustment parameter lambda (.e. use estimate retention factor) lambdamax maximal multiplicative adjustment parameter lambda (.e. use estimate retention factor) steplambda stepsize adjustment parameter lambda alphaCImin minimal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) alphaCImax maximal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) stepalphaCI stepsize alphaCI alpha one-sided significance level beta 1-beta power calculation number events phase III Schoenfeld (1981) formula xi2 event rate phase II xi3 event rate phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g., constraint S constraint expected probability successful program, default: -Inf, e.g., constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"output function data.frame object containing optimization results: Adj optimal adjustment parameter (lambda alphaCI according Method) u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value HRgo optimal threshold value decision rule go phase III d2 optimal total number events phase II d3 total expected number events phase III; rounded next natural number d total expected number events program; d = d2 + d3 n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, last access 15.05.19. Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2020). Optimal designs phase II/III drug development programs including methods discounting phase II results. Submitted peer-review journal. Schoenfeld, D. (1981). asymptotic properties nonparametric tests comparing survival distributions. Biometrika, 68(1), 316-319.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for time-to-event endpoints when discounting phase II results ‚Äî optimal_bias","text":"","code":"# Activate progress bar (optional) if (FALSE) { # \\dontrun{ progressr::handlers(global = TRUE) } # } # Optimize # \\donttest{ optimal_bias(w = 0.3,                       # define parameters for prior   hr1 = 0.69, hr2 = 0.88, id1 = 210, id2 = 420,      # (https://web.imbi.uni-heidelberg.de/prior/)   d2min = 20, d2max = 100, stepd2 = 5,               # define optimization set for d2   hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05,     # define optimization set for HRgo   adj = \"both\",                                      # choose type of adjustment   lambdamin = 0.2, lambdamax = 1, steplambda = 0.05, # define optimization set for lambda   alphaCImin = 0.025, alphaCImax = 0.5,   stepalphaCI = 0.025,                               # define optimization set for alphaCI   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,   # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,           # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                        # set constraints   steps1 = 1,                                        # define lower boundary for \"small\"   stepm1 = 0.95,                                     # \"medium\"   stepl1 = 0.85,                                     # and \"large\" effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                   # define expected benefits    fixed = FALSE,                                     # true treatment effects are fixed/random   num_cl = 1)                                        # number of coresfor parallelized computing  #> Optimization result with multiplicative adjustment of the treatment effect: #>  Utility: 98.28 #>  Bias adjustment parameter: 0.75 #>  Sample size: #>    phase II: 122, phase III: 218, total: 340 #>  Expected number of events: #>    phase II: 85, phase III: 153, total: 238 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.36 #>  Total cost: #>    phase II: 192, phase III: 273, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.24 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.04, medium: 0.08, large: 0.12 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.75 [HRgo]  #>  Parameters of the prior distribution:  #>    hr1: 0.69,  hr2: 0.88, id1: 210, id2: 420, w: 0.3 #>  #> Optimization result with additive adjustment of the treatment effect: #>  Utility: 75.95 #>  Bias adjustment parameter: 0.475 #>  Sample size: #>    phase II: 130, phase III: 230, total: 360 #>  Expected number of events: #>    phase II: 90, phase III: 161, total: 251 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.45 #>  Total cost: #>    phase II: 198, phase III: 298, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.26 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.05, medium: 0.09, large: 0.11 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.8 [HRgo]  #>  Parameters of the prior distribution:  #>    hr1: 0.69,  hr2: 0.88, id1: 210, id2: 420, w: 0.3 #>    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"function optimal_bias_binary drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules including methods discounting phase II results binary endpoints (Preussler et. al, 2020). discounting may necessary programs proceed phase III can overoptimistic treatment effect (.e. biased). assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"","code":"optimal_bias_binary(   w,   p0,   p11,   p12,   in1,   in2,   n2min,   n2max,   stepn2,   rrgomin,   rrgomax,   steprrgo,   adj = \"both\",   lambdamin = NULL,   lambdamax = NULL,   steplambda = NULL,   alphaCImin = NULL,   alphaCImax = NULL,   stepalphaCI = NULL,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"w weight mixture prior distribution p0 assumed true rate control group, see details p11 assumed true rate treatment group, see details p12 assumed true rate treatment group, see details in1 amount information p11 terms sample size, see details in2 amount information p12 terms sample size, see details n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number rrgomin minimal threshold value go/-go decision rule rrgomax maximal threshold value go/-go decision rule steprrgo step size optimization RRgo adj choose type adjustment: \"multiplicative\", \"additive\", \"\" \"\". using \"\", res[1,] contains results using multiplicative method res[2,] contains results using additive method. using \"\", also res[3,] res[4,], containing results multiplicative additive method adjust treatment effect also threshold value decision rule. lambdamin minimal multiplicative adjustment parameter lambda (.e. use estimate retention factor) lambdamax maximal multiplicative adjustment parameter lambda (.e. use estimate retention factor) steplambda stepsize adjustment parameter lambda alphaCImin minimal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) alphaCImax maximal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) stepalphaCI stepsize alphaCI alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" fixed choose true treatment effects fixed random, TRUE p11 used fixed effect p1 num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"output function data.frame object containing optimization results: Adj optimal adjustment parameter (lambda alphaCI according Method) u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value RRgo optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning when discounting phase II results with binary endpoint ‚Äî optimal_bias_binary","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_bias_binary(w = 0.3,                 # define parameters for prior   p0 = 0.6, p11 =  0.3, p12 = 0.5,   in1 = 30, in2 = 60,                                 # (https://web.imbi.uni-heidelberg.de/prior/)   n2min = 20, n2max = 100, stepn2 = 10,               # define optimization set for n2   rrgomin = 0.7, rrgomax = 0.9, steprrgo = 0.05,      # define optimization set for RRgo   adj = \"both\",                                       # choose type of adjustment   alpha = 0.025, beta = 0.1,                          # drug development planning parameters   lambdamin = 0.2, lambdamax = 1, steplambda = 0.05,  # define optimization set for lambda   alphaCImin = 0.025, alphaCImax = 0.5,   stepalphaCI = 0.025,                                # define optimization set for alphaCI   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,            # fixed and variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                         # set constraints   steps1 = 1,                                         # define lower boundary for \"small\"   stepm1 = 0.95,                                      # \"medium\"   stepl1 = 0.85,                                      # and \"large\" effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                    # define expected benefits   fixed = TRUE,                                       # true treatment effects are fixed/random   num_cl = 1)                                         # number of cores for parallelized computing #> Optimization result with multiplicative adjustment of the treatment effect: #>  Utility: 2034.08 #>  Bias adjustment parameter: 0.65 #>  Sample size: #>    phase II: 100, phase III: 380, total: 480 #>  Probability to go to phase III: 0.97 #>  Total cost: #>    phase II: 175, phase III: 526, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.94 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.02, medium: 0.06, large: 0.87 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.8 [RRgo]  #>  Assumed true effect: #>   rate in the control: 0.6, rate in the treatment group: 0.3 #>  #> Optimization result with additive adjustment of the treatment effect: #>  Utility: 1893.98 #>  Bias adjustment parameter: 0.1 #>  Sample size: #>    phase II: 100, phase III: 298, total: 398 #>  Probability to go to phase III: 0.95 #>  Total cost: #>    phase II: 175, phase III: 441, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.89 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.03, medium: 0.09, large: 0.77 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.75 [RRgo]  #>  Assumed true effect: #>   rate in the control: 0.6, rate in the treatment group: 0.3 #>    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing drug development programs with bias adjustment ‚Äî optimal_bias_generic","title":"Generic function for optimizing drug development programs with bias adjustment ‚Äî optimal_bias_generic","text":"Generic function optimizing drug development programs bias adjustment","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing drug development programs with bias adjustment ‚Äî optimal_bias_generic","text":"","code":"optimal_bias_generic(   adj = \"both\",   lambdamin = NULL,   lambdamax = NULL,   steplambda = NULL,   alphaCImin = NULL,   alphaCImax = NULL,   stepalphaCI = NULL )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing drug development programs with bias adjustment ‚Äî optimal_bias_generic","text":"adj choose type adjustment: \"multiplicative\", \"additive\", \"\" \"\". using \"\", res[1,] contains results using multiplicative method res[2,] contains results using additive method. using \"\", also res[3,] res[4,], containing results multiplicative additive method adjust treatment effect also threshold value decision rule. lambdamin minimal multiplicative adjustment parameter lambda (.e. use estimate retention factor) lambdamax maximal multiplicative adjustment parameter lambda (.e. use estimate retention factor) steplambda stepsize adjustment parameter lambda alphaCImin minimal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) alphaCImax maximal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) stepalphaCI stepsize alphaCI","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"function optimal_bias_normal drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules including methods discounting phase II results normally distributed endpoints (Preussler et. al, 2020). discounting may necessary programs proceed phase III can overoptimistic treatment effect (.e. biased). assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"","code":"optimal_bias_normal(   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   adj = \"both\",   lambdamin = NULL,   lambdamax = NULL,   steplambda = NULL,   alphaCImin = NULL,   alphaCImax = NULL,   stepalphaCI = NULL,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 0,   stepm1 = 0.5,   stepl1 = 0.8,   b1,   b2,   b3,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"w weight mixture prior distribution Delta1 assumed true prior treatment effect measured standardized difference means, see details Delta2 assumed true prior treatment effect measured standardized difference means, see details in1 amount information Delta1 terms sample size, see details in2 amount information Delta2 terms sample size, see details lower boundary truncation prior distribution b upper boundary truncation prior distribution n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa adj choose type adjustment: \"multiplicative\", \"additive\", \"\" \"\". using \"\", res[1,] contains results using multiplicative method res[2,] contains results using additive method. using \"\", also res[3,] res[4,], containing results multiplicative additive method adjust treatment effect also threshold value decision rule. lambdamin minimal multiplicative adjustment parameter lambda (.e. use estimate retention factor) lambdamax maximal multiplicative adjustment parameter lambda (.e. use estimate retention factor) steplambda stepsize adjustment parameter lambda alphaCImin minimal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) alphaCImax maximal additive adjustment parameter alphaCI (.e. adjust lower bound one-sided confidence interval) stepalphaCI stepsize alphaCI alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation sample size phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ fixed choose true treatment effects fixed following prior distribution, TRUE Delta1 used fixed effect num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"output function data.frame object containing optimization results: Adj optimal adjustment parameter (lambda alphaCI according Method) u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value Kappa optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"Cohen, J. (1988). Statistical power analysis behavioral sciences.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_bias_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning when discounting phase II results with normally distributed endpoint ‚Äî optimal_bias_normal","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_bias_normal(w=0.3,             # define parameters for prior   Delta1 = 0.375, Delta2 = 0.625, in1=300, in2=600,    # (https://web.imbi.uni-heidelberg.de/prior/)   a = 0.25, b = 0.75,   n2min = 20, n2max = 100, stepn2 = 10,                # define optimization set for n2   kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02,   # define optimization set for kappa   adj = \"both\",                                        # choose type of adjustment   lambdamin = 0.2, lambdamax = 1, steplambda = 0.05,   # define optimization set for lambda   alphaCImin = 0.025, alphaCImax = 0.5,   stepalphaCI = 0.025,                                 # define optimization set for alphaCI   alpha = 0.025, beta = 0.1,                           # drug development planning parameters   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,           # fixed and variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                          # set constraints   steps1 = 0,                                          # define lower boundary for \"small\"   stepm1 = 0.5,                                        # \"medium\"   stepl1 = 0.8,                                        # and \"large\" effect size categories   b1 = 3000, b2 = 8000, b3 = 10000,                    # define expected benefits   fixed = TRUE,                                        # true treatment effects are fixed/random   num_cl = 1)                                          # number of coresfor parallelized computing  #> Optimization result with multiplicative adjustment of the treatment effect: #>  Utility: 1854.94 #>  Bias adjustment parameter: 0.8 #>  Sample size: #>    phase II: 100, phase III: 628, total: 728 #>  Probability to go to phase III: 0.9 #>  Total cost: #>    phase II: 82, phase III: 470, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.8 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.8, medium: 0, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.12 [Kappa]  #>  Assumed true effect: 0.375 [Delta]  #>  #> Optimization result with additive adjustment of the treatment effect: #>  Utility: 1768.13 #>  Bias adjustment parameter: 0.5 #>  Sample size: #>    phase II: 100, phase III: 460, total: 560 #>  Probability to go to phase III: 0.92 #>  Total cost: #>    phase II: 82, phase III: 350, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.73 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.73, medium: 0, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.1 [Kappa]  #>  Assumed true effect: 0.375 [Delta]  #>    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"optimal_binary function drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules binary endpoints. case, treatment effect measured risk ratio (RR). assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"","code":"optimal_binary(   w,   p0,   p11,   p12,   in1,   in2,   n2min,   n2max,   stepn2,   rrgomin,   rrgomax,   steprrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   skipII = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"w weight mixture prior distribution p0 assumed true rate control group, see details p11 assumed true rate treatment group, see details p12 assumed true rate treatment group, see details in1 amount information p11 terms sample size, see details in2 amount information p12 terms sample size, see details n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number rrgomin minimal threshold value go/-go decision rule rrgomax maximal threshold value go/-go decision rule steprrgo step size optimization RRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" gamma model different populations phase II III choose gamma != 0, default: 0, see details fixed choose true treatment effects fixed random, TRUE p11 used fixed effect p1 skipII skipII choose skipping phase II option, default: FALSE; TRUE, program calculates expected utility case phase II skipped compares situation phase II skipped. results returned two-row data frame, res[1, ] results including phase II res[2, ] skipping phase II. res[2, ] additional parameter, res[2, ]$median_prior_RR, assumed effect size used planning phase III study phase II skipped. num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"output function data.frame object containing optimization results: RRgo optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, last access 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning with binary endpoint ‚Äî optimal_binary","text":"","code":"# Activate progress bar (optional) if (FALSE) { # \\dontrun{ progressr::handlers(global = TRUE) } # } # Optimize # \\donttest{ optimal_binary(w = 0.3,                             # define parameters for prior   p0 = 0.6, p11 =  0.3, p12 = 0.5,   in1 = 30, in2 = 60,                               # (https://web.imbi.uni-heidelberg.de/prior/)   n2min = 20, n2max = 100, stepn2 = 4,              # define optimization set for n2   rrgomin = 0.7, rrgomax = 0.9, steprrgo = 0.05,    # define optimization set for RRgo   alpha = 0.025, beta = 0.1,                        # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,          # fixed and variable costs for phase II/III,   K = Inf, N = Inf, S = -Inf,                       # set constraints   steps1 = 1,                                       # define lower boundary for \"small\"   stepm1 = 0.95,                                    # \"medium\"   stepl1 = 0.85,                                    # and \"large\" treatment effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                  # define expected benefits   gamma = 0,                                        # population structures in phase II/III   fixed = FALSE,                                    # true treatment effects are fixed/random   skipII = FALSE,                                   # choose if skipping phase II is an option   num_cl = 2)                                       # number of cores for parallelized computing #> Optimization result: #>  Utility: 574.64 #>  Sample size: #>    phase II: 100, phase III: 222, total: 322 #>  Probability to go to phase III: 0.66 #>  Total cost: #>    phase II: 175, phase III: 321, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.44 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.06, medium: 0.13, large: 0.25 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [RRgo]  #>  Parameters of the prior distribution:  #>    p0: 0.6,  p11: 0.3, p12: 0.5, in1: 30, in2: 60, w: 0.3 #>  Treatment effect offset between phase II and III: 0 [gamma]    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing programs with binary endpoints ‚Äî optimal_binary_generic","title":"Generic function for optimizing programs with binary endpoints ‚Äî optimal_binary_generic","text":"Generic function optimizing programs binary endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing programs with binary endpoints ‚Äî optimal_binary_generic","text":"","code":"optimal_binary_generic(   w,   p0,   p11,   p12,   in1,   in2,   n2min,   n2max,   stepn2,   rrgomin,   rrgomax,   steprrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_binary_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing programs with binary endpoints ‚Äî optimal_binary_generic","text":"w weight mixture prior distribution p0 assumed true rate control group, see details p11 assumed true rate treatment group, see details p12 assumed true rate treatment group, see details in1 amount information p11 terms sample size, see details in2 amount information p12 terms sample size, see details n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number rrgomin minimal threshold value go/-go decision rule rrgomax maximal threshold value go/-go decision rule steprrgo step size optimization RRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" gamma model different populations phase II III choose gamma != 0, default: 0, see details fixed choose true treatment effects fixed random, TRUE p11 used fixed effect p1 num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing drug development programs ‚Äî optimal_generic","title":"Generic function for optimizing drug development programs ‚Äî optimal_generic","text":"Generic function optimizing drug development programs","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing drug development programs ‚Äî optimal_generic","text":"","code":"optimal_generic(beta, alpha, c2, c3, c02, c03, K, N, S, b1, b2, b3, num_cl)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing drug development programs ‚Äî optimal_generic","text":"c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"function optimal_multiarm drugdevelopR package enables planning multi-arm phase II/III drug development programs optimal sample size allocation go/-go decision rules (Preussler et. al, 2019) time--event endpoints. far, three-arm trials two treatments one control supported. assumed true treatment effects assumed fixed (planning also possible via user-friendly R Shiny App: multiarm). Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"","code":"optimal_multiarm(   hr1,   hr2,   ec,   n2min,   n2max,   stepn2,   hrgomin,   hrgomax,   stephrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   strategy,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"hr1 assumed true treatment effect HR scale treatment 1 hr2 assumed true treatment effect HR scale treatment 2 ec control arm event rate phase II III n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo step size optimization HRgo alpha one-sided significance level/family-wise error rate beta type-II error rate pair, .e. 1 - beta (-pair) power calculation number events phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" strategy choose strategy: 1 (best promising candidate), 2 (promising candidates) 3 (strategies) num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"output function data.frame object containing optimization results: u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value HRgo optimal threshold value decision rule go phase III d2 optimal total number events phase II d3 total expected number events phase III; rounded next natural number d total expected number events program; d = d2 + d3 n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg2 probability successful program two arms phase III sProg3 probability successful program three arms phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal Designs Multi-Arm Phase II/III Drug Development Programs. Submitted peer-review journal. IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for multi-arm programs with time-to-event endpoint ‚Äî optimal_multiarm","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multiarm(hr1 = 0.75, hr2 = 0.80,    # define assumed true HRs    ec = 0.6,                                          # control arm event rate   n2min = 30, n2max = 90, stepn2 = 6,                # define optimization set for n2   hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05,     # define optimization set for HRgo   alpha = 0.025, beta = 0.1,                         # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,           # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                        # set constraints   steps1 = 1,                                        # define lower boundary for \"small\"   stepm1 = 0.95,                                     # \"medium\"   stepl1 = 0.85,                                     # and \"large\" effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                   # define expected benefit    strategy = 1,                                      # choose strategy: 1, 2 or 3   num_cl = 1)                                        # number of cores for parallelized computing  #> Optimization result: #>  Utility: 56.47 #>  Sample size: #>    phase II: 90, phase III: 420, total: 510 #>  Probability to go to phase III: 0.77 #>  Total cost: #>    phase II: 168, phase III: 535, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.37 #>  Success probability for a trial with: #>    two arms in phase III: 0.37, three arms in phase III: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [HRgo]  #>  Assumed true effects [HR]:  #>    treatment 1: 0.75,  treatment 2: 0.8 #>  Control arm event rate: 0.6   # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"optimal_multiarm_binary function enables planning multi-arm phase II/III drug development programs optimal sample size allocation go/-go decision rules. binary endpoints treatment effect measured risk ratio (RR). far, three-arm trials two treatments one control supported. assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"","code":"optimal_multiarm_binary(   p0,   p11,   p12,   n2min,   n2max,   stepn2,   rrgomin,   rrgomax,   steprrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   strategy,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"p0 assumed true rate control group p11 assumed true rate treatment arm 1 p12 assumed true rate treatment arm 2 n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 rrgomin minimal threshold value go/-go decision rule rrgomax maximal threshold value go/-go decision rule steprrgo step size optimization RRgo alpha one-sided significance level/family-wise error rate beta type-II error rate pair, .e. 1 - beta (-pair) power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" strategy choose strategy: 1 (best promising candidate), 2 (promising candidates) 3 (strategies) num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"output function data.frame object containing optimization results: u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value RRgo optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg2 probability successful program two arms phase III sProg3 probability successful program three arms phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for multi-arm programs with binary endpoint ‚Äî optimal_multiarm_binary","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multiarm_binary( p0 = 0.6,    p11 =  0.3, p12 = 0.5,    n2min = 20, n2max = 100, stepn2 = 4,               # define optimization set for n2   rrgomin = 0.7, rrgomax = 0.9, steprrgo = 0.05,     # define optimization set for RRgo   alpha = 0.025, beta = 0.1,                         # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,           # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                        # set constraints   steps1 = 1,                                        # define lower boundary for \"small\"   stepm1 = 0.95,                                     # \"medium\"   stepl1 = 0.85,                                     # and \"large\" effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                   # define expected benefits    strategy = 1, num_cl = 1)                          # number of cores for parallelized computing  #> Optimization result: #>  Utility: 1562.11 #>  Sample size: #>    phase II: 100, phase III: 193, total: 293 #>  Probability to go to phase III: 0.97 #>  Total cost: #>    phase II: 175, phase III: 338, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.76 #>  Success probability for a trial with: #>    two arms in phase III: 0.76, three arms in phase III: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [RRgo]  #>  Assumed true rates:  #>    control group: 0.6,  treatment 1: 0.3, treatment 2: 0.5   # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing multi-arm programs ‚Äî optimal_multiarm_generic","title":"Generic function for optimizing multi-arm programs ‚Äî optimal_multiarm_generic","text":"Generic function optimizing multi-arm programs","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing multi-arm programs ‚Äî optimal_multiarm_generic","text":"","code":"optimal_multiarm_generic(   n2min,   n2max,   stepn2,   beta,   alpha,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   strategy,   num_cl )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing multi-arm programs ‚Äî optimal_multiarm_generic","text":"n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 beta type-II error rate pair, .e. 1 - beta (-pair) power calculation sample size phase III alpha one-sided significance level/family-wise error rate c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" strategy choose strategy: 1 (best promising candidate), 2 (promising candidates) 3 (strategies) num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"optimal_multiarm_normal function enables planning multi-arm phase II/III drug development programs optimal sample size allocation go/-go decision rules. normally distributed endpoints, treatment effect measured standardized difference means (Delta). far, three-arm trials two treatments one control supported. assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"","code":"optimal_multiarm_normal(   Delta1,   Delta2,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 0,   stepm1 = 0.5,   stepl1 = 0.8,   b1,   b2,   b3,   strategy,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"Delta1 assumed true treatment effect standardized difference means treatment arm 1 Delta2 assumed true treatment effect standardized difference means treatment arm 2 n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa alpha one-sided significance level/family-wise error rate beta type-II error rate pair, .e. 1 - beta (-pair) power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" strategy choose strategy: 1 (best promising candidate), 2 (promising candidates) 3 (strategies) num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"output function data.frame object containing optimization results: u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value Kappa optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg2 probability successful program two arms phase III sProg3 probability successful program three arms phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"Cohen, J. (1988). Statistical power analysis behavioral sciences.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiarm_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for multi-arm programs with normally distributed endpoint ‚Äî optimal_multiarm_normal","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multiarm_normal(Delta1 = 0.375, Delta2 = 0.625,        n2min = 20, n2max = 100, stepn2 = 4,                 # define optimization set for n2   kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02,   # define optimization set for kappa   alpha = 0.025, beta = 0.1,                           # drug development planning parameters   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,           # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                          # set constraints   steps1 = 0,                                          # define lower boundary for \"small\"   stepm1 = 0.5,                                        # \"medium\"   stepl1 = 0.8,                                        # and \"large\" effect size categories   b1 = 3000, b2 = 8000, b3 = 10000,                    # define expected benefits    strategy = 1,   num_cl = 1)                                          # number of cores for parallelized computing  #> Optimization result: #>  Utility: 2628.89 #>  Sample size: #>    phase II: 100, phase III: 201, total: 301 #>  Probability to go to phase III: 0.99 #>  Total cost: #>    phase II: 82, phase III: 165, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.78 #>  Success probability for a trial with: #>    two arms in phase III: 0.78, three arms in phase III: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.06 [Kappa]  #>  Assumed true effects [Delta]:  #>    treatment 1: 0.375, treatment 2: 0.625   # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing drug development programs with multiple endpoints ‚Äî optimal_multiple_generic","title":"Generic function for optimizing drug development programs with multiple endpoints ‚Äî optimal_multiple_generic","text":"function used documentation generation.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing drug development programs with multiple endpoints ‚Äî optimal_multiple_generic","text":"","code":"optimal_multiple_generic(rho, alpha, n2min, n2max, stepn2, fixed)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing drug development programs with multiple endpoints ‚Äî optimal_multiple_generic","text":"rho correlation two endpoints alpha one-sided significance level/family-wise error rate n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 fixed assumed fixed treatment effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_generic.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generic function for optimizing drug development programs with multiple endpoints ‚Äî optimal_multiple_generic","text":"return value","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"function optimal_multiple_normal drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules two-arm trials two normally  distributed endpoints one control group (Preussler et. al, 2019).","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"","code":"optimal_multiple_normal(   Delta1,   Delta2,   in1,   in2,   sigma1,   sigma2,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 0,   stepm1 = 0.5,   stepl1 = 0.8,   b1,   b2,   b3,   rho,   fixed,   relaxed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"Delta1 assumed true treatment effect endpoint 1 measured difference means Delta2 assumed true treatment effect endpoint 2 measured difference means in1 amount information Delta1 terms number events in2 amount information Delta2 terms number events sigma1 variance endpoint 1 sigma2 variance endpoint 2 n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa alpha one-sided significance level/family-wise error rate beta type-II error rate pair, .e. 1 - beta (-pair) power calculation sample size phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ rho correlation two endpoints fixed assumed fixed treatment effect relaxed relaxed strict decision rule num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"output function data.frame object containing optimization results: Kappa optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"setting, drug development program defined successful proceeds phase II phase III endpoints show statistically significant treatment effect phase III. example, situation found Alzheimer‚Äôs disease trials, drug show significant results improving cognition (cognitive endpoint) well improving activities daily living (functional endpoint). effect size categories small, medium large applied endpoints. order define overall effect size two individual effect sizes, function implements two different combination rules: strict rule (relaxed = FALSE) assigning large overall effect case endpoints show effect large size, small overall effect case least one endpoints shows small effect, medium overall effect otherwise, relaxed rule (relaxed = TRUE) assigning large overall effect least one endpoints shows large effect, small effect endpoints show  small effect, medium overall effect otherwise. Fast computing enabled parallel programming. Monte Carlo simulations applied calculating utility, event count operating characteristics setting. Hence, results affected random uncertainty.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"Meinhard Kieser, Marietta Kirchner, Eva D√∂lger, Heiko G√∂tte (2018). Optimal planning phase II/III programs clinical trials multiple endpoints IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for programs with multiple normally distributed endpoints ‚Äî optimal_multiple_normal","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ set.seed(123) # This function relies on Monte Carlo integration optimal_multiple_normal(Delta1 = 0.75,   Delta2 = 0.80, in1=300, in2=600,                   # define assumed true HRs   sigma1 = 8, sigma2= 12,                            # variances for both endpoints   n2min = 30, n2max = 90, stepn2 = 10,               # define optimization set for n2   kappamin = 0.05, kappamax = 0.2, stepkappa = 0.05, # define optimization set for HRgo   alpha = 0.025, beta = 0.1,                         # planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,           # fixed/variable costs: phase II/III   K = Inf, N = Inf, S = -Inf,                        # set constraints   steps1 = 0,                                        # define lower boundary for \"small\"   stepm1 = 0.5,                                      # \"medium\"   stepl1 = 0.8,                                      # and \"large\" effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                   # define expected benefit   rho = 0.5, relaxed = TRUE,                         # strict or relaxed rule   fixed = TRUE,                                      # treatment effect   num_cl = 1)                                        # parallelized computing #> Optimization result: #>  Utility: -126.46 #>  Sample size: #>    phase II: 30, phase III: 29, total: 59 #>  Probability to go to phase III: 0.37 #>  Total cost: #>    phase II: 122, phase III: 84, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 0 (1000), medium: 0.5 (2000), large: 0.8 (3000) #>  Success probability: 0.08 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.08, medium: 0, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.05 [Kappa]  #>  Assumed true effects [Delta]:  #>    endpoint 1: 0.75, endpoint 2: 0.8 #>  Correlation between endpoints: 0.5   # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"function optimal_multiple_tte drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules (Preussler et. al, 2019) two-arm trial two time--event endpoints.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"","code":"optimal_multiple_tte(   hr1,   hr2,   id1,   id2,   n2min,   n2max,   stepn2,   hrgomin,   hrgomax,   stephrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   b11,   b21,   b31,   b12,   b22,   b32,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   rho,   fixed = TRUE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"hr1 assumed true treatment effect HR scale endpoint 1 (e.g. OS) hr2 assumed true treatment effect HR scale endpoint 2 (e.g. PFS) id1 amount information hr1 terms number events id2 amount information hr2 terms number events n2min minimal total sample size phase II, must divisible 3 n2max maximal total sample size phase II, must divisible 3 stepn2 stepsize optimization n2, must divisible 3 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo step size optimization HRgo alpha one-sided significance level/family-wise error rate beta type-II error rate pair, .e. 1 - beta (-pair) power calculation number events phase III c2 variable per-patient cost phase II 10^5 $. c3 variable per-patient cost phase III 10^5 $. c02 fixed cost phase II 10^5 $. c03 fixed cost phase III 10^5 $. K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b11 expected gain effect size category \"small\" endpoint 1 significant (endpoint 2 may may significant) b21 expected gain effect size category \"medium\" endpoint 1 significant (endpoint 2 may may significant) b31 expected gain effect size category \"large\" endpoint 1 significant (endpoint 2 may may significant) b12 expected gain effect size category \"small\" endpoint 1 significant, endpoint 2 b22 expected gain effect size category \"medium\"endpoint 1 significant, endpoint 2 b32 expected gain effect size category \"large\" endpoint 1 significant, endpoint 2 steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 rho correlation two endpoints fixed assumed fixed treatment effect num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"output function data.frame object containing optimization results: u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value HRgo optimal threshold value decision rule go phase III d2 optimal total number events phase II d3 total expected number events phase III; rounded next natural number d total expected number events program; d = d2 + d3 n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"setting, drug development program defined successful proceeds phase II phase III least one endpoint shows statistically significant treatment effect phase III. example, situation found oncology trials, overall survival (OS) progression-free survival (PFS) two endpoints interest. gain successful program may differ according importance endpoint significant. endpoint 1 significant (matter whether endpoint 2 significant ), gains b11, b21 b31 used calculation utility. endpoint 2 significant,  b12, b22 b32 used. also matches oncology example, OS (.e. endpoint 1) implicates larger expected gains PFS alone (.e. endpoint 2). Fast computing enabled parallel programming. Monte Carlo simulations applied calculating utility, event count operating characteristics setting. Hence, results affected random uncertainty. extent uncertainty discussed (Kieser et al. 2018).","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"Kieser, M., Kirchner, M. D√∂lger, E., G√∂tte, H. (2018).Optimal planning phase II/III programs clinical trials multiple endpoints, Pharm Stat. 2018 Sep; 17(5):437-457. Preussler, S., Kirchner, M., Goette, H., Kieser, M. (2019). Optimal Designs Multi-Arm Phase II/III Drug Development Programs. Submitted peer-review journal. IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multiple_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning for programs with multiple time-to-event endpoints ‚Äî optimal_multiple_tte","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ set.seed(123) # This function relies on Monte Carlo integration optimal_multiple_tte(hr1 = 0.75,   hr2 = 0.80, id1 = 210, id2 = 420,          # define assumed true HRs   n2min = 30, n2max = 90, stepn2 = 6,        # define optimization set for n2   hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05, # define optimization set for HRgo   alpha = 0.025, beta = 0.1,                 # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,   # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                # set constraints   steps1 = 1,                                # define lower boundary for \"small\"   stepm1 = 0.95,                             # \"medium\"   stepl1 = 0.85,                             # and \"large\" effect size categories   b11 = 1000, b21 = 2000, b31 = 3000,   b12 = 1000, b22 = 1500, b32 = 2000,        # define expected benefits (both scenarios)   rho = 0.6, fixed = TRUE,                   # correlation and treatment effect   num_cl = 1)                                # number of cores for parallelized computing #> Optimization result: #>  Utility: 171.6 #>  Sample size: #>    phase II: 90, phase III: 301, total: 391 #>  Probability to go to phase III: 0.79 #>  Total cost: #>    phase II: 168, phase III: 420, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories: #>   small: 1 medium: 0.95 large: 0.85 #>  Expected gains if endpoint 1 is significant: #>   small: 1000 medium: 2000 large: 3000 #>  Expected gains if only endpoint 2 is significant: #>   small: 1000 medium: 1500 large: 2000 #>  Success probability: 0.43 #>  Joint probability of success and observed effect of size ... in phase III: #>    medium: 0.23, large: 0.09 #>  Probability of endpoint 1 being significant in phase III: 0.61 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [HRgo]  #>  Assumed true effects [HR]:  #>    endpoint 1: 0.75,  endpoint2 2: 0.8 #>  Correlation between endpoints: 0.6  # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"function optimal_multitrial drugdevelopR package enables planning phase II/III drug development programs time--event endpoints programs several phase III trials (Preussler et. al, 2019). main output values optimal sample size allocation optimal go/-go decision rules. assumed true treatment effects can assumed fixed (planning also possible via user friendly R Shiny App: multitrial) can modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"","code":"optimal_multitrial(   w,   hr1,   hr2,   id1,   id2,   d2min,   d2max,   stepd2,   hrgomin,   hrgomax,   stephrgo,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   b1,   b2,   b3,   case,   strategy = TRUE,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"w weight mixture prior distribution, see Shiny application choice weights hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events d2min minimal number events phase II d2max maximal number events phase II stepd2 step size optimization d2 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo step size optimization HRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III Schoenfeld's formula (Schoenfeld 1981) xi2 assumed event rate phase II, used calculating sample size phase II via n2 = d2/xi2 xi3 event rate phase III, used calculating sample size phase III analogy xi2 c2 variable per-patient cost phase II 10^5 $. c3 variable per-patient cost phase III 10^5 $. c02 fixed cost phase II 10^5 $. c03 fixed cost phase III 10^5 $. K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" case choose case: \"least 1, 2 3 significant trials needed approval\" strategy choose strategy: \"conduct 1, 2, 3 4 trials order achieve case's goal\"; TRUE calculates strategies selected case fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect hr2 ignored num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"output function data.frame object containing optimization results: Strategy Strategy: \"number trials conducted order achieve goal case\" u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value HRgo optimal threshold value decision rule go phase III d2 optimal total number events phase II d3 total expected number events phase III; rounded next natural number d total expected number events program; d = d2 + d3 n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III (lower boundary HR scale set 1, proposed IQWiG (2016)) sProg2 probability successful program \"medium\" treatment effect phase III (lower boundary HR scale set 0.95, proposed IQWiG (2016)) sProg3 probability successful program \"large\" treatment effect phase III (lower boundary HR scale set 0.85, proposed IQWiG (2016)) K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"effect-sizes","dir":"Reference","previous_headings":"","what":"Effect sizes","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"settings, definition \"small\", \"medium\" \"large\" effect sizes can user-specified using input parameters steps1, stepm1 stepl1. Due complexity multitrial setting, feature included setting. Instead, effect sizes set predefined values explained sProg1, sProg2 sProg3 Value section.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19. Preussler, S., Kieser, M., Kirchner, M. (2019). Optimal sample size allocation go/-go decision rules phase II/III programs several phase III trials performed. Biometrical Journal, 61(2), 357-378. Schoenfeld, D. (1981). asymptotic properties nonparametric tests comparing survival distributions. Biometrika, 68(1), 316-319.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning where several phase III trials are performed for time-to-event endpoints ‚Äî optimal_multitrial","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multitrial(w = 0.3,                # define parameters for prior   hr1 = 0.69, hr2 = 0.88, id1 = 210, id2 = 420,     # (https://web.imbi.uni-heidelberg.de/prior/)   d2min = 20, d2max = 100, stepd2 = 5,              # define optimization set for d2   hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05,    # define optimization set for HRgo   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,  # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,          # fixed and variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                       # set constraints   b1 = 1000, b2 = 2000, b3 = 3000,                  # expected benefit for each effect size   case = 1, strategy = TRUE,                        # chose Case and Strategy   fixed = TRUE,                                     # true treatment effects are fixed/random   num_cl = 1)                                       # number of cores for parallelized computing #> Optimization result with 1 significant trial(s) needed, strategy 1: #>  Utility: 859.71 #>  Sample size: #>    phase II: 144, phase III: 446, total: 590 #>  Expected number of events: #>    phase II: 100, phase III: 312, total: 412 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.85 #>  Total cost: #>    phase II: 208, phase III: 574, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.67 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.07, medium: 0.21, large: 0.38 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [HRgo]  #>  Assumed true effect: 0.69 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  #> Optimization result with 1 significant trial(s) needed, strategy 2: #>  Utility: 714.39 #>  Sample size: #>    phase II: 144, phase III: 628, total: 772 #>  Expected number of events: #>    phase II: 100, phase III: 440, total: 540 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.77 #>  Total cost: #>    phase II: 208, phase III: 859, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.68 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.05, medium: 0.18, large: 0.46 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.8 [HRgo]  #>  Assumed true effect: 0.69 [hr]  #>  Treatment effect offset between phase II and III: 0 [gamma]  #>  # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"optimal_multitrial_binary function enables planning phase II/III drug development programs several phase III trials binary endpoint. main output values optimal sample size allocation go/-go decision rules. binary endpoints, treatment effect measured risk ratio (RR).","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"","code":"optimal_multitrial_binary(   w,   p0,   p11,   p12,   in1,   in2,   n2min,   n2max,   stepn2,   rrgomin,   rrgomax,   steprrgo,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   b1,   b2,   b3,   case,   strategy = TRUE,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"w weight mixture prior distribution p0 assumed true rate control group, see details p11 assumed true rate treatment group, see details p12 assumed true rate treatment group, see details in1 amount information p11 terms sample size, see details in2 amount information p12 terms sample size, see details n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number rrgomin minimal threshold value go/-go decision rule rrgomax maximal threshold value go/-go decision rule steprrgo step size optimization RRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" case choose case: \"least 1, 2 3 significant trials needed approval\" strategy choose strategy: \"conduct 1, 2, 3 4 trials order achieve case's goal\"; TRUE calculates strategies selected case fixed choose true treatment effects fixed random, TRUE p11 used fixed effect p1 num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"output function data.frame object containing optimization results: Strategy Strategy: \"number trials conducted order achieve goal case\" u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value RRgo optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III (lower boundary HR scale set 1, proposed IQWiG (2016)) sProg2 probability successful program \"medium\" treatment effect phase III (lower boundary HR scale set 0.95, proposed IQWiG (2016)) sProg3 probability successful program \"large\" treatment effect phase III (lower boundary HR scale set 0.85, proposed IQWiG (2016)) K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"effect-sizes","dir":"Reference","previous_headings":"","what":"Effect sizes","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"settings, definition \"small\", \"medium\" \"large\" effect sizes can user-specified using input parameters steps1, stepm1 stepl1. Due complexity multitrial setting, feature included setting. Instead, effect sizes set predefined values explained sProg1, sProg2 sProg3 Value section.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, assessed last 15.05.19.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_binary","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multitrial_binary(w = 0.3,         # define parameters for prior   p0 = 0.6, p11 =  0.3, p12 = 0.5,   in1 = 30, in2 = 60,                             # (https://web.imbi.uni-heidelberg.de/prior/)   n2min = 20, n2max = 100, stepn2 = 4,            # define optimization set for n2   rrgomin = 0.7, rrgomax = 0.9, steprrgo = 0.05,  # define optimization set for RRgo   alpha = 0.025, beta = 0.1,                      # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,        # fixed and variable costs for phase II/III,   K = Inf, N = Inf, S = -Inf,                     # set constraints   b1 = 1000, b2 = 2000, b3 = 3000,                # expected benefit for a each effect size   case = 1, strategy = TRUE,                      # chose Case and Strategy                                      fixed = TRUE,                                   # true treatment effects are fixed/random   num_cl = 1)                                     # number of cores for parallelized computing #> Optimization result with 1 significant trial(s) needed, strategy 1: #>  Utility: 1705.68 #>  Sample size: #>    phase II: 100, phase III: 180, total: 280 #>  Probability to go to phase III: 0.98 #>  Total cost: #>    phase II: 175, phase III: 328, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.8 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.04, medium: 0.12, large: 0.65 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.85 [RRgo]  #>  Assumed true effect: #>   rate in the control: 0.6, rate in the treatment group: 0.3 #>  #> Optimization result with 1 significant trial(s) needed, strategy 2: #>  Utility: 1794.26 #>  Sample size: #>    phase II: 100, phase III: 324, total: 424 #>  Probability to go to phase III: 0.97 #>  Total cost: #>    phase II: 175, phase III: 616, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.9 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.02, medium: 0.08, large: 0.8 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.8 [RRgo]  #>  Assumed true effect: #>   rate in the control: 0.6, rate in the treatment group: 0.3 #>    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing multi-trial programs ‚Äî optimal_multitrial_generic","title":"Generic function for optimizing multi-trial programs ‚Äî optimal_multitrial_generic","text":"Generic function optimizing multi-trial programs","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing multi-trial programs ‚Äî optimal_multitrial_generic","text":"","code":"optimal_multitrial_generic(case, strategy = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing multi-trial programs ‚Äî optimal_multitrial_generic","text":"case choose case: \"least 1, 2 3 significant trials needed approval\" strategy choose strategy: \"conduct 1, 2, 3 4 trials order achieve case's goal\"; TRUE calculates strategies selected case","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_generic.html","id":"effect-sizes","dir":"Reference","previous_headings":"","what":"Effect sizes","title":"Generic function for optimizing multi-trial programs ‚Äî optimal_multitrial_generic","text":"settings, definition \"small\", \"medium\" \"large\" effect sizes can user-specified using input parameters steps1, stepm1 stepl1. Due complexity multitrial setting, feature included setting. Instead, effect sizes set predefined values explained sProg1, sProg2 sProg3 Value section.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"optimal_multitrial_normal function enables planning phase II/III drug development programs several phase III trials normally distributed endpoint. main output values optimal sample size allocation go/-go decision rules. normally distributed endpoints, treatment effect measured standardized difference means (Delta). assumed true treatment effects can assumed fixed modelled prior distribution.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"","code":"optimal_multitrial_normal(   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   b1,   b2,   b3,   case,   strategy = TRUE,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"w weight mixture prior distribution Delta1 assumed true prior treatment effect measured standardized difference means, see details Delta2 assumed true prior treatment effect measured standardized difference means, see details in1 amount information Delta1 terms sample size, see details in2 amount information Delta2 terms sample size, see details lower boundary truncation prior distribution b upper boundary truncation prior distribution n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation sample size phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ case choose case: \"least 1, 2 3 significant trials needed approval\" strategy choose strategy: \"conduct 1, 2, 3 4 trials order achieve case's goal\"; TRUE calculates strategies selected case fixed choose true treatment effects fixed following prior distribution, TRUE Delta1 used fixed effect num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"output function data.frame object containing optimization results: Strategy Strategy: \"number trials conducted order achieve goal case\" u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value Kappa optimal threshold value decision rule go phase III n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III (lower boundary HR scale set 0, proposed Cohen (1988)) sProg2 probability successful program \"medium\" treatment effect phase III (lower boundary HR scale set 0.5, proposed Cohen (1988)) sProg3 probability successful program \"large\" treatment effect phase III (lower boundary HR scale set 0.8, proposed Cohen (1988)) K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"effect-sizes","dir":"Reference","previous_headings":"","what":"Effect sizes","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"settings, definition \"small\", \"medium\" \"large\" effect sizes can user-specified using input parameters steps1, stepm1 stepl1. Due complexity multitrial setting, feature included setting. Instead, effect sizes set predefined values explained sProg1, sProg2 sProg3 Value section.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"Cohen, J. (1988). Statistical power analysis behavioral sciences.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_multitrial_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning where several phase III trials are performed ‚Äî optimal_multitrial_normal","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_multitrial_normal(w = 0.3,           # define parameters for prior   Delta1 = 0.375, Delta2 = 0.625,   in1 = 300, in2 = 600,                               # (https://web.imbi.uni-heidelberg.de/prior/)   a = 0.25, b = 0.75,   n2min = 20, n2max = 100, stepn2 = 4,                # define optimization set for n2   kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02,  # define optimization set for kappa   alpha = 0.025, beta = 0.1,                          # drug development planning parameters   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,          # fixed and variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                         # set constraints   b1 = 3000, b2 = 8000, b3 = 10000,                   # expected benefit for each effect size                                            case = 1, strategy = TRUE,                          # chose Case and Strategy   fixed = TRUE,                                       # true treatment effects are fixed/random   num_cl = 1)                                         # number of cores for parallelized computing #> Optimization result with 1 significant trial(s) needed, strategy 1: #>  Utility: 1768.13 #>  Sample size: #>    phase II: 100, phase III: 460, total: 560 #>  Probability to go to phase III: 0.92 #>  Total cost: #>    phase II: 82, phase III: 350, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.73 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.73, medium: 0, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.1 [Kappa]  #>  Assumed true effect: 0.375 [Delta]  #>  #> Optimization result with 1 significant trial(s) needed, strategy 2: #>  Utility: 1774.37 #>  Sample size: #>    phase II: 100, phase III: 712, total: 812 #>  Probability to go to phase III: 0.88 #>  Total cost: #>    phase II: 82, phase III: 548, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.8 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.79, medium: 0, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.14 [Kappa]  #>  Assumed true effect: 0.375 [Delta]  #>    # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"function optimal_normal drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules normally distributed endpoints. treatment effect measured standardized difference means. assumed true treatment effects can assumed fixed modelled prior distribution. R Shiny application prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"","code":"optimal_normal(   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 0,   stepm1 = 0.5,   stepl1 = 0.8,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   skipII = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"w weight mixture prior distribution Delta1 assumed true prior treatment effect measured standardized difference means, see details Delta2 assumed true prior treatment effect measured standardized difference means, see details in1 amount information Delta1 terms sample size, see details in2 amount information Delta2 terms sample size, see details lower boundary truncation prior distribution b upper boundary truncation prior distribution n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation sample size phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ gamma model different populations phase II III choose gamma != 0, default: 0, see details fixed choose true treatment effects fixed following prior distribution, TRUE Delta1 used fixed effect skipII choose skipping phase II option, default: FALSE; TRUE, program calculates expected utility case phase II skipped compares situation phase II skipped. results returned two-row data frame, res[1, ] results including phase II res[2, ] skipping phase II. res[2, ] additional parameter, res[2, ]$median_prior_Delta, assumed effect size used planning phase III study phase II skipped. num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"output function optimal_normal data.frame containing optimization results: u maximal expected utility optimization constraints, .e. expected utility optimal sample size threshold value Kappa optimal threshold value decision rule go phase III n2 total sample size phase II n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data.frame object lists used optimization sequences, start finish date optimization procedure. Taking attr(,\"trace\") returns utility values parameter combinations visited optimization","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"Cohen, J. (1988). Statistical power analysis behavioral sciences.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning with normally distributed endpoint ‚Äî optimal_normal","text":"","code":"# Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize # \\donttest{ optimal_normal(w=0.3,                       # define parameters for prior   Delta1 = 0.375, Delta2 = 0.625, in1=300, in2=600,  # (https://web.imbi.uni-heidelberg.de/prior/)   a = 0.25, b = 0.75,   n2min = 20, n2max = 100, stepn2 = 4,               # define optimization set for n2   kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02, # define optimization set for kappa   alpha = 0.025, beta = 0.1,                          # drug development planning parameters   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,         # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                        # set constraints   steps1 = 0,                                        # define lower boundary for \"small\"   stepm1 = 0.5,                                      # \"medium\"   stepl1 = 0.8,                                      # and \"large\" effect size categories   b1 = 3000, b2 = 8000, b3 = 10000,                  # benefit for each effect size category   gamma = 0,                                         # population structures in phase II/III   fixed = FALSE,                                     # true treatment effects are fixed/random   skipII = FALSE,                                    # skipping phase II   num_cl = 1)                                        # number of cores for parallelized computing #> Optimization result: #>  Utility: 2090.29 #>  Sample size: #>    phase II: 100, phase III: 372, total: 472 #>  Probability to go to phase III: 0.93 #>  Total cost: #>    phase II: 82, phase III: 287, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.76 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.03, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.1 [Kappa]  #>  Parameters of the prior distribution:  #>    Delta1: 0.375, Delta2: 0.625, in1: 300, in2: 600, #>    a: 0.25, b: 0.75, w: 0.3 #>  Treatment effect offset between phase II and III: 0 [gamma]  # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimizing normally distributed endpoints ‚Äî optimal_normal_generic","title":"Generic function for optimizing normally distributed endpoints ‚Äî optimal_normal_generic","text":"Generic function optimizing normally distributed endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimizing normally distributed endpoints ‚Äî optimal_normal_generic","text":"","code":"optimal_normal_generic(   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   n2min,   n2max,   stepn2,   kappamin,   kappamax,   stepkappa,   alpha,   beta,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 0,   stepm1 = 0.5,   stepl1 = 0.8,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_normal_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimizing normally distributed endpoints ‚Äî optimal_normal_generic","text":"w weight mixture prior distribution Delta1 assumed true prior treatment effect measured standardized difference means, see details Delta2 assumed true prior treatment effect measured standardized difference means, see details in1 amount information Delta1 terms sample size, see details in2 amount information Delta2 terms sample size, see details lower boundary truncation prior distribution b upper boundary truncation prior distribution n2min minimal total sample size phase II; must even number n2max maximal total sample size phase II, must even number stepn2 step size optimization n2; must even number kappamin minimal threshold value kappa go/-go decision rule kappamax maximal threshold value  kappa go/-go decision rule stepkappa step size optimization threshold value kappa alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation sample size phase III c2 variable per-patient cost phase II 10^5 $ c3 variable per-patient cost phase III 10^5 $ c02 fixed cost phase II 10^5 $ c03 fixed cost phase III 10^5 $ K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" 10^5 $ b2 expected gain effect size category \"medium\" 10^5 $ b3 expected gain effect size category \"large\" 10^5 $ gamma model different populations phase II III choose gamma != 0, default: 0, see details fixed choose true treatment effects fixed following prior distribution, TRUE Delta1 used fixed effect num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_return_doc.html","id":null,"dir":"Reference","previous_headings":"","what":"Function for generating documentation of return values ‚Äî optimal_return_doc","title":"Function for generating documentation of return values ‚Äî optimal_return_doc","text":"Generates documentation return value optimal function including custom text.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_return_doc.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Function for generating documentation of return values ‚Äî optimal_return_doc","text":"","code":"optimal_return_doc(type, setting = \"basic\")"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_return_doc.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Function for generating documentation of return values ‚Äî optimal_return_doc","text":"type string deciding whether return text normal, binary time--event endpoints setting string containing setting, .e. \"basic\", \"bias\", \"multitrial\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_return_doc.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Function for generating documentation of return values ‚Äî optimal_return_doc","text":"string containing documentation return value.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"function optimal_tte drugdevelopR package enables planning phase II/III drug development programs optimal sample size allocation go/-go decision rules time--event endpoints (Kirchner et al., 2016). assumed true treatment effects can assumed fixed modelled prior distribution. assuming fixed true treatment effects, planning can also done user-friendly R Shiny app basic. app prior visualizes prior distributions used package. Fast computing enabled parallel programming.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"","code":"optimal_tte(   w,   hr1,   hr2,   id1,   id2,   d2min,   d2max,   stepd2,   hrgomin,   hrgomax,   stephrgo,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   skipII = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"data.frame containing optimization results (see Value)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"w weight mixture prior distribution, see Shiny application choice weights hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events d2min minimal number events phase II d2max maximal number events phase II stepd2 step size optimization d2 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo step size optimization HRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III Schoenfeld's formula (Schoenfeld 1981) xi2 assumed event rate phase II, used calculating sample size phase II via n2 = d2/xi2 xi3 event rate phase III, used calculating sample size phase III analogy xi2 c2 variable per-patient cost phase II 10^5 $. c3 variable per-patient cost phase III 10^5 $. c02 fixed cost phase II 10^5 $. c03 fixed cost phase III 10^5 $. K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" gamma model different populations phase II III choose gamma != 0, default: 0 fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect hr2 ignored skipII choose skipping phase II option, default: FALSE; TRUE, program calculates expected utility case phase II skipped compares situation phase II skipped. results returned two-row data frame, res[1, ] results including phase II res[2, ] skipping phase II. res[2, ] additional parameter, res[2, ]$median_prior_HR, assumed hazards ratio used planning phase III study phase II skipped. calculated exponential function median prior function. num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"output function data.frame object containing optimization results: HRgo optimal threshold value decision rule go phase III d2 optimal total number events phase II d3 total expected number events phase III; rounded next natural number d total expected number events program; d = d2 + d3 n2 total sample size phase II; rounded next even natural number n3 total sample size phase III; rounded next even natural number n total sample size program; n = n2 + n3 K maximal costs program (.e. cost constraint, set sum K2+K3 cost constraint set) pgo probability go phase III sProg probability successful program sProg1 probability successful program \"small\" treatment effect phase III sProg2 probability successful program \"medium\" treatment effect phase III sProg3 probability successful program \"large\" treatment effect phase III K2 expected costs phase II K3 expected costs phase III input parameters. Taking cat(comment()) data frame lists used optimization sequences, start finish time optimization procedure. attribute attr(,\"trace\") returns utility values parameter combinations visited optimization.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"Kirchner, M., Kieser, M., Goette, H., & Schueler, . (2016). Utility-based optimization phase II/III programs. Statistics Medicine, 35(2), 305-316. IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available https://www.iqwig.de/ueber-uns/methoden/methodenpapier/, last access 15.05.19. Schoenfeld, D. (1981). asymptotic properties nonparametric tests comparing survival distributions. Biometrika, 68(1), 316-319.","code":""},{"path":[]},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Optimal phase II/III drug development planning with time-to-event endpoint ‚Äî optimal_tte","text":"","code":"# Activate progress bar (optional) if (FALSE) { # \\dontrun{ progressr::handlers(global = TRUE) } # } # Optimize # \\donttest{ optimal_tte(w = 0.3,                    # define parameters for prior   hr1 = 0.69, hr2 = 0.88, id1 = 210, id2 = 420,   # (https://web.imbi.uni-heidelberg.de/prior/)   d2min = 20, d2max = 100, stepd2 = 5,            # define optimization set for d2   hrgomin = 0.7, hrgomax = 0.9, stephrgo = 0.05,  # define optimization set for HRgo   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7, # drug development planning parameters   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,        # fixed/variable costs for phase II/III   K = Inf, N = Inf, S = -Inf,                     # set constraints   steps1 = 1,                                     # define lower boundary for \"small\"   stepm1 = 0.95,                                  # \"medium\"   stepl1 = 0.85,                                  # and \"large\" treatment effect size categories   b1 = 1000, b2 = 2000, b3 = 3000,                # expected benefit for each effect size category   gamma = 0,                                      # population structures in phase II/III   fixed = FALSE,                                  # true treatment effects are fixed/random   skipII = FALSE,                                 # skipping phase II    num_cl = 1)                                     # number of cores for parallelized computing  #> Optimization result: #>  Utility: 75.8 #>  Sample size: #>    phase II: 122, phase III: 210, total: 332 #>  Expected number of events: #>    phase II: 85, phase III: 147, total: 232 #>  Assumed event rate: #>    phase II: 0.7, phase III: 0.7 #>  Probability to go to phase III: 0.46 #>  Total cost: #>    phase II: 192, phase III: 278, cost constraint: Inf #>  Fixed cost: #>    phase II: 100, phase III: 150 #>  Variable cost per patient: #>    phase II: 0.75, phase III: 1 #>  Effect size categories (expected gains): #>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000) #>  Success probability: 0.24 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.05, medium: 0.09, large: 0.11 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.8 [HRgo]  #>  Parameters of the prior distribution:  #>    hr1: 0.69,  hr2: 0.88, id1: 210, id2: 420, w: 0.3 #>  Treatment effect offset between phase II and III: 0 [gamma]  # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte_generic.html","id":null,"dir":"Reference","previous_headings":"","what":"Generic function for optimal planning of time-to-event endpoints ‚Äî optimal_tte_generic","title":"Generic function for optimal planning of time-to-event endpoints ‚Äî optimal_tte_generic","text":"Generic function optimal planning time--event endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte_generic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generic function for optimal planning of time-to-event endpoints ‚Äî optimal_tte_generic","text":"","code":"optimal_tte_generic(   w,   hr1,   hr2,   id1,   id2,   d2min,   d2max,   stepd2,   hrgomin,   hrgomax,   stephrgo,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K = Inf,   N = Inf,   S = -Inf,   steps1 = 1,   stepm1 = 0.95,   stepl1 = 0.85,   b1,   b2,   b3,   gamma = 0,   fixed = FALSE,   num_cl = 1 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/optimal_tte_generic.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generic function for optimal planning of time-to-event endpoints ‚Äî optimal_tte_generic","text":"w weight mixture prior distribution, see Shiny application choice weights hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events d2min minimal number events phase II d2max maximal number events phase II stepd2 step size optimization d2 hrgomin minimal threshold value go/-go decision rule hrgomax maximal threshold value go/-go decision rule stephrgo step size optimization HRgo alpha one-sided significance level beta type II error rate; .e. 1 - beta power calculation number events phase III Schoenfeld's formula (Schoenfeld 1981) xi2 assumed event rate phase II, used calculating sample size phase II via n2 = d2/xi2 xi3 event rate phase III, used calculating sample size phase III analogy xi2 c2 variable per-patient cost phase II 10^5 $. c3 variable per-patient cost phase III 10^5 $. c02 fixed cost phase II 10^5 $. c03 fixed cost phase III 10^5 $. K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" gamma model different populations phase II III choose gamma != 0, default: 0 fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect hr2 ignored num_cl number clusters used parallel computing, default: 1","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/os_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability that endpoint OS significant ‚Äî os_tte","title":"Probability that endpoint OS significant ‚Äî os_tte","text":"function calculate probability endpoint OS statistically significant. context cancer research OS stands overall survival, positive treatment effect endpoints thus sufficient successful program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/os_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability that endpoint OS significant ‚Äî os_tte","text":"","code":"os_tte(HRgo, n2, alpha, beta, hr1, hr2, id1, id2, fixed, rho, rsamp)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/os_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability that endpoint OS significant ‚Äî os_tte","text":"HRgo threshold value go/-go decision rule; n2 total sample size phase II; must even number alpha one- sided significance level beta 1-beta power calculation number events phase III Schoenfeld (1981) formula hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/os_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability that endpoint OS significant ‚Äî os_tte","text":"output function os_tte() probability endpoint OS significant.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","title":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","text":"Given parameters function calculates probability go phase III second phase conducted. considered strategies follows:  Strategy: best promising treatment goes phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","text":"","code":"pgo_binary(RRgo, n2, p0, p11, p12, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","text":"RRgo threshold value go/-go decision rule n2 total sample size phase II; must even number p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","text":"function pgo_binary() returns probability go phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability to go to phase III for multiarm programs with binary distributed outcomes ‚Äî pgo_binary","text":"","code":"res <- pgo_binary(RRgo = 0.8 ,n2 = 50 ,p0 = 0.6, p11 =  0.3, p12 = 0.5,strategy = 2, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability to go to phase III for multiple endpoints with normally distributed outcomes ‚Äî pgo_multiple_normal","title":"Probability to go to phase III for multiple endpoints with normally distributed outcomes ‚Äî pgo_multiple_normal","text":"function calculated probability go phase III, .e. results phase II promising enough get successful drug development program. Successful means endpoints show statistically significant positive treatment effect phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability to go to phase III for multiple endpoints with normally distributed outcomes ‚Äî pgo_multiple_normal","text":"","code":"pgo_multiple_normal(   kappa,   n2,   Delta1,   Delta2,   in1,   in2,   sigma1,   sigma2,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability to go to phase III for multiple endpoints with normally distributed outcomes ‚Äî pgo_multiple_normal","text":"kappa threshold value go/-go decision rule; vector endpoints n2 total sample size phase II; must even number Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability to go to phase III for multiple endpoints with normally distributed outcomes ‚Äî pgo_multiple_normal","text":"output function pgo_multiple_normal() probability go phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability to go to phase III for multiple endpoints in the time-to-event setting ‚Äî pgo_multiple_tte","title":"Probability to go to phase III for multiple endpoints in the time-to-event setting ‚Äî pgo_multiple_tte","text":"function calculates probability go phase III, .e. results phase II promising enough get successful drug development program. Successful means least one endpoint shows statistically significant positive treatment effect phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability to go to phase III for multiple endpoints in the time-to-event setting ‚Äî pgo_multiple_tte","text":"","code":"pgo_multiple_tte(HRgo, n2, hr1, hr2, id1, id2, fixed, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability to go to phase III for multiple endpoints in the time-to-event setting ‚Äî pgo_multiple_tte","text":"HRgo threshold value go/-go decision rule; n2 total sample size phase II; must even number hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability to go to phase III for multiple endpoints in the time-to-event setting ‚Äî pgo_multiple_tte","text":"output function pgo_multiple_tte() probability go phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","title":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","text":"Given parameters function calculates probability go phase III second phase conducted. considered strategies follows:  Strategy: best promising treatment goes phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","text":"","code":"pgo_normal(kappa, n2, Delta1, Delta2, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","text":"kappa threshold value go/-go decision rule n2 total sample size phase II; must even number Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","text":"function pgo_normal() returns probability go phase III multiarm programs normally distributed outcomes","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability to go to phase III for multiarm programs with normally distributed outcomes ‚Äî pgo_normal","text":"","code":"res <- pgo_normal(kappa = 0.1, n2 = 50, Delta1 = 0.375, Delta2 = 0.625, strategy = 2, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","title":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","text":"Given parameters function calculates probability go phase III second phase conducted. considered strategies follows:  Strategy: best promising treatment goes phase III","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","text":"","code":"pgo_tte(HRgo, n2, ec, hr1, hr2, strategy, case)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","text":"HRgo threshold value go/-go decision rule n2 total sample size phase II, must divisible 3 ec control arm event rate phase II III hr1 assumed true treatment effect HR scale treatment 1 hr2 assumed true treatment effect HR scale treatment 2 strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") case different cases: 1 (\"nogo\"), 21 (treatment 1 promising, treatment 2 ), 22 (treatment 2 promising, treatment 1 ), 31 (treatments promising, treatment 1 better), 32 (treatments promising, treatment 2 better)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","text":"function pgo_tte() returns probability go phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pgo_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Probability to go to phase III for multiarm programs with time-to-event outcomes ‚Äî pgo_tte","text":"","code":"res <- pgo_tte(HRgo = 0.8, n2 = 48 , ec = 0.6, hr1 = 0.7, hr2 = 0.8, strategy = 2, case = 31)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/posp_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Probability of a successful program, when going to phase III for multiple endpoint with normally distributed outcomes ‚Äî posp_normal","title":"Probability of a successful program, when going to phase III for multiple endpoint with normally distributed outcomes ‚Äî posp_normal","text":"getting \"go\"-decision go phase III, .e. results phase II predefined threshold kappa, function calculates probability, program successfull, .e. endpoints show statistically significant positive treatment effect phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/posp_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probability of a successful program, when going to phase III for multiple endpoint with normally distributed outcomes ‚Äî posp_normal","text":"","code":"posp_normal(   kappa,   n2,   alpha,   beta,   Delta1,   Delta2,   sigma1,   sigma2,   in1,   in2,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/posp_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probability of a successful program, when going to phase III for multiple endpoint with normally distributed outcomes ‚Äî posp_normal","text":"kappa threshold value go/-go decision rule; n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/posp_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probability of a successful program, when going to phase III for multiple endpoint with normally distributed outcomes ‚Äî posp_normal","text":"output function posp_normal() probability successful program, going phase III.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print.drugdevelopResult.html","id":null,"dir":"Reference","previous_headings":"","what":"Printing a drugdevelopResult Object ‚Äî print.drugdevelopResult","title":"Printing a drugdevelopResult Object ‚Äî print.drugdevelopResult","text":"Displays details optimal results drugdevelopResult object.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print.drugdevelopResult.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Printing a drugdevelopResult Object ‚Äî print.drugdevelopResult","text":"","code":"# S3 method for class 'drugdevelopResult' print(x, sequence = FALSE, ...)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print.drugdevelopResult.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Printing a drugdevelopResult Object ‚Äî print.drugdevelopResult","text":"x Data frame class drugdevelopResult. sequence logical, print optimization sequence (default = FALSE)? ... arguments.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print.drugdevelopResult.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Printing a drugdevelopResult Object ‚Äî print.drugdevelopResult","text":"","code":"# \\donttest{ # Activate progress bar (optional) if (FALSE) progressr::handlers(global = TRUE) # \\dontrun{} # Optimize res <- optimal_normal(w=0.3,                          Delta1 = 0.375, Delta2 = 0.625, in1=300, in2=600,     a = 0.25, b = 0.75,   n2min = 20, n2max = 100, stepn2 = 4,                  kappamin = 0.02, kappamax = 0.2, stepkappa = 0.02,    alpha = 0.025, beta = 0.1,                          c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,      K = Inf, N = Inf, S = -Inf,                           steps1 = 0,                                         stepm1 = 0.5,                                         stepl1 = 0.8,                                         b1 = 3000, b2 = 8000, b3 = 10000,                     gamma = 0,                                            fixed = FALSE,                                       skipII = FALSE,                                       num_cl = 1) # Print results print(res)                                   #> Optimization result: #>  Utility: 2090.29 #>  Sample size: #>    phase II: 100, phase III: 372, total: 472 #>  Probability to go to phase III: 0.93 #>  Total cost: #>    phase II: 82, phase III: 287, cost constraint: Inf #>  Fixed cost: #>    phase II: 15, phase III: 20 #>  Variable cost per patient: #>    phase II: 0.675, phase III: 0.72 #>  Effect size categories (expected gains): #>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000) #>  Success probability: 0.76 #>  Joint probability of success and observed effect of size ... in phase III: #>    small: 0.72, medium: 0.03, large: 0 #>  Significance level: 0.025 #>  Targeted power: 0.9 #>  Decision rule threshold: 0.1 [Kappa]  #>  Parameters of the prior distribution:  #>    Delta1: 0.375, Delta2: 0.625, in1: 300, in2: 600, #>    a: 0.25, b: 0.75, w: 0.3 #>  Treatment effect offset between phase II and III: 0 [gamma]  # }"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print_drugdevelopResult_helper.html","id":null,"dir":"Reference","previous_headings":"","what":"Helper function for printing a drugdevelopResult Object ‚Äî print_drugdevelopResult_helper","title":"Helper function for printing a drugdevelopResult Object ‚Äî print_drugdevelopResult_helper","text":"Helper function printing drugdevelopResult Object","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print_drugdevelopResult_helper.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Helper function for printing a drugdevelopResult Object ‚Äî print_drugdevelopResult_helper","text":"","code":"print_drugdevelopResult_helper(x, ...)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print_drugdevelopResult_helper.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Helper function for printing a drugdevelopResult Object ‚Äî print_drugdevelopResult_helper","text":"x Data frame ... arguments.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/print_drugdevelopResult_helper.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Helper function for printing a drugdevelopResult Object ‚Äî print_drugdevelopResult_helper","text":"return value, called printing console using cat()","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/prior_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","title":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","text":"assume treatment effects fixed, .e. fixed = FALSE, function prior_tte allows us model treatment effect following prior distribution. details concerning definition prior distribution, see vignette priors well Shiny app.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/prior_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","text":"","code":"prior_tte(x, w, hr1, hr2, id1, id2)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/prior_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","text":"x integration variable w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/prior_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","text":"output functions Epgo_tte() expected number participants phase III conservative decision rule sample size calculation.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/prior_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Prior distribution for time-to-event outcomes ‚Äî prior_tte","text":"","code":"res <- prior_tte(x = 0.5, w = 0.5, hr1 = 0.69, hr2 = 0.88, id1 = 240, id2 = 420)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pw.html","id":null,"dir":"Reference","previous_headings":"","what":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","title":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","text":"function calculated probability treatment effect endpoint one (endpoint x) larger endpoint two (endpoint y), .e. P(x>y) = P(x-y>0)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pw.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","text":"","code":"pw(n2, hr1, hr2, id1, id2, fixed, rho)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pw.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","text":"n2 total sample size phase II; must even number hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms number events id2 amount information hr2 terms number events fixed choose true treatment effects fixed random rho correlation two endpoints","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pw.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","text":"output function pw() probability endpoint one better result endpoint two","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/pw.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Probabilty that effect in endpoint one is larger than in endpoint two ‚Äî pw","text":"Z=X-Y normally distributed expectation mu_x - mu_y variance sigma_x + sigma_y- 2 rho sdx sdy","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","text":"Depending results phase II strategy ,.e. whether proceed best promising treatment (l = 1) promising treatments (l = 2), program calculates number participants phase III. l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","text":"","code":"ss_binary(alpha, beta, p0, p11, y, l)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","text":"alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group p11 assumed true rate treatment group y hat_theta_2; estimator phase II l number treatments phase III: l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","text":"function ss_binary() returns total sample size phase III trial l treatments equal allocation ratio","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for binary outcomes ‚Äî ss_binary","text":"","code":"res <- ss_binary(alpha = 0.05, beta = 0.1, p0 = 0.6, p11 = 0.3, y = 0.5, l = 1)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","text":"Depending results phase II strategy ,.e. whether proceed best promising treatment (l = 1) promising treatments (l = 2), program calculates number participants phase III. l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","text":"","code":"ss_normal(alpha, beta, y, l)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","text":"alpha significance level beta 1-'beta' power calculation sample size phase III y y_hat_theta_2; estimator phase II l number treatments phase III: l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","text":"function ss_normal() returns total sample size phase III trial l treatments equal allocation ratio","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for normally distributed outcomes ‚Äî ss_normal","text":"","code":"res <- ss_normal(alpha = 0.05, beta = 0.1, y = 0.5, l = 1)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","text":"Depending results phase II strategy ,.e. whether proceed best promising treatment (l = 1) promising treatments (l = 2), program calculates number participants phase III. l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","text":"","code":"ss_tte(alpha, beta, ec, ek, y, l)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","text":"alpha significance level beta 1-beta power calculation sample size phase III ec control arm event rate phase II III ek event rate arm k (either arm 1 arm 2) y hat_theta_2; estimator phase II l number treatments phase III: l=1: according Schoenfeld guarantee power log rank test detect treatment effect phase II; l=2: according Dunnett guarantee y -pair power (Horn & Vollandt)","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","text":"function ss_tte() returns total sample size phase III trial l treatments equal allocation ratio","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/ss_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Total sample size for phase III trial with l treatments and equal allocation ratio for time-to-event outcomes ‚Äî ss_tte","text":"","code":"res <- ss_tte(alpha = 0.05, beta = 0.1, ec = 0.6, ek = 0.8, y = 0.5, l=1)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","title":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","text":"","code":"utility23(   d2,   HRgo,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","text":"d2 total sample size phase II; must even number HRgo threshold value go/-go decision rule w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events alpha significance level beta 1-beta power calculation sample size phase III xi2 event rate phase II xi3 event rate phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","text":"output function utility23() expected utility program depending whether two three phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs deciding between two or three phase III trials in a time-to-event setting ‚Äî utility23","text":"","code":"utility23(d2 = 50, HRgo = 0.8,  w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420,                                   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  b1 = 1000, b2 = 2000, b3 = 3000) #>  [1] -247.53104852  300.00000000    0.35085950    0.54390933  591.17280041 #>  [6]  224.78876488    0.03652261    0.10882798    0.05761021   72.00000000 #> [11]  428.00000000    0.16525843  140.00000000  200.00000000    0.03165033 #> [16]    0.08497412    0.03127425"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","title":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial_binary() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","text":"","code":"utility23_binary(   n2,   RRgo,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","text":"n2 total sample size phase II; must even number RRgo threshold value go/-go decision rule w weight mixture prior distribution p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","text":"output function utility23_binary() expected utility program depending whether two three phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs deciding between two or three phase III trials for a binary distributed outcome ‚Äî utility23_binary","text":"","code":"utility23_binary(n2 = 50, RRgo = 0.8,  w = 0.3,                                   alpha = 0.05, beta = 0.1,                                  p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600,                                   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  b1 = 1000, b2 = 2000, b3 = 3000) #>  [1] 740.604220885 216.000000000   0.499091626   0.578956997 389.687099203 #>  [6]  53.551862445   0.024463090   0.192325146   0.253532810  50.000000000 #> [11] 216.000000000   0.063679083  44.000000000   0.006986181  -0.079291991 #> [16]   0.101076391"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","title":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial_normal() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","text":"","code":"utility23_normal(   n2,   kappa,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","text":"n2 total sample size phase II; must even number kappa threshold value go/-go decision rule w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","text":"output function utility23_normal() expected utility program depending whether two three phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility23_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs deciding between two or three phase III trials for a normally distributed outcome ‚Äî utility23_normal","text":"","code":"utility23_normal(n2 = 50, kappa = 0.2, w = 0.3, alpha = 0.025, beta = 0.1,                                 Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                  a = 0.25, b = 0.75,                                  c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,                                 b1 = 3000, b2 = 8000, b3 = 10000) #>  [1] 1.844231e+03 3.680000e+02 5.666107e-01 7.885549e-01 2.965022e+02 #>  [6] 1.421218e+01 4.658394e-01 8.456348e-03 3.450019e-06 2.066088e-01 #> [11] 1.400000e+01 0.000000e+00 9.231153e-02 0.000000e+00"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","title":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_bias() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","text":"","code":"utility_L(   d2,   HRgo,   Adj,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_L2(   d2,   HRgo,   Adj,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_R(   d2,   HRgo,   Adj,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_R2(   d2,   HRgo,   Adj,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","text":"d2 total events phase II; must even number HRgo threshold value go/-go decision rule Adj adjustment parameter w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events alpha significance level beta 1-beta power calculation sample size phase III xi2 event rate phase II xi3 event rate phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","text":"output functions utility_L(), utility_L2(), utility_R() utility_R2() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for bias adjustment programs with time-to-event outcomes. ‚Äî utility_bias","text":"","code":"res <- utility_L(d2 = 50, HRgo = 0.8, Adj = 0.4, w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420, xi2 = 0.7, xi3 = 0.7,                                  alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_L2(d2 = 50, HRgo = 0.8, Adj = 0.4, w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420, xi2 = 0.7, xi3 = 0.7,                                  alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_R(d2 = 50, HRgo = 0.8, Adj = 0.9, w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420, xi2 = 0.7, xi3 = 0.7,                                  alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_R2(d2 = 50, HRgo = 0.8, Adj = 0.9, w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420, xi2 = 0.7, xi3 = 0.7,                                  alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","title":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_bias_binary() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","text":"","code":"utility_binary_L(   n2,   RRgo,   Adj,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_binary_L2(   n2,   RRgo,   Adj,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_binary_R(   n2,   RRgo,   Adj,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_binary_R2(   n2,   RRgo,   Adj,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","text":"n2 total sample size phase II; must even number RRgo threshold value go/-go decision rule Adj adjustment parameter w weight mixture prior distribution p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" fixed choose true treatment effects fixed random, TRUE p11 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","text":"output functions utility_binary_L(), utility_binary_L2(), utility_binary_R() utility_binary_R2() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for bias adjustment programs with binary distributed outcomes. ‚Äî utility_bias_binary","text":"","code":"res <- utility_binary_L(n2 = 50, RRgo = 0.8, Adj = 0.1, w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600,                                   alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_binary_L2(n2 = 50, RRgo = 0.8, Adj = 0.1, w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600,                                   alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_binary_R(n2 = 50, RRgo = 0.8, Adj = 0.9, w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600,                                   alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)          res <- utility_binary_R2(n2 = 50, RRgo = 0.8, Adj = 0.9, w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600,                                   alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","title":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_bias_normal() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","text":"","code":"utility_normal_L(   n2,   kappa,   Adj,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_normal_L2(   n2,   kappa,   Adj,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_normal_R(   n2,   kappa,   Adj,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )  utility_normal_R2(   n2,   kappa,   Adj,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","text":"n2 total sample size phase II; must even number kappa threshold value go/-go decision rule Adj adjustment parameter w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","text":"output functions utility_normal_L(), utility_normal_L2(), utility_normal_R() utility_normal_R2() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_bias_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for bias adjustment programs with normally distributed outcomes. ‚Äî utility_bias_normal","text":"","code":"res <- utility_normal_L(kappa = 0.1, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                   steps1 = 0, stepm1 = 0.5, stepl1 = 0.8,                                  b1 = 3000, b2 = 8000, b3 = 10000,                                   fixed = TRUE)           res <- utility_normal_L2(kappa = 0.1, n2 = 50, Adj = 0,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                   steps1 = 0, stepm1 = 0.5, stepl1 = 0.8,                                  b1 = 3000, b2 = 8000, b3 = 10000,                                   fixed = TRUE)           res <- utility_normal_R(kappa = 0.1, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                   steps1 = 0, stepm1 = 0.5, stepl1 = 0.8,                                  b1 = 3000, b2 = 8000, b3 = 10000,                                   fixed = TRUE)           res <- utility_normal_R2(kappa = 0.1, n2 = 50, Adj = 1,                                   alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625,                                   in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                   steps1 = 0, stepm1 = 0.5, stepl1 = 0.8,                                  b1 = 3000, b2 = 8000, b3 = 10000,                                   fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","title":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters sample size expected probability successful program. utility step maximized optimal_multiarm() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","text":"","code":"utility_multiarm(   n2,   HRgo,   alpha,   beta,   hr1,   hr2,   strategy,   ec,   c2,   c02,   c3,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","text":"n2 total sample size phase II; must divisible three HRgo threshold value go/-go decision rule alpha significance level beta 1-beta power calculation sample size phase III hr1 assumed true treatment effect HR scale treatment 1 hr2 assumed true treatment effect HR scale treatment 2 strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") ec control arm event rate phase II III c2 variable per-patient cost phase II c02 fixed cost phase II c3 variable per-patient cost phase III c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","text":"output function utility_multiarm() expected utility program","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multiarm programs with time-to-event outcomes ‚Äî utility_multiarm","text":"","code":"utility_multiarm(n2 = 50, HRgo = 0.8, alpha = 0.05, beta = 0.1,                             hr1 = 0.7, hr2 = 0.8, strategy = 2, ec = 0.6,                             c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                             K = Inf, N = Inf, S = -Inf,                               steps1 = 1, stepm1 = 0.95,  stepl1 = 0.85,                             b1 = 1000, b2 = 2000, b3 = 3000) #> [1] 466.6809795 399.0000000   0.4740608   0.7254157   0.2042078   0.2698530 #> [7] 137.5000000 507.8123506"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","title":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters sample size expected probability successful program. utility step maximized optimal_multiarm_binary() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","text":"","code":"utility_multiarm_binary(   n2,   RRgo,   alpha,   beta,   p0 = p0,   p11 = p11,   p12 = p12,   strategy,   c2,   c02,   c3,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","text":"n2 total sample size phase II; must even number RRgo threshold value go/-go decision rule alpha significance level beta 1-beta power calculation sample size phase III p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") c2 variable per-patient cost phase II c02 fixed cost phase II c3 variable per-patient cost phase III c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","text":"output function utility_multiarm_binary() expected utility program","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multiarm programs with binary distributed outcomes ‚Äî utility_multiarm_binary","text":"","code":"res <- utility_multiarm_binary(n2 = 50, RRgo = 0.8, alpha = 0.05, beta = 0.1,                             p0 = 0.6, p11 =  0.3, p12 = 0.5, strategy = 1,                             c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                             K = Inf, N = Inf, S = -Inf,                               steps1 = 1, stepm1 = 0.95,   stepl1 = 0.85,                             b1 = 1000, b2 = 2000, b3 = 3000)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","title":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters sample size expected probability successful program. utility step maximized optimal_multiarm_normal() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","text":"","code":"utility_multiarm_normal(   n2,   kappa,   alpha,   beta,   Delta1,   Delta2,   strategy,   c2,   c02,   c3,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3 )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","text":"n2 total sample size phase II; must even number kappa threshold value go/-go decision rule alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means strategy choose Strategy: 1 (\"best promising\"), 2 (\"promising\") c2 variable per-patient cost phase II c02 fixed cost phase II c3 variable per-patient cost phase III c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\", default: 0 stepm1 lower boundary effect size category \"medium\" = upper boundary effect size category \"small\" default: 0.5 stepl1 lower boundary effect size category \"large\" = upper boundary effect size category \"medium\", default: 0.8 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\"","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","text":"output function utility_multiarm_normal() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiarm_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multiarm programs with normally distributed outcomes ‚Äî utility_multiarm_normal","text":"","code":"res <- utility_multiarm_normal(n2 = 50, kappa = 0.8, alpha = 0.05, beta = 0.1,                             Delta1 = 0.375, Delta2 = 0.625, strategy = 1,                             c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                             K = Inf, N = Inf, S = -Inf,                               steps1 = 0, stepm1 = 0.5,   stepl1 = 0.8,                             b1 = 1000, b2 = 2000, b3 = 3000)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multiple endpoints with normally distributed outcomes. ‚Äî utility_multiple_normal","title":"Utility function for multiple endpoints with normally distributed outcomes. ‚Äî utility_multiple_normal","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multiple_normal() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multiple endpoints with normally distributed outcomes. ‚Äî utility_multiple_normal","text":"","code":"utility_multiple_normal(   kappa,   n2,   alpha,   beta,   Delta1,   Delta2,   in1,   in2,   sigma1,   sigma2,   c2,   c02,   c3,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   fixed,   rho,   relaxed,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multiple endpoints with normally distributed outcomes. ‚Äî utility_multiple_normal","text":"kappa threshold value go/-go decision rule; vector endpoints n2 total sample size phase II; must even number alpha significance level beta 1-beta power calculation sample size phase III Delta1 assumed true treatment effect given difference means endpoint 1 Delta2 assumed true treatment effect given difference means endpoint 2 in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size sigma1 standard deviation first endpoint sigma2 standard deviation second endpoint c2 variable per-patient cost phase II c02 fixed cost phase II c3 variable per-patient cost phase III c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" fixed choose true treatment effects fixed random, TRUE Delta1 used fixed effect rho correlation two endpoints relaxed relaxed strict decision rule","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multiple endpoints with normally distributed outcomes. ‚Äî utility_multiple_normal","text":"output function utility_multiple_normal() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multiple endpoints in a time-to-event-setting ‚Äî utility_multiple_tte","title":"Utility function for multiple endpoints in a time-to-event-setting ‚Äî utility_multiple_tte","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multiple_tte() function. Note, calculating utility program, two different benefit triples necessary: one triple case important endpoint overall survival (OS) shows significant positive treatment effect one triple endpoint progression-free survival (PFS) shows significant positive treatment effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multiple endpoints in a time-to-event-setting ‚Äî utility_multiple_tte","text":"","code":"utility_multiple_tte(   n2,   HRgo,   alpha,   beta,   hr1,   hr2,   id1,   id2,   c2,   c02,   c3,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b11,   b21,   b31,   b12,   b22,   b32,   fixed,   rho,   rsamp )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multiple endpoints in a time-to-event-setting ‚Äî utility_multiple_tte","text":"n2 total sample size phase II; must even number HRgo threshold value go/-go decision rule; alpha significance level beta 1-beta power calculation sample size phase III hr1 assumed true treatment effect HR scale endpoint OS hr2 assumed true treatment effect HR scale endpoint PFS id1 amount information hr1 terms sample size id2 amount information hr2 terms sample size c2 variable per-patient cost phase II c02 fixed cost phase II c3 variable per-patient cost phase III c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" HR scale, default: 1 stepm1 lower boundary effect size category \"medium\" HR scale = upper boundary effect size category \"small\" HR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" HR scale = upper boundary effect size category \"medium\" HR scale, default: 0.85 b11 expected gain effect size category \"small\" endpoint OS significant b21 expected gain effect size category \"medium\"endpoint OS significant b31 expected gain effect size category \"large\" endpoint OS significant b12 expected gain effect size category \"small\" endpoint OS significant b22 expected gain effect size category \"medium\"endpoint OS significant b32 expected gain effect size category \"large\" endpoint OS significant fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect rho correlation two endpoints rsamp sample data set Monte Carlo integration","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multiple_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multiple endpoints in a time-to-event-setting ‚Äî utility_multiple_tte","text":"output function utility_multiple_tte() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","title":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","text":"","code":"utility2(   d2,   HRgo,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility3(   d2,   HRgo,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility4(   d2,   HRgo,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","text":"d2 total number events phase II HRgo threshold value go/-go decision rule w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events alpha significance level beta 1-beta power calculation sample size phase III xi2 event rate phase II xi3 event rate phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" case choose case: \"least 1, 2 3 significant trials needed approval\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","text":"output functions utility2(), utility3() utility4() expected utility program 2, 3 4 phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs in a time-to-event setting ‚Äî utility_multitrial","text":"","code":"res <- utility2(d2 = 50, HRgo = 0.8,  w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420,                                   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 2, fixed = TRUE)           res <- utility3(d2 = 50, HRgo = 0.8,  w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420,                                   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 2, fixed = TRUE)          res <- utility4(d2 = 50, HRgo = 0.8,  w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 210, id2 = 420,                                   alpha = 0.025, beta = 0.1, xi2 = 0.7, xi3 = 0.7,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 3, fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_binary.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","title":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial_binary() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_binary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","text":"","code":"utility2_binary(   n2,   RRgo,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility3_binary(   n2,   RRgo,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility4_binary(   n2,   RRgo,   w,   p0,   p11,   p12,   in1,   in2,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_binary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","text":"n2 total sample size phase II; must even number RRgo threshold value go/-go decision rule w weight mixture prior distribution p0 assumed true rate control group p11 assumed true rate treatment group p12 assumed true rate treatment group in1 amount information p11 terms sample size in2 amount information p12 terms sample size alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" case choose case: \"least 1, 2 3 significant trials needed approval\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_binary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","text":"output functions utility2_binary(), utility3_binary() utility4_binary() expected utility program 2, 3 4 phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_binary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs with binary distributed outcomes ‚Äî utility_multitrial_binary","text":"","code":"res <- utility2_binary(n2 = 50, RRgo = 0.8,  w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 2, fixed = TRUE)           res <- utility3_binary(n2 = 50, RRgo = 0.8,  w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 2, fixed = TRUE)          res <- utility4_binary(n2 = 50, RRgo = 0.8,  w = 0.3,                                   p0 = 0.6, p11 =  0.3, p12 = 0.5,                                   in1 = 300, in2 = 600, alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   case = 3, fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_normal.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","title":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_multitrial_normal() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_normal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","text":"","code":"utility2_normal(   n2,   kappa,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility3_normal(   n2,   kappa,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )  utility4_normal(   n2,   kappa,   w,   Delta1,   Delta2,   in1,   in2,   a,   b,   alpha,   beta,   c2,   c3,   c02,   c03,   K,   N,   S,   b1,   b2,   b3,   case,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_normal.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","text":"n2 total sample size phase II; must even number kappa threshold value go/-go decision rule w weight mixture prior distribution Delta1 assumed true treatment effect standardized difference means Delta2 assumed true treatment effect standardized difference means in1 amount information Delta1 terms sample size in2 amount information Delta2 terms sample size lower boundary truncation b upper boundary truncation alpha significance level beta 1-beta power calculation sample size phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" case choose case: \"least 1, 2 3 significant trials needed approval\" fixed choose true treatment effects fixed random","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_normal.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","text":"output functions utility2_normal(), utility3_normal() utility4_normal() expected utility program 2, 3 4 phase III trials performed.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_multitrial_normal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for multitrial programs with normally distributed outcomes ‚Äî utility_multitrial_normal","text":"","code":"res <- utility2_normal(kappa = 0.1, n2 = 50,  alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,                                  K = Inf, N = Inf, S = -Inf,                                   b1 = 3000, b2 = 8000, b3 = 10000,                                   case = 2, fixed = TRUE)           res <- utility3_normal(kappa = 0.1, n2 = 50,  alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,                                  K = Inf, N = Inf, S = -Inf,                                  b1 = 3000, b2 = 8000, b3 = 10000,                                   case = 2, fixed = TRUE)                                   res <- utility4_normal(kappa = 0.1, n2 = 50,  alpha = 0.025, beta = 0.1, w = 0.3,                                  Delta1 = 0.375, Delta2 = 0.625, in1 = 300, in2 = 600,                                   a = 0.25, b = 0.75,                                   c2 = 0.675, c3 = 0.72, c02 = 15, c03 = 20,                                  K = Inf, N = Inf, S = -Inf,                                   b1 = 3000, b2 = 8000, b3 = 10000,                                   case = 3, fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_tte.html","id":null,"dir":"Reference","previous_headings":"","what":"Utility function for time-to-event outcomes. ‚Äî utility_tte","title":"Utility function for time-to-event outcomes. ‚Äî utility_tte","text":"utility function calculates expected utility drug development program given gains minus costs depends parameters expected probability successful program. utility step maximized optimal_tte() function.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_tte.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Utility function for time-to-event outcomes. ‚Äî utility_tte","text":"","code":"utility_tte(   d2,   HRgo,   w,   hr1,   hr2,   id1,   id2,   alpha,   beta,   xi2,   xi3,   c2,   c3,   c02,   c03,   K,   N,   S,   steps1,   stepm1,   stepl1,   b1,   b2,   b3,   gamma,   fixed )"},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_tte.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Utility function for time-to-event outcomes. ‚Äî utility_tte","text":"d2 total events phase II; must even number HRgo threshold value go/-go decision rule w weight mixture prior distribution hr1 first assumed true treatment effect HR scale prior distribution hr2 second assumed true treatment effect HR scale prior distribution id1 amount information hr1 terms number events id2 amount information hr2 terms number events alpha significance level beta 1-beta power calculation sample size phase III xi2 event rate phase II xi3 event rate phase III c2 variable per-patient cost phase II c3 variable per-patient cost phase III c02 fixed cost phase II c03 fixed cost phase III K constraint costs program, default: Inf, e.g. constraint N constraint total expected sample size program, default: Inf, e.g. constraint S constraint expected probability successful program, default: -Inf, e.g. constraint steps1 lower boundary effect size category \"small\" RR scale, default: 1 stepm1 lower boundary effect size category \"medium\" RR scale = upper boundary effect size category \"small\" RR scale, default: 0.95 stepl1 lower boundary effect size category \"large\" RR scale = upper boundary effect size category \"medium\" RR scale, default: 0.85 b1 expected gain effect size category \"small\" b2 expected gain effect size category \"medium\" b3 expected gain effect size category \"large\" gamma difference treatment effect due different population structures phase II III fixed choose true treatment effects fixed random, TRUE hr1 used fixed effect","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_tte.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Utility function for time-to-event outcomes. ‚Äî utility_tte","text":"output functions utility_tte() expected utility program.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/reference/utility_tte.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Utility function for time-to-event outcomes. ‚Äî utility_tte","text":"","code":"res <- utility_tte(d2 = 50, HRgo = 0.8, w = 0.3,                                   hr1 =  0.69, hr2 = 0.81,                                   id1 = 280, id2 = 420, xi2 = 0.7, xi3 = 0.7,                                  alpha = 0.025, beta = 0.1,                                  c2 = 0.75, c3 = 1, c02 = 100, c03 = 150,                                  K = Inf, N = Inf, S = -Inf,                                  steps1 = 1, stepm1 = 0.95, stepl1 = 0.85,                                  b1 = 1000, b2 = 2000, b3 = 3000,                                   gamma = 0, fixed = TRUE)"},{"path":"https://sterniii3.github.io/drugdevelopR/news/index.html","id":"drugdevelopr-102","dir":"Changelog","previous_headings":"","what":"drugdevelopR 1.0.2","title":"drugdevelopR 1.0.2","text":"Improvements work Shiny apps * Adding trace optimal_*() functions.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/news/index.html","id":"drugdevelopr-101","dir":"Changelog","previous_headings":"","what":"drugdevelopR 1.0.1","title":"drugdevelopR 1.0.1","text":"CRAN release: 2024-01-10 Incorporating suggestions CRAN submission: * Replacing \\dontrun{} \\donttest{} examples can run theory, long run practice. * Replacing non-suppressable output console custom print function output objects customizable progress bars using progressr. * removed function code setting seed specific number R/functions_multiple_normal.R; R/functions_multiple_tte.R.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/news/index.html","id":"drugdevelopr-100","dir":"Changelog","previous_headings":"","what":"drugdevelopR 1.0.0","title":"drugdevelopR 1.0.0","text":"Complete validated version full documentation user-relevant functions.","code":""},{"path":"https://sterniii3.github.io/drugdevelopR/news/index.html","id":"drugdevelopr-010","dir":"Changelog","previous_headings":"","what":"drugdevelopR 0.1.0","title":"drugdevelopR 0.1.0","text":"Added NEWS.md file track changes package.","code":""}]
